Devices, systems, and kits for electroporation and methods of use thereof
The device and system for electroporating cells in a liquid flow address the limitations of viral gene transfer methods by providing a high-throughput, automated, and efficient non-viral solution for gene transfer, enhancing research efficiency and reducing costs.
Patent Information
- Application Number
- JP2024137014
- Authority / Receiving Office
- JP · JP
- Patent Type
- Applications
- Current Assignee / Owner
- Priority Date
- 2019-07-02
- Filing Date
- 2024-08-16
- Publication Date
- 2024-11-08
- Estimated Expiration
- 2039-10-28
AI Technical Summary
Current high-throughput gene transfer methods rely on viral delivery, which is time-consuming, costly, and not suitable for all cell types, creating a bottleneck in biotechnology and pharmaceutical research.
A device and system for electroporating cells in a liquid flow using electrodes and an electroporation zone with controlled dimensions and shapes, enabling efficient, non-viral gene transfer.
Facilitates high-throughput, automated, and efficient gene transfer without viral mechanisms, reducing discovery time and costs, and improving cell viability.
Smart Images

Figure 2024159810000003 
Figure 2024159810000004 
Figure 2024159810000005
Abstract
Description
[Technical field]
[0001] STATEMENT OF FEDERALLY SPONSORED RESEARCH This invention was made with Government support under Phase I SBIR Grant No. 1747096 and Phase II SBIR Grant No. 1853194 from the National Science Foundation (NSF). The Government has certain rights in this invention. [Background technology]
[0002] Immunotherapy is currently at the forefront of both basic science research and pharmaceutical driven clinical applications. This trend is due, in part, to recent strides in targeted gene modification and the expanding use of CRISPR / Cas complex editing for therapeutic development. To identify genetic modifications of therapeutic interest, research organizations must often screen thousands of genetic variants, which can involve modifications of endogenous genes or insertions of engineered genes. This drug discovery process is laborious, requires significant manual labor in the laboratory, and creates an industry-wide bottleneck due to the lack of sufficient high-throughput technologies.
[0003] Biotech and pharmaceutical R&D activities are moving towards automating almost every step of the process. Workflows include liquid handling robots with advanced laboratory management software to enable high throughput discovery. However, the transfection step is limited to low throughput, low efficiency techniques, and user intensive systems that cannot be automated. An automation platform for transfection not only has the potential to substantially reduce process costs, but also reduces discovery time allied to increasing cell viability and the amount of normal engineered cells, which is critical in the competitive immunotherapy space.
[0004] The unique strength of electroporation is RNA delivery. Existing viral methods for delivering DNA appear to be comparable to electroporation, but there is a lack of GMP-quality non-retroviral RNA viruses. Therefore, companies with electroporation platforms are targets for collaborations and acquisitions with the aim of delivering mRNA into cells.
[0005] Current high-throughput gene transfer methods typically require the use of viral delivery (e.g., lentiviral vectors) where viral particles infect cells and transduce the genetic modification of interest. Although viral methodologies can be applied to high-throughput automated systems, production has limitations that extend the timeline for research efforts, i.e., viral vectors must be cloned and transfected into viral production lines, and then viral particles must be purified. This process can take research organizations several months, significantly impacting the timeline of platform development while increasing the cost of drug discovery. In addition, the use of viral transduction for gene transfer is not suitable for genetic modification of all cell types, as some cells (such as specific immune cell subsets) are resistant to viral infection. Thus, there is an unmet need within the biotechnology industry to have a high-throughput automated system for gene transfer that does not rely on viral delivery mechanisms. Summary of the Invention
[0006] A device for electroporating a plurality of cells suspended in a liquid (e.g., a liquid flowing through the device), the device comprising a first electrode and a second electrode and an electroporation zone, the first electrode comprising a first lumen having a first inlet, a first outlet, and a minimum cross-sectional dimension, and the second electrode comprising a second lumen having a second inlet, a second outlet, and a minimum cross-sectional dimension. The electroporation zone is disposed between the first outlet and the second inlet and has a minimum cross-sectional dimension greater than about 100 μm (e.g., 100 μm to 10 mm, 150 μm to 15 mm, 200 μm to 10 mm, 250 μm to 5 mm, 500 μm to 10 mm, 1 mm to 10 mm, 1 mm to 50 mm, 5 mm to 25 mm, or 20 mm to 50 mm, e.g., about 0.5 mm, about 1.0 mm, about 1.5 mm, about 2 mm, about 5 mm, about 10 mm, about 15 mm, about 25 mm, or about 50 mm), and the electroporation zone has a substantially uniform cross-sectional area. The first outlet, the electroporation zone, and the second inlet are in fluid communication.
[0007] In some embodiments, the cross-section of the electroporation zone is a shape selected from the group consisting of a circle, a disk, an ellipse, a regular polygon, an irregular polygon, a curved shape, a star, a parallelogram, a trapezoid, and an irregular shape (e.g., a shape having protrusions, such as a protruding slot or groove, an irregular polygon, and / or a curved shape). In some embodiments, the cross-section of the electroporation zone varies along the length (i.e., the longitudinal axis or direction of flow) of the electroporation zone. In some embodiments, the shape is consistent along the length but changes position relative to a central longitudinal axis along the length of the electroporation zone (e.g., the cross-sectional shape rotates around a central axis from one end of the electroporation zone to the other, such as a spiral). In certain embodiments, the electroporation zone has a substantially circular cross-section. In some embodiments, the electroporation zone has a diameter of about 7,850 μm. 2 ~ approx. 2,000mm 2 (For example, about 8,000 μm 2 ~about 1mm 2 , about 8,000μm 2 ~about 10mm 2 , about 8,000μm 2 ~ approx. 100mm 2, about 9,000μm 2 ~5mm 2 , about 1mm 2 ~About 10mm 2 , about 1mm 2 ~About 100mm 2 , about 3mm 2 ~About 20mm 2 , about 10mm 2 ~About 50mm 2 , about 25mm 2 ~About 75mm 2 、About 50mm 2 ~About 100mm 2 、Approx. 75mm 2 ~About 200mm 2 , about 100mm 2 ~About 350mm 2 , about 150mm 2 ~About 500mm 2 , about 300mm 2 ~About 750mm 2 , about 500mm 2 ~About 1,000mm 2 、About 750mm 2 ~About 1,500mm 2 、またはabout 950mm 2 ~About 2,000mm 2 , example, about 8,000μm 2 , about 9,000μm 2 , about 1mm 2 , about 5mm 2 , about 10mm 2 , about 15mm 2 , about 20mm 2 , about 25mm 2 , about 50mm 2 、Approx. 60mm 2 、Approx. 75mm 2 、About 80mm 2 , about 100mm 2 , about 150mm 2 , about 200mm 2 , about 250mm 2 , about 300mm 2 、About 350mm 2 , about 400mm 2 、Approx. 450mm 2 , about 500mm 2 、About 600mm 2 、About 700mm2 , about 800 mm 2 , about 900mm 2 , about 1,000 mm 2 , approx. 1,100 mm 2 , approx. 1,200mm 2 , approx. 1,300mm 2 , approx. 1,400 mm 2 , about 1,500 mm 2 , approx. 1,600 mm 2 , approx. 1,700mm 2 , approx. 1,800 mm 2 , approx. 1,900 mm 2 , or approximately 2,000 mm 2 ) cross-sectional area.
[0008] In some embodiments, the electroporation zone is between 0.005 mm and 50 mm (e.g., 0.005 mm to 0.05 mm, 0.005 mm to 0.5 mm, 0.005 mm to 25 mm, 0.01 mm to 1 mm, 0.05 mm to 5 mm, 0.1 mm to 10 mm, 0.1 mm to 50 mm, 0.5 mm to 5 mm, 0.5 mm to 25 mm, 1 mm to 5 mm, 1 mm to 10 mm, 1 mm to 25 mm, 3 mm to 15 mm, 3 mm to 50 mm, 10 mm to 20 mm, 10 mm to 50 mm, 15 mm to 25 mm, 20 mm to 30 mm, 25 mm to 40, or 30 mm to 50 mm, for example, about 0.005 mm, about 0.01 mm, about 0.05 mm, about 0.1 mm, about 0.5 mm, about 1.0 mm, about 1.5 mm, about 2 mm, about 3 mm, about 4 mm, about 5 mm, about 6 mm, about 7 mm, about 8 mm, about 9 mm, about 10 mm, about 15 mm, about 20 mm, about 25 mm, about 30 mm, about 35 mm, about 40 mm, about 45 mm, or about 50 mm). In some embodiments, the electroporation zone is between 0.005 mm and 25 mm (e.g., 0.005 mm and 0.05 mm, 0.005 mm and 0.5 mm, 0.01 mm and 1 mm, 0.05 mm and 5 mm, 0.1 mm and 10 mm, 0.5 mm and 5 mm, 0.5 mm and 10 mm, 1 mm and 5 mm, 1 mm and 10 mm, 1 mm and 25 mm, 3 mm and 10 mm, 7 mm and 15 mm, 1 The length of the endothelial cell is about 0 mm to 20 mm, or 15 mm to 25 mm, for example, about 0.005 mm, about 0.01 mm, about 0.05 mm, about 0.1 mm, about 0.5 mm, about 1.0 mm, about 1.5 mm, about 2 mm, about 3 mm, about 4 mm, about 5 mm, about 6 mm, about 7 mm, about 8 mm, about 10 mm, about 12 mm, about 15 mm, about 18 mm, about 20 mm, about 23 mm, or about 25 mm.
[0009] In some embodiments, the lumen of any of the first electrode and / or second electrode is between 0.01 mm and 500 mm (e.g., 0.01 mm to 0.1 mm, 0.01 mm to 0.5 mm, 0.01 mm to 10 mm, 0.05 mm to 5 mm, 0.1 mm to 10 mm, 0.5 mm to 5 mm, 0.5 mm to 50 mm, 1 mm to 5 mm, 1 mm to 10 mm, 1 mm to 25 mm, 3 mm to 15 mm, 3 mm to 50 mm, 10 mm to 20 mm, 10 mm to 100 mm, 15 mm to 30 mm, 20 mm to 40 mm, 20 mm to 200 mm, 30 mm to 50, 30 mm to 300 mm, 45 mm to 60 mm, 50 mm to 100 mm, 50 mm to 500 mm, 75 mm to 150 mm, 75 mm to 300 mm, 100 mm). m to 200 mm, 100 mm to 500 mm, 150 mm to 300 mm, 200 mm to 400 mm, 300 mm to 450 mm, or 350 mm to 500 mm, for example, about 0.005 mm, about 0.01 mm, about 0.05 mm, about 0.1 mm, about 0.5 mm, about 1.0 mm, about 1.5 mm, about 2 mm, about 3 mm, about 4 mm, about 5 mm, about 6 mm, about 7 mm m, about 8 mm, about 10 mm, about 15 mm, about 25 mm, about 30 mm, about 35 mm, about 40 mm, about 45 mm, about 50 mm, about 60 mm, about 70 mm, about 80 mm, about 90 mm, about 100 mm, about 150 mm, about 200 mm, about 250 mm, about 300 mm, about 350 mm, about 400 mm, about 450 mm, or about 500 mm).
[0010] In some embodiments, the ratio of the smallest cross-sectional dimension of the lumen of either the first electrode or the second electrode to the smallest cross-sectional dimension of the electroporation zone is 1:10 to 10:1 (e.g., 1:10 to 1:5, 1:10 to 1:2, 1:10 to 1:1, 1:10 to 2:1, 1:10 to 5:1, 1:5 to 1:2, 1:5 to 1:1, 1:5 to 2:1, 1:5 to 5:1, 1:2 to 2:3, 1:2 to 1:1, 1:2 to 2:1, 1:2 to 6:1, 2:3 to 2:1, 2:3 to 4:1, 1:1 to 2:1, 1:1 to 3:1, 1 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, 100, 101, 102, 103, 104, 105, 106, 107, 108, 108, 109, 102, 108, 109, 102, 109, 104, 109, 108, 109, 109, 102, 103, 104, 105
[0011] In some embodiments, the ratio of the smallest cross-sectional dimension of the electroporation zone to the length of the electroporation zone is between 1:100 and 100:1 (e.g., between 1:100 and 1:50, between 1:100 and 1:25, between 1:100 and 1:10, between 1:100 and 1:1, between 1:50 and 1:5, between 1:50 and 1:2, between 1:50 and 2:1, between 1:25 and 1:10, between 1:25 and 1:5, between 1:25 and 1:1, between 1:25 and 10:1, between 1:10 and 1:1, between 1:10 and 2:1, between 1:10 and 5:1, between 1:5 and 1:2, between 1:5 and 1:1, between 1:5 and 2:1, between 1:2 and 1:1, between 1:2 and 2:1, between 1:1 and 2:1, between 1:1 and 5:1, between 1:1 and 10:1). , 1:1 to 50:1, 1:1 to 100:1, 2:1 to 5:1, 2:1 to 20:1, 3:1 to 10:1, 4:1 to 25:1, 5:1 to 50:1, 10:1 to 50:1, 40:1 to 80:1, 50:1 to 100:1, or 75:1 to 90:1, for example, about 1:100, about 1:75, about 1:50 , about 1:25, about 1:10, about 1:5, about 1:2, about 1:1, about 3:2, about 2:1, about 5:2, about 3:1, about 7:2, about 4:1, about 5:1, about 10:1, about 20:1, about 30:1, about 40:1, about 50:1, about 60:1, about 70:1, about 80:1, about 90:1, or about 100:1).
[0012] In some embodiments of any of the preceding devices, the ratio of the cross-sectional area of the lumen of any of the first electrode and / or second electrode to the cross-sectional area of the electroporation zone is 1:100 to 100:1 (e.g., 1:100 to 1:50, 1:100 to 1:25, 1:100 to 1:10, 1:100 to 1:1, 1:50 to 1:5, 1:50 to 1:2, 1:50 to 2:1, 1:25 to 1:10, 1:25 to 1:5, 1:25 to 1:1, 1:25 to 10:1, 1:10 to 1:1, 1:10 to 2:1, 1:10 to 5:1, 1:5 to 1:2, 1:5 to 1:1, 1:5 to 2:1, 1:2 to 1:1, 1:2 to 2:1, 1:1 to 2 :1, 1:1 to 5:1, 1:1 to 10:1, 1:1 to 50:1, 1:1 to 100:1, 2:1 to 5:1, 2:1 to 20:1, 3:1 to 10:1, 4:1 to 25:1, 5:1 to 50:1, 10:1 to 50:1, 40:1 to 80:1, 50:1 to 100:1, or 75:1 to 90:1, for example, about 1:100, about 1 1:75, about 1:50, about 1:25, about 1:10, about 1:5, about 1:2, about 1:1, about 3:2, about 2:1, about 5:2, about 3:1, about 7:2, about 4:1, about 5:1, about 10:1, about 20:1, about 30:1, about 40:1, about 50:1, about 60:1, about 70:1, about 80:1, about 90:1, or about 100:1).
[0013] In some embodiments, the device further includes a first reservoir (e.g., a sample bag) in fluid communication with the first inlet and / or a second reservoir (e.g., a collection bag, e.g., a recovery bag) in fluid communication with the second outlet. In addition, the device may include a third reservoir in fluid communication with the first lumen or the second lumen. The third reservoir may contain one or more reagents for transfection, e.g., a genetic composition to be delivered to the cells. In some embodiments, either the first electrode or the second electrode has an additional inlet or outlet for fluid communication with the third reservoir.
[0014] In some embodiments, either the first electrode or the second electrode may be porous or may be a conductive fluid (eg, a conductive liquid).
[0015] The device of any of the preceding embodiments may include a delivery source in fluid communication with the first inlet. The delivery source may be configured to deliver a plurality of cells in liquid and / or suspension through the first lumen to the second outlet. The delivery source may also be configured to deliver other components, such as genetic material to be introduced into the cells (e.g., as a transfection reagent reservoir).
[0016] In some embodiments, the device further comprises one or more additional electroporation zones (e.g., 1, 2, 3, 4, 6, 8, 10, 11, 12, 24, 27, 36, 48, 64, 96, 384, 1536, or more) that may be configured in parallel, in series, or a combination thereof. The one or more additional electroporation zones may each have a substantially uniform cross-sectional area.
[0017] In some of any of the foregoing embodiments, the device may further include a housing configured to enclose the first electrode, the second electrode, and the electroporation zone. The housing may include a first electrical input operably coupled to the first electrode and a second electrical input operably coupled to the second electrode. In some embodiments, the housing further includes a thermal controller configured to increase the temperature of the device and / or the liquid in which the plurality of cells are suspended, the thermal controller being a heating element selected from the group consisting of a heat block, a liquid flow, a battery-powered heater, and a thin film heater. In some embodiments, the housing further includes a thermal controller configured to decrease the temperature of the device and / or the liquid in which the plurality of cells are suspended, the thermal controller being a cooling element selected from the group consisting of a liquid flow, an evaporative cooler, and a Peltier device. The housing may be integral to the device or may be releasably connected.
[0018] In another aspect, the invention includes a device for electroporating a plurality of cells suspended in a liquid, the device comprising a first electrode comprising a first inlet, a first outlet, and a first lumen comprising a minimum cross-sectional dimension; a second electrode comprising a second inlet, a second outlet, and a second lumen comprising a minimum cross-sectional dimension; a third inlet and a third outlet, the third inlet and the third outlet in fluid communication with the first lumen, the third inlet and the third outlet intersecting the first electrode between the first inlet and the first outlet; and a fourth inlet and a fourth outlet, the fourth inlet and the fourth outlet in fluid communication with the second lumen, the fourth inlet and the fourth outlet in fluid communication with the second lumen, the fourth inlet and the fourth outlet in fluid communication with the second lumen, and an electroporation zone disposed between the first outlet and the second inlet, the electroporation zone comprising a minimum cross-sectional dimension greater than about 100 μm (e.g., 100 μm to 10 mm, 150 μm to 15 mm, 200 μm to 10 mm, 250 μm to 5 mm, 500 μm to 10 mm, 1 mm to 10 mm, 1 mm to 50 mm, 5 mm to 25 mm, or 20 mm to 50 mm, e.g., about 0.5 mm, about 1.0 mm, about 1.5 mm, about 2 mm, about 5 mm, about 10 mm, about 15 mm, about 25 mm, or about 50 mm), and the electroporation zone having a substantially uniform cross-sectional area. The first outlet, the electroporation zone, and the second inlet are in fluid communication. The cross-section of the electroporation zone is a shape selected from the group consisting of a circle, a disk, an ellipse, a regular polygon, an irregular polygon, a curved shape, a star, a parallelogram, a trapezoid, and an irregular shape (e.g., a shape having protrusions, such as a protruding slot or groove, an irregular polygon, and / or a curved shape). In some embodiments, the cross-section of the electroporation zone varies along the length (i.e., the longitudinal axis or direction of flow) of the electroporation zone. In some embodiments, the shape is consistent along the length but changes position relative to a central longitudinal axis along the length of the electroporation zone (e.g., the cross-sectional shape rotates around a central axis from one end of the electroporation zone to the other, such as a spiral). In certain embodiments, the electroporation zone has a substantially circular cross-section. In some embodiments, the electroporation zone is approximately 7850 μm 2 ~about 2000mm 2(Example: about 8,000μm 2 ~about 1mm 2 、About 8,000μm 2 ~About 10mm 2 、About 8,000μm 2 ~About 100mm 2 , about 9,000μm 2 ~5mm 2 , about 1mm 2 ~About 10mm 2 , about 1mm 2 ~About 100mm 2 , about 3mm 2 ~About 20mm 2 , about 10mm 2 ~About 50mm 2 , about 25mm 2 ~About 75mm 2 , about 50mm 2 ~About 100mm 2 、Approx. 75mm 2 ~About 200mm 2 , about 100mm 2 ~About 350mm 2 , about 150mm 2 ~About 500mm 2 , about 300mm 2 ~About 750mm 2 , about 500mm 2 ~About 1,000mm 2 、About 750mm 2 ~About 1,500mm 2 、またはabout 950mm 2 ~About 2,000mm 2 , example, about 8,000μm 2 , about 9,000μm 2 , about 1mm 2 , about 5mm 2 , about 10mm 2 , about 15mm 2 , about 20mm 2 , about 25mm 2 , about 50mm 2 、Approx. 60mm 2 、Approx. 75mm 2 、About 80mm 2 , about 100mm 2 , about 150mm 2 , about 200mm 2 , about 250mm 2, about 300mm 2 , about 350mm 2 , about 400 mm 2 , about 450mm 2 , about 500 mm 2 , about 600 mm 2 , about 700mm 2 , about 800 mm 2 , about 900mm 2 , about 1,000 mm 2 , approx. 1,100 mm 2 , approx. 1,200mm 2 , approx. 1,300mm 2 , approx. 1,400 mm 2 , about 1,500 mm 2 , approx. 1,600 mm 2 , approx. 1,700mm 2 , approx. 1,800 mm 2 , approx. 1,900 mm 2 , or approximately 2,000 mm 2 ) cross-sectional area.
[0019] In some embodiments, the electroporation zone is between 0.1 mm and 50 mm (e.g., 0.1 mm to 0.5 mm, 0.1 mm to 1 mm, 0.1 mm to 5 mm, 0.1 mm to 10 mm, 0.5 mm to 5 mm, 1 mm to 5 mm, 1 mm to 10 mm, 1 mm to 25 mm, 3 mm to 15 mm, 3 mm to 50 mm, 10 mm to 20 mm, 10 mm to 100 mm, 15 mm to 30 mm, 20 mm to 40 mm, 20 mm to 200 mm, 30 mm to 50, 45 mm to 60 mm, 50 mm to 1 The diameter of the cross-sectional area of the tubular member is about 0.00 mm, 75 mm to 150 mm, 100 mm to 200 mm, 150 mm to 300 mm, 200 mm to 400 mm, 300 mm to 450 mm, or 350 mm to 500 mm, for example, about 0.1 mm, about 0.5 mm, about 1.0 mm, about 1.5 mm, about 2 mm, about 3 mm, about 4 mm, about 5 mm, about 6 mm, about 7 mm, about 8 mm, about 10 mm, about 15 mm, about 25 mm, about 30 mm, about 35 mm, about 40 mm, about 45 mm, or about 50 mm.
[0020] In some embodiments, the electroporation zone is between 0.005 mm and 50 mm (e.g., 0.005 mm to 0.05 mm, 0.005 mm to 0.5 mm, 0.005 mm to 25 mm, 0.01 mm to 1 mm, 0.05 mm to 5 mm, 0.1 mm to 10 mm, 0.1 mm to 50 mm, 0.5 mm to 5 mm, 0.5 mm to 25 mm, 1 mm to 5 mm, 1 mm to 10 mm, 1 mm to 25 mm, 3 mm to 15 mm, 3 mm to 50 mm, 10 mm to 20 mm, 10 mm to 50 mm, 15 mm to 25 mm, 20 mm to 30 mm, 25 mm to 40, or 30 mm to 50 mm, for example, about 0.005 mm, about 0.01 mm, about 0.05 mm, about 0.1 mm, about 0.5 mm, about 1.0 mm, about 1.5 mm, about 2 mm, about 3 mm, about 4 mm, about 5 mm, about 6 mm, about 7 mm, about 8 mm, about 9 mm, about 10 mm, about 15 mm, about 20 mm, about 25 mm, about 30 mm, about 35 mm, about 40 mm, about 45 mm, or about 50 mm). In some embodiments, the electroporation zone is between 0.005 mm and 25 mm (e.g., 0.005 mm and 0.05 mm, 0.005 mm and 0.5 mm, 0.01 mm and 1 mm, 0.05 mm and 5 mm, 0.1 mm and 10 mm, 0.5 mm and 5 mm, 0.5 mm and 10 mm, 1 mm and 5 mm, 1 mm and 10 mm, 1 mm and 25 mm, 3 mm and 10 mm, 7 mm and 15 mm, 1 The length of the endothelial cell is about 0 mm to 20 mm, or 15 mm to 25 mm, for example, about 0.005 mm, about 0.01 mm, about 0.05 mm, about 0.1 mm, about 0.5 mm, about 1.0 mm, about 1.5 mm, about 2 mm, about 3 mm, about 4 mm, about 5 mm, about 6 mm, about 7 mm, about 8 mm, about 10 mm, about 12 mm, about 15 mm, about 18 mm, about 20 mm, about 23 mm, or about 25 mm.
[0021] In some embodiments, the lumen of any of the first electrode and / or second electrode is between 0.01 mm and 500 mm (e.g., 0.01 mm to 0.1 mm, 0.01 mm to 0.5 mm, 0.01 mm to 10 mm, 0.05 mm to 5 mm, 0.1 mm to 10 mm, 0.5 mm to 5 mm, 0.5 mm to 50 mm, 1 mm to 5 mm, 1 mm to 10 mm, 1 mm to 25 mm, 3 mm to 15 mm, 3 mm to 50 mm, 10 mm to 20 mm, 10 mm to 100 mm, 15 mm to 30 mm, 20 mm to 40 mm, 20 mm to 200 mm, 30 mm to 50, 30 mm to 300 mm, 45 mm to 60 mm, 50 mm to 100 mm, 50 mm to 500 mm, 75 mm to 150 mm, 75 mm to 300 mm, 100 mm). m to 200 mm, 100 mm to 500 mm, 150 mm to 300 mm, 200 mm to 400 mm, 300 mm to 450 mm, or 350 mm to 500 mm, for example, about 0.005 mm, about 0.01 mm, about 0.05 mm, about 0.1 mm, about 0.5 mm, about 1.0 mm, about 1.5 mm, about 2 mm, about 3 mm, about 4 mm, about 5 mm, about 6 mm, about 7 mm m, about 8 mm, about 10 mm, about 15 mm, about 25 mm, about 30 mm, about 35 mm, about 40 mm, about 45 mm, about 50 mm, about 60 mm, about 70 mm, about 80 mm, about 90 mm, about 100 mm, about 150 mm, about 200 mm, about 250 mm, about 300 mm, about 350 mm, about 400 mm, about 450 mm, or about 500 mm).In some embodiments, the ratio of the smallest cross-sectional dimension of the lumen of either the first electrode or the second electrode to the smallest cross-sectional dimension of the electroporation zone is 1:10 to 10:1 (e.g., 1:10 to 1:5, 1:10 to 1:2, 1:10 to 1:1, 1:10 to 2:1, 1:10 to 5:1, 1:5 to 1:2, 1:5 to 1:1, 1:5 to 2:1, 1:5 to 5:1, 1:2 to 2:3, 1:2 to 1:1, 1:2 to 2:1, 1:2 to 6:1, 2:3 to 2:1, 2:3 to 4:1, 1:1 to 2:1, 1:1 to 3:1, 1:1 to 10:1, 3:2 to 3:1, 3:2 to 6:1, 2:1 to 3:1, 2:1 to 5:1, 5:2 to 5:1, 3:1 to 4:1, 7:2 to 5:1, 7:2 to 10:1, 4:1 to 8:1, 5:1 to 10:1, or 7:1 to 10:1, for example, about 1:10, about 1:5, about 1:2, about 2:3, about 1:1, about 3:2, about 2:1, about 5:2, about 3:1, about 7:2, about 4:1, about 9:2, about 5:1, about 6:1, about 7:1, about 8:1, about 9:1, or about 10:1).
[0022] In some embodiments, the ratio of the smallest cross-sectional dimension of the electroporation zone to the length of the electroporation zone is between 1:100 and 100:1 (e.g., between 1:100 and 1:50, between 1:100 and 1:25, between 1:100 and 1:10, between 1:100 and 1:1, between 1:50 and 1:5, between 1:50 and 1:2, between 1:50 and 2:1, between 1:25 and 1:10, between 1:25 and 1:5, between 1:25 and 1:1, between 1:25 and 10:1, between 1:10 and 1:1, between 1:10 and 2:1, between 1:10 and 5:1, between 1:5 and 1:2, between 1:5 and 1:1, between 1:5 and 2:1, between 1:2 and 1:1, between 1:2 and 2:1, between 1:1 and 2:1, between 1:1 and 5:1, between 1:1 and 10:1). , 1:1 to 50:1, 1:1 to 100:1, 2:1 to 5:1, 2:1 to 20:1, 3:1 to 10:1, 4:1 to 25:1, 5:1 to 50:1, 10:1 to 50:1, 40:1 to 80:1, 50:1 to 100:1, or 75:1 to 90:1, for example, about 1:100, about 1:75, about 1:50 , about 1:25, about 1:10, about 1:5, about 1:2, about 1:1, about 3:2, about 2:1, about 5:2, about 3:1, about 7:2, about 4:1, about 5:1, about 10:1, about 20:1, about 30:1, about 40:1, about 50:1, about 60:1, about 70:1, about 80:1, about 90:1, or about 100:1).In some embodiments, the ratio of the cross-sectional area of the lumen of any of the first electrode and / or second electrode to the cross-sectional area of the electroporation zone is 1:100 to 100:1 (e.g., 1:100 to 1:50, 1:100 to 1:25, 1:100 to 1:10, 1:100 to 1:1, 1:50 to 1:5, 1:50 to 1:2, 1:50 to 2:1, 1:25 to 1:10, 1:25 to 1:5, 1:25 to 1:1, 1:25 to 10:1, 1:10 to 1:1, 1:10 to 2:1, 1:10 to 5:1, 1:5 to 1:2, 1:5 to 1:1, 1:5 to 2:1, 1:2 to 1:1, 1:2 to 2:1, 1:1 to 2:1, 1:1 to 5: 1, 1:1 to 10:1, 1:1 to 50:1, 1:1 to 100:1, 2:1 to 5:1, 2:1 to 20:1, 3:1 to 10:1, 4:1 to 25:1, 5:1 to 50:1, 10:1 to 50:1, 40:1 to 80:1, 50:1 to 100:1, or 75:1 to 90:1, for example, about 1:100, about 1:75, about 1:50, about 1:25, about 1:10, about 1:5, about 1:2, about 1:1, about 3:2, about 2:1, about 5:2, about 3:1, about 7:2, about 4:1, about 5:1, about 10:1, about 20:1, about 30:1, about 40:1, about 50:1, about 60:1, about 70:1, about 80:1, about 90:1, or about 100:1). Either the first electrode or the second electrode, or both, can be porous or can be a conductive fluid (e.g., a liquid).
[0023] In some embodiments, the device further comprises a first reservoir in fluid communication with the first inlet. In some embodiments, the device further comprises a second reservoir in fluid communication with the second outlet. In some embodiments, the device further comprises a third reservoir in fluid communication with the third inlet and the third outlet. In some embodiments, the device further comprises a fourth reservoir in fluid communication with the fourth inlet and the fourth outlet. In some embodiments, the device further comprises a fifth reservoir in fluid communication with a lumen of either the first electrode or the second electrode, either the first electrode or the second electrode having at least one additional inlet for fluid communication with the fifth reservoir. In some embodiments, the device further comprises a fluid delivery source in fluid communication with the first inlet, the fluid delivery source configured to deliver a plurality of cells in liquid and / or suspension through the first lumen to the second outlet. In some embodiments, the device further comprises a plurality of electroporation zones (e.g., arranged in series, in parallel, or a combination thereof). Each of the multiple electroporation zones can have a substantially uniform cross-sectional area.
[0024] In some embodiments, the device further comprises a housing comprising a housing configured to enclose the first electrode, the second electrode, and at least one electroporation zone of the device. The housing may comprise a first electrical input operably coupled to the first electrode and a second electrical input operably coupled to the second electrode. In some embodiments, the housing further comprises a thermal controller configured to increase the temperature of the device and / or the liquid in which the plurality of cells are suspended, the thermal controller being a heating element selected from the group consisting of a heat block, a liquid flow, a battery-powered heater, and a thin film heater. In some embodiments, the housing further comprises a thermal controller configured to decrease the temperature of the device and / or the liquid in which the plurality of cells are suspended, the thermal controller being a cooling element selected from the group consisting of a liquid flow, an evaporative cooler, and a Peltier device. In some embodiments, the housing is either integral to the device or releasably connected to the device.
[0025] In another aspect, the invention includes a system for electroporating a plurality of cells suspended in a liquid, the system including any of the aforementioned embodiments of the device.
[0026] In another aspect, the invention includes a system for electroporating a plurality of cells suspended in a liquid, comprising a cell perforation device and an electrical potential source. The cell perforation device comprises a first electrode, a second electrode, and an electroporation zone. The first electrode comprises a first lumen having a first inlet, a first outlet, and a minimum cross-sectional dimension, and the second electrode comprises a second lumen having a second inlet, a second outlet, and a minimum cross-sectional dimension. The electroporation zone is disposed between the first outlet and the second inlet and has a minimum cross-sectional dimension of greater than about 100 μm (e.g., 100 μm to 10 mm, 150 μm to 15 mm, 200 μm to 10 mm, 250 μm to 5 mm, 500 μm to 10 mm, 1 mm to 10 mm, 1 mm to 50 mm, 5 mm to 25 mm, or 20 mm to 50 mm, e.g., about 0.5 mm, about 1.0 mm, about 1.5 mm, about 2 mm, about 5 mm, about 10 mm, about 15 mm, about 25 mm, or about 50 mm). The electroporation zone has a substantially uniform cross-sectional area. The first outlet, the electroporation zone, and the second inlet are in fluid communication. The system further includes an electric potential source, and the first electrode and the second electrode of the device are in releasable operative contact with the electric potential source. In some embodiments, the device further comprises a first reservoir in fluid communication with the first inlet and / or a second reservoir in fluid communication with the second outlet.
[0027] In some embodiments of the system, the cross-section of the electroporation zone is a shape selected from the group consisting of a circle, a disk, an ellipse, a regular polygon, an irregular polygon, a curvilinear shape, a star, a parallelogram, a trapezoid, and an irregular shape. In some embodiments, the electroporation zone has a substantially circular cross-section. In some embodiments, the electroporation zone has a diameter of 0.1 mm to 50 mm (e.g., 0.1 mm to 0.5 mm, 0.1 mm to 1 mm, 0.1 mm to 5 mm, 0.1 mm to 10 mm, 0.5 mm to 5 mm, 1 mm to 5 mm, 1 mm to 10 mm, 1 mm to 25 mm, 3 mm to 15 mm, 3 mm to 50 mm, 10 mm to 20 mm, 10 mm to 100 mm, 15 mm to 30 mm, 20 mm to 40 mm, 20 mm to 200 mm, 30 mm to 50, 45 mm to 60 mm, 50 mm to 100 mm, 50 mm to 100 mm, 60 mm to 70 mm, 80 mm to 120 mm, 90 mm to 140 mm, 100 mm to 160 mm, 120 mm to 180 mm, 160 mm to 200 mm, 180 mm to 220 mm, 180 mm to 260 mm, 180 mm to 280 mm, 180 mm to 300 mm, 180 mm to 280 mm, 180 mm to 320 mm, 180 mm to 28 ... The diameter of the cross-sectional area of the tubular member is about 0.00 mm, 75 mm to 150 mm, 100 mm to 200 mm, 150 mm to 300 mm, 200 mm to 400 mm, 300 mm to 450 mm, or 350 mm to 500 mm, for example, about 0.1 mm, about 0.5 mm, about 1.0 mm, about 1.5 mm, about 2 mm, about 3 mm, about 4 mm, about 5 mm, about 6 mm, about 7 mm, about 8 mm, about 10 mm, about 15 mm, about 25 mm, about 30 mm, about 35 mm, about 40 mm, about 45 mm, or about 50 mm.
[0028] In some embodiments of the present system, the electroporation zone is about 7,850 μm 2 ~ approx. 2,000mm 2 (For example, about 8,000 μm 2 ~about 1mm 2 , about 8,000μm 2 ~about 10mm 2 , about 8,000μm 2 ~ approx. 100mm 2 , about 9,000μm 2 ~5mm 2 , about 1mm 2 ~about 10mm 2 , about 1mm 2 ~ approx. 100mm 2 , about 3mm 2 ~about 20mm 2 , about 10mm 2 ~ approx. 50mm 2 , about 25mm 2 ~about 75mm2 , about 50 mm 2 ~ approx. 100mm 2 , about 75mm 2 ~about 200mm 2 , about 100 mm 2 ~about 350mm 2 , about 150mm 2 ~ approx. 500mm 2 , about 300mm 2 ~about 750mm 2 , about 500 mm 2 ~ approx. 1,000mm 2 , about 750mm 2 ~ approx. 1,500mm 2 , or about 950 mm 2 ~ approx. 2,000mm 2 , for example, about 8,000 μm 2 , about 9,000μm 2 , about 1mm 2 , about 5mm 2 , about 10mm 2 , about 15mm 2 , about 20mm 2 , about 25mm 2 , about 50 mm 2 , about 60mm 2 , about 75mm 2 , about 80mm 2 , about 100 mm 2 , about 150mm 2 , about 200mm 2 , about 250mm 2 , about 300mm 2 , about 350mm 2 , about 400 mm 2 , about 450mm 2 , about 500 mm 2 , about 600 mm 2 , about 700mm 2 , about 800 mm 2 , about 900mm 2 , about 1,000 mm 2 , approx. 1,100 mm 2 , approx. 1,200mm 2 , approx. 1,300mm 2 , approx. 1,400 mm 2 , about 1,500 mm 2 , approx. 1,600 mm 2 , approx. 1,700mm2 , approx. 1,800 mm 2 , approx. 1,900 mm 2 , or approximately 2,000 mm 2 ) cross-sectional area.
[0029] In some embodiments, the electroporation zone is between 0.005 mm and 50 mm (e.g., 0.005 mm to 0.05 mm, 0.005 mm to 0.5 mm, 0.005 mm to 25 mm, 0.01 mm to 1 mm, 0.05 mm to 5 mm, 0.1 mm to 10 mm, 0.1 mm to 50 mm, 0.5 mm to 5 mm, 0.5 mm to 25 mm, 1 mm to 5 mm, 1 mm to 10 mm, 1 mm to 25 mm, 3 mm to 15 mm, 3 mm to 50 mm, 10 mm to 20 mm, 10 mm to 50 mm, 15 mm to 25 mm, 20 mm to 30 mm, 25 mm to 40, or 30 mm to 50 mm, for example, about 0.005 mm, about 0.01 mm, about 0.05 mm, about 0.1 mm, about 0.5 mm, about 1.0 mm, about 1.5 mm, about 2 mm, about 3 mm, about 4 mm, about 5 mm, about 6 mm, about 7 mm, about 8 mm, about 9 mm, about 10 mm, about 15 mm, about 20 mm, about 25 mm, about 30 mm, about 35 mm, about 40 mm, about 45 mm, or about 50 mm). In some embodiments of the system, the length of the electroporation zone is between 0.005 mm and 25 mm (e.g., 0.005 mm and 0.05 mm, 0.005 mm and 0.5 mm, 0.01 mm and 1 mm, 0.05 mm and 5 mm, 0.1 mm and 10 mm, 0.5 mm and 5 mm, 0.5 mm and 10 mm, 1 mm and 5 mm, 1 mm and 10 mm, 1 mm and 25 mm, 3 mm and 10 mm, 7 mm and 15 mm, 10 mm to 20 mm, or 15 mm to 25 mm, for example, about 0.005 mm, about 0.01 mm, about 0.05 mm, about 0.1 mm, about 0.5 mm, about 1.0 mm, about 1.5 mm, about 2 mm, about 3 mm, about 4 mm, about 5 mm, about 6 mm, about 7 mm, about 8 mm, about 10 mm, about 12 mm, about 15 mm, about 18 mm, about 20 mm, about 23 mm, or about 25 mm).
[0030] In some embodiments, the lumen of any of the first electrode and / or second electrode is between 0.01 mm and 500 mm (e.g., 0.01 mm to 0.1 mm, 0.01 mm to 0.5 mm, 0.01 mm to 10 mm, 0.05 mm to 5 mm, 0.1 mm to 10 mm, 0.5 mm to 5 mm, 0.5 mm to 50 mm, 1 mm to 5 mm, 1 mm to 10 mm, 1 mm to 25 mm, 3 mm to 15 mm, 3 mm to 50 mm, 10 mm to 20 mm, 10 mm to 100 mm, 15 mm to 30 mm, 20 mm to 40 mm, 20 mm to 200 mm, 30 mm to 50, 30 mm to 300 mm, 45 mm to 60 mm, 50 mm to 100 mm, 50 mm to 500 mm, 75 mm to 150 mm, 75 mm to 300 mm, 100 mm). m to 200 mm, 100 mm to 500 mm, 150 mm to 300 mm, 200 mm to 400 mm, 300 mm to 450 mm, or 350 mm to 500 mm, for example, about 0.005 mm, about 0.01 mm, about 0.05 mm, about 0.1 mm, about 0.5 mm, about 1.0 mm, about 1.5 mm, about 2 mm, about 3 mm, about 4 mm, about 5 mm, about 6 mm, about 7 mm m, about 8 mm, about 10 mm, about 15 mm, about 25 mm, about 30 mm, about 35 mm, about 40 mm, about 45 mm, about 50 mm, about 60 mm, about 70 mm, about 80 mm, about 90 mm, about 100 mm, about 150 mm, about 200 mm, about 250 mm, about 300 mm, about 350 mm, about 400 mm, about 450 mm, or about 500 mm).
[0031] In some embodiments of the systems of the invention, the ratio of the smallest cross-sectional dimension of the lumen of either the first electrode or the second electrode to the smallest cross-sectional dimension of the electroporation zone is 1:10 to 10:1 (e.g., 1:10 to 1:5, 1:10 to 1:2, 1:10 to 1:1, 1:10 to 2:1, 1:10 to 5:1, 1:5 to 1:2, 1:5 to 1:1, 1:5 to 2:1, 1:5 to 5:1, 1:2 to 2:3, 1:2 to 1:1, 1:2 to 2:1, 1:2 to 6:1, 2:3 to 2:1, 2:3 to 4:1, 1:1 to 2:1, 1:1 to 3: 1, 1:1 to 10:1, 3:2 to 3:1, 3:2 to 6:1, 2:1 to 3:1, 2:1 to 5:1, 5:2 to 5:1, 3:1 to 4:1, 7:2 to 5:1, 7:2 to 10:1, 4:1 to 8:1, 5:1 to 10:1, or 7:1 to 10:1, for example, about 1:10, about 1:9, about 1:8, about 1:7, about 1:6, about 1:5, about 1:2, about 2:3, about 1:1, about 3:2, about 2:1, about 5:2, about 3:1, about 7:2, about 4:1, about 9:2, about 5:1, about 6:1, about 7:1, about 8:1, about 9:1, or about 10:1). In some embodiments, the ratio of the smallest cross-sectional dimension of the electroporation zone to the length of the electroporation zone is between 1:100 and 100:1 (e.g., between 1:100 and 1:50, between 1:100 and 1:25, between 1:100 and 1:10, between 1:100 and 1:1, between 1:50 and 1:5, between 1:50 and 1:2, between 1:50 and 2:1, between 1:25 and 1:10, between 1:25 and 1:5, between 1:25 and 1:1, between 1:25 and 10:1, between 1:10 and 1:1, between 1:10 and 2:1, between 1:10 and 5:1, between 1:5 and 1:2, between 1:5 and 1:1, between 1:5 and 2:1, between 1:2 and 1:1, between 1:2 and 2:1, between 1:1 and 2:1, between 1:1 and 5:1, between 1:1 and 10:1). , 1:1 to 50:1, 1:1 to 100:1, 2:1 to 5:1, 2:1 to 20:1, 3:1 to 10:1, 4:1 to 25:1, 5:1 to 50:1, 10:1 to 50:1, 40:1 to 80:1, 50:1 to 100:1, or 75:1 to 90:1, for example, about 1:100, about 1:75, about 1:50 , about 1:25, about 1:10, about 1:5, about 1:2, about 1:1, about 3:2, about 2:1, about 5:2, about 3:1, about 7:2, about 4:1, about 5:1, about 10:1, about 20:1, about 30:1, about 40:1, about 50:1, about 60:1, about 70:1, about 80:1, about 90:1, or about 100:1).
[0032] In some embodiments, the ratio of the cross-sectional area of the lumen of either the first electrode and / or the second electrode to the cross-sectional area of the electroporation zone is between 1:100 and 100:1 (e.g., between 1:100 and 1:50, between 1:100 and 1:25, between 1:100 and 1:10, between 1:100 and 1:1, between 1:50 and 1:5, between 1:50 and 1:2, between 1:50 and 2:1, between 1:25 and 1:1 0, 1:25~1:5, 1:25~1:1, 1:25~10:1, 1:10~1:1, 1:10~2:1, 1:10~5:1, 1:10~10:1, 1:5~1:2, 1:5~1:1, 1:5~2:1, 1:5~50:1, 1:2~1:1, 1:2~2:1, 1:2~10:1, 1:1~2:1, 1:1~5:1, 1:1~10:1, 1:1~50:1, 1 :1 to 100:1, 2:1 to 5:1, 2:1 to 20:1, 2:1 to 50:1, 3:1 to 10:1, 3:1 to 30:1, 4:1 to 25:1, 5:1 to 10:1, 5:1 to 50:1, 10:1 to 50:1, 10:1 to 100:1, 40:1 to 80:1, 50:1 to 100:1, or 75:1 to 90:1, for example, about 1:100, about 1:75, about 1:50, about 1 1:25, about 1:10, about 1:5, about 1:2, about 1:1, about 3:2, about 2:1, about 5:2, about 3:1, about 7:2, about 4:1, about 5:1, about 6:1, about 7:1, about 8:1, about 9:1, about 10:1, about 15:1, about 20:1, about 25:1, about 30:1, about 40:1, about 50:1, about 60:1, about 70:1, about 80:1, about 90:1, or about 100:1). Either the first electrode or the second electrode, or both, may be porous or may be a conductive fluid (e.g., a liquid).
[0033] In some embodiments, the system includes a third reservoir in fluid communication with a lumen of either the first electrode or the second electrode, where either the first electrode or the second electrode has an additional inlet for fluid communication with the third reservoir. In some embodiments, the system further includes a fluid delivery source in fluid communication with the first inlet, where the fluid delivery source is configured to deliver the plurality of cells in liquid and / or suspension through the first lumen to the second outlet.
[0034] In some embodiments, the systems of the invention further include a controller operably coupled to the electric potential source to deliver a voltage pulse to the first electrode and the second electrode, the voltage pulse generating an electric potential difference between the first electrode and the second electrode, thus generating an electric field in the electroporation zone. In some embodiments, the system includes a plurality of electroporation zones (e.g., as part of any embodiment(s) of the devices provided herein). Each of the plurality of electroporation zones can have a substantially uniform or non-uniform cross-sectional area.
[0035] In some embodiments, the system further includes an outer structure including a housing configured to enclose the first electrode, the second electrode, and at least one electroporation zone of the device (e.g., the outer structure further includes a first electrical input operably coupled to the first electrode and a second electrical input operably coupled to the second electrode). The housing may include a thermal controller configured to increase the temperature of the device and / or the liquid in which the plurality of cells are suspended. The thermal controller may be a heating element selected from the group consisting of a heat block, a liquid flow, a battery-powered heater, and a thin film heater. Additionally or alternatively, the thermal controller may be configured to decrease the temperature of the device and / or the liquid in which the plurality of cells are suspended, and the thermal controller is a cooling element selected from the group consisting of a liquid flow, an evaporative cooler, and a Peltier device.
[0036] In some embodiments of the system of the present invention, the electric potential source is releasably connected to the first and second electrical inputs of the outer structure. The releasable connection between the first or second electrical input and the electric potential source may be selected from the group consisting of a clamp, clip, spring, sheath, wire brush, mechanical connection, inductive connection, or combinations thereof. The outer structure may be integral to or releasably connected to the device. In some embodiments, the housing is configured to energize the multiple devices in parallel, in series, or offset in time, the housing further comprising a tray housing the multiple electroporation devices, the tray decorated with two grid electrodes, the first grid electrode being electrically isolated from the second grid electrode, an exterior of the first electrode of each of the multiple devices being in releasable operative contact with either the first spring-loaded electrode, the first mechanically connected electrode, or the first inductively connected electrode, and an exterior of the second electrode of each of the multiple devices being in releasable operative contact with the second spring-loaded electrode, the second mechanically connected electrode, or the first inductively connected electrode. each of the plurality of devices releasably enters the housing through an opening in the grid electrode, and either the first spring-loaded electrode, the first mechanically connected electrode, or the first inductively connected electrode of each device is in operative contact with the first grid electrode, and either the second spring-loaded electrode, the second mechanically connected electrode, or the second inductively connected electrode of each device is in operative contact with the second grid electrode, the grid electrodes being connected to a source of electrical potential.
[0037] In some embodiments of the system, the electric potential source delivers voltage pulses to the grid electrodes, where a first grid electrode is energized with a particular applied voltage while a second grid electrode is energized with a particular applied voltage, and each of the plurality of devices is energized by the grid electrode with the same applied voltage pulse such that the magnitude of the electric field generated within each of the at least one electroporation zone of each device is substantially the same. In some embodiments, the electric potential source includes additional circuitry or programming configured to modulate the delivery of the voltage pulses to the grid electrodes, where each of the plurality of devices may receive a different voltage from the grid electrode, and the magnitude of the electric field generated within each of the at least one electroporation zone of each device is different.
[0038] In another aspect, the present invention provides a system for electroporating a plurality of cells suspended in a liquid, the system comprising a cell poration device comprising: a first electrode comprising a first inlet, a first outlet, and a first lumen; a second electrode comprising a second inlet, a second outlet, and a second lumen; a third inlet and a third outlet, the third inlet and the third outlet being in fluid communication with the first lumen, the third inlet and the third outlet intersecting the first electrode between the first inlet and the first outlet; and a fourth inlet and a fourth outlet, the fourth inlet and the fourth outlet being in fluid communication with the first lumen. a fourth inlet and a fourth outlet in fluid communication with the second lumen, the fourth inlet and the fourth outlet intersecting the second electrode between the second inlet and the second outlet, an electroporation zone disposed between the fourth inlet and the fourth outlet and the first outlet and the second inlet, the electroporation zone being between 0.005 mm and 50 mm (e.g., 0.005 mm to 0.05 mm, 0.005 mm to 0.5 mm, 0.005 mm to 25 mm, 0.01 mm to 1 mm, 0.05 mm to 5 mm, 0.1 mm to 10 mm, 0.1 mm to 50 mm, 0.5 mm to 5 mm, 0.5 mm to 25 mm, 1 mm to 5 mm, 1 mm to 5 mm, m~10mm, 1mm~25mm, 3mm~15mm, 3mm~50mm, 10mm~20mm, 10mm~50mm, 15mm~25mm, 20mm~30mm, 25mm~40, or 30mm~50mm, such as about 0.005mm, about 0.01mm, about 0.05mm, 0.1mm, 0.5mm, 1.0mm, 1.5mm, 2mm, 3mm, 4mm, 5mm, 6mm, 7mm, 8mm, 9mm, 10mm, 15mm, 20mm, 25mm, 30mm, 35mm, 40mm, 45mm, or 50mm) and a minimum cross-sectional dimension of greater than about 100 μm (e.g., 100 μm to 10 mm, 150 μm to 15 mm, 200 μm to 10 mm, 250 μm to 5 mm, 500 μm to 10 mm, 1 mm to 10 mm, 1 mm to 50 mm, 5 mm to 25 mm, or 20 mm to 50 mm, e.g., about 0.5 mm, about 1.0 mm, about 1.5 mm, about 2 mm, about 5 mm, about 10 mm, about 15 mm, about 25 mm, or about 50 mm), the cross-sectional area of the electroporation zone is substantially uniform, and the ratio of the minimum cross-sectional dimension of the first lumen to the minimum cross-sectional dimension of the electroporation zone is1:10~10:1 (e.g. 1:10~1:5, 1:10~1:2, 1:10~1:1, 1:10~2:1, 1:10~5:1, 1:5~1:2, 1:5~1:1, 1:5~2:1, 1:5~5:1, 1:2~2:3, 1:2~1:1, 1:2~2:1, 1:2~6:1, 2:3~2:1, 2:3~4:1, 1:1~2:1, 1:1~3:1, 1:1~10:1, 3:2~3:1, 3:2~6:1, 2:1~3:1, 2:1~5:1, 5:2~5:1, 3:1~4:1, 7:2~ 5:1, 7:2 to 10:1, 4:1 to 8:1, 5:1 to 10:1, or 7:1 to 10:1, e.g., about 1:10, about 1:5, about 1:2, about 2:3, about 1:1, about 3:2, about 2:1, about 5:2, about 3:1, about 7:2, about 4:1, about 9:2, about 5:1, about 6:1, about 7:1, about 8:1, about 9:1, or about 10:1, and the ratio of the minimum cross-sectional dimension of the second lumen to the minimum cross-sectional dimension of the electroporation zone is 1:10 to 10:1 (e.g., 1:10 to 1:5, 1:10 to 1:2, 1:10 ~1:1, 1:10~2:1, 1:10~5:1, 1:5~1:2, 1:5~1:1, 1:5~2:1, 1:5~5:1, 1:2~2:3, 1:2~1:1, 1:2~2:1, 1:2~6:1, 2:3~2:1, 2:3~4:1, 1:1~2:1, 1:1~3:1, 1:1~10:1, 3:2~3:1, 3:2~6:1, 2:1~3:1, 2:1~5:1, 5:2~5:1, 3:1~4:1, 7:2~5:1, 7:2~10:1, 4:1~8:1, 5:1~10:1, or 7:1 and an electroporation zone, the first outlet, the electroporation zone, and the second inlet being in fluid communication with each other, the electroporation zone having a ratio of about 1:10 to about 10:1, e.g., about 1:10, about 1:5, about 1:2, about 2:3, about 1:1, about 3:2, about 2:1, about 5:2, about 3:1, about 7:2, about 4:1, about 9:2, about 5:1, about 6:1, about 7:1, about 8:1, about 9:1, or about 10:1), and the first outlet, the electroporation zone, and the second inlet being in fluid communication with each other; and an electric potential source, the first electrode and the second electrode of the device being in releasable operative contact with the electric potential source. The cross-section of the electroporation zone is a closed shape selected from the group consisting of a circle, a disk, an ellipse, a regular polygon, an irregular polygon, a curved shape, a star, a parallelogram, a trapezoid, and an irregular shape. The electroporation zone may have a substantially circular cross-section.
[0039] In some embodiments of the system, the electroporation zone is between 0.1 mm and 50 mm (e.g., 0.1 mm to 0.5 mm, 0.1 mm to 1 mm, 0.1 mm to 5 mm, 0.1 mm to 10 mm, 0.5 mm to 5 mm, 1 mm to 5 mm, 1 mm to 10 mm, 1 mm to 25 mm, 3 mm to 15 mm, 3 mm to 50 mm, 10 mm to 20 mm, 10 mm to 100 mm, 15 mm to 30 mm, 20 mm to 40 mm, 20 mm to 200 mm, 30 mm to 50, 45 mm to 60 mm, 50 mm to 70 mm, 80 mm to 90 mm, 100 mm to 110 mm, 15 mm to 30 mm, 20 mm to 40 mm, 20 mm to 200 mm, 30 mm to 50, 45 mm to 60 mm, 50 mm to 70 mm, 10 mm to 120 mm, 15 mm to 25 mm, 20 mm to 30 mm, 25 mm to 30 mm, 25 mm to 40 mm, 25 mm to 50 mm, 30 mm to 50 mm, 45 mm to 60 mm, 50 mm to 60 mm, 50 mm to 70 mm, 50 mm to 80 mm, 50 mm to 90 mm, 50 mm to 10 ... In some embodiments, the cross-sectional dimension is about 0.1 mm, about 0.5 mm, about 1.0 mm, about 1.5 mm, about 2 mm, about 3 mm, about 4 mm, about 5 mm, about 6 mm, about 7 mm, about 8 mm, about 10 mm, about 15 mm, about 25 mm, about 30 mm, about 35 mm, about 40 mm, about 45 mm, or about 50 mm.
[0040] In some embodiments, the electroporation zone is about 7,850 μm 2 ~ approx. 2,000mm 2 (For example, about 8,000 μm 2 ~about 1mm 2 , about 8,000μm 2 ~about 10mm 2 , about 8,000μm 2 ~ approx. 100mm 2 , about 9,000μm 2 ~5mm 2 , about 1mm 2 ~about 10mm 2 , about 1mm 2 ~ approx. 100mm 2 , about 3mm 2 ~about 20mm 2 , about 10mm 2 ~ approx. 50mm 2 , about 25mm 2 ~about 75mm 2 , about 50 mm 2 ~ approx. 100mm 2 , about 75mm 2 ~about 200mm 2 , about 100 mm 2 ~about 350mm2 , about 150mm 2 ~ approx. 500mm 2 , about 300mm 2 ~about 750mm 2 , about 500 mm 2 ~ approx. 1,000mm 2 , about 750mm 2 ~ approx. 1,500mm 2 , or about 950 mm 2 ~ approx. 2,000mm 2 , for example, about 8,000 μm 2 , about 9,000μm 2 , about 1mm 2 , about 5mm 2 , about 10mm 2 , about 15mm 2 , about 20mm 2 , about 25mm 2 , about 50 mm 2 , about 60mm 2 , about 75mm 2 , about 80mm 2 , about 100 mm 2 , about 150mm 2 , about 200mm 2 , about 250mm 2 , about 300mm 2 , about 350mm 2 , about 400 mm 2 , about 450mm 2 , about 500 mm 2 , about 600 mm 2 , about 700mm 2 , about 800 mm 2 , about 900mm 2 , about 1,000 mm 2 , approx. 1,100 mm 2 , approx. 1,200mm 2 , approx. 1,300mm 2 , approx. 1,400 mm 2 , about 1,500 mm 2 , approx. 1,600 mm 2 , approx. 1,700mm 2 , approx. 1,800 mm 2 , approx. 1,900 mm 2 , or approximately 2,000 mm 2 ) cross-sectional area.
[0041] In some embodiments, the electroporation zone is between 0.005 mm and 50 mm (e.g., 0.005 mm to 0.05 mm, 0.005 mm to 0.5 mm, 0.005 mm to 25 mm, 0.01 mm to 1 mm, 0.05 mm to 5 mm, 0.1 mm to 10 mm, 0.1 mm to 50 mm, 0.5 mm to 5 mm, 0.5 mm to 25 mm, 1 mm to 5 mm, 1 mm to 10 mm, 1 mm to 25 mm, 3 mm to 15 mm, 3 mm to 50 mm, 10 mm to 20 mm, 10 mm to 50 mm, 15 mm to 25 mm, 20 mm to 30 mm, 25 mm to 40, or 30 mm to 50 mm, for example, about 0.005 mm, about 0.01 mm, about 0.05 mm, about 0.1 mm, about 0.5 mm, about 1.0 mm, about 1.5 mm, about 2 mm, about 3 mm, about 4 mm, about 5 mm, about 6 mm, about 7 mm, about 8 mm, about 9 mm, about 10 mm, about 15 mm, about 20 mm, about 25 mm, about 30 mm, about 35 mm, about 40 mm, about 45 mm, or about 50 mm). In some embodiments of the systems of the invention, the length of the electroporation zone is between 0.005 mm and 25 mm (e.g., 0.005 mm and 0.05 mm, 0.005 mm and 0.5 mm, 0.01 mm and 1 mm, 0.05 mm and 5 mm, 0.1 mm and 10 mm, 0.5 mm and 5 mm, 0.5 mm and 10 mm, 1 mm and 5 mm, 1 mm and 10 mm, 1 mm and 25 mm, 3 mm and 10 mm, 7 mm, about 0.005 mm, about 0.01 mm, about 0.05 mm, about 0.1 mm, about 0.5 mm, about 1.0 mm, about 1.5 mm, about 2 mm, about 3 mm, about 4 mm, about 5 mm, about 6 mm, about 7 mm, about 8 mm, about 10 mm, about 12 mm, about 15 mm, about 18 mm, about 20 mm, about 23 mm, or about 25 mm).
[0042] In some embodiments, the lumen of any of the first electrode and / or second electrode is between 0.01 mm and 500 mm (e.g., 0.01 mm to 0.1 mm, 0.01 mm to 0.5 mm, 0.01 mm to 10 mm, 0.05 mm to 5 mm, 0.1 mm to 10 mm, 0.5 mm to 5 mm, 0.5 mm to 50 mm, 1 mm to 5 mm, 1 mm to 10 mm, 1 mm to 25 mm, 3 mm to 15 mm, 3 mm to 50 mm, 10 mm to 20 mm, 10 mm to 100 mm, 15 mm to 30 mm, 20 mm to 40 mm, 20 mm to 200 mm, 30 mm to 50, 30 mm to 300 mm, 45 mm to 60 mm, 50 mm to 100 mm, 50 mm to 500 mm, 75 mm to 150 mm, 75 mm to 300 mm, 100 mm). m to 200 mm, 100 mm to 500 mm, 150 mm to 300 mm, 200 mm to 400 mm, 300 mm to 450 mm, or 350 mm to 500 mm, for example, about 0.005 mm, about 0.01 mm, about 0.05 mm, about 0.1 mm, about 0.5 mm, about 1.0 mm, about 1.5 mm, about 2 mm, about 3 mm, about 4 mm, about 5 mm, about 6 mm, about 7 mm m, about 8 mm, about 10 mm, about 15 mm, about 25 mm, about 30 mm, about 35 mm, about 40 mm, about 45 mm, about 50 mm, about 60 mm, about 70 mm, about 80 mm, about 90 mm, about 100 mm, about 150 mm, about 200 mm, about 250 mm, about 300 mm, about 350 mm, about 400 mm, about 450 mm, or about 500 mm).
[0043] In some embodiments, the ratio of the smallest cross-sectional dimension of the lumen of either the first electrode or the second electrode to the smallest cross-sectional dimension of the electroporation zone is 1:10 to 10:1 (e.g., 1:10 to 1:5, 1:10 to 1:2, 1:10 to 1:1, 1:10 to 2:1, 1:10 to 5:1, 1:5 to 1:2, 1:5 to 1:1, 1:5 to 2:1, 1:5 to 5:1, 1:2 to 2:3, 1:2 to 1:1, 1:2 to 2:1, 1:2 to 6:1, 2:3 to 2:1, 2:3 to 4:1, 1:1 to 2:1, 1:1 to 3:1, 1:1 to 10:1, 3:2 to 3:1, 3:2 to 6:1, 2:1 to 3:1, 2:1 to 5:1, 5:2 to 5:1, 3:1 to 4:1, 7:2 to 5:1, 7:2 to 10:1, 4:1 to 8:1, 5:1 to 10:1, or 7:1 to 10:1, for example, about 1:10, about 1:5, about 1:2, about 2:3, about 1:1, about 3:2, about 2:1, about 5:2, about 3:1, about 7:2, about 4:1, about 9:2, about 5:1, about 6:1, about 7:1, about 8:1, about 9:1, or about 10:1).In some embodiments, the ratio of the smallest cross-sectional dimension of the electroporation zone to the length of the electroporation zone is between 1:100 and 100:1 (e.g., 1:100 to 1:50, 1:100 to 1:25, 1:100 to 1:10, 1:100 to 1:1, 1:50 to 1:5, 1:50 to 1:2, 1:50 to 2:1, 1:25 to 1:10, 1:25 to 1:5, 1:25 ~1:1, 1:25~10:1, 1:10~1:1, 1:10~2:1, 1:10~5:1, 1:10~10:1, 1:5~1:2, 1:5~1:1, 1:5~2:1, 1:5~50:1, 1:2~1:1, 1:2~2:1, 1:2~10:1, 1:1~2:1, 1:1~5:1, 1:1~10:1, 1:1~50:1, 1:1~100:1, 2 :1 to 5:1, 2:1 to 20:1, 2:1 to 50:1, 3:1 to 10:1, 3:1 to 30:1, 4:1 to 25:1, 5:1 to 10:1, 5:1 to 50:1, 10:1 to 50:1, 10:1 to 100:1, 40:1 to 80:1, 50:1 to 100:1, or 75:1 to 90:1, for example, about 1:100, about 1:75, about 1:50, about 1:25, about 1:10, about 1:5, about 1:2, about 1:1, about 3:2, about 2:1, about 5:2, about 3:1, about 7:2, about 4:1, about 5:1, about 6:1, about 7:1, about 8:1, about 9:1, about 10:1, about 15:1, about 20:1, about 25:1, about 30:1, about 40:1, about 50:1, about 60:1, about 70:1, about 80:1, about 90:1, or about 100:1).In some embodiments, the ratio of the cross-sectional area of the lumen of either the first electrode and / or the second electrode to the cross-sectional area of the electroporation zone is between 1:100 and 100:1 (e.g., between 1:100 and 1:50, between 1:100 and 1:25, between 1:100 and 1:10, between 1:100 and 1:1, between 1:50 and 1:5, between 1:50 and 1:2, between 1:50 and 2:1, between 1:25 and 1:1 0, 1:25~1:5, 1:25~1:1, 1:25~10:1, 1:10~1:1, 1:10~2:1, 1:10~5:1, 1:10~10:1, 1:5~1:2, 1:5~1:1, 1:5~2:1, 1:5~50:1, 1:2~1:1, 1:2~2:1, 1:2~10:1, 1:1~2:1, 1:1~5:1, 1:1~10:1, 1:1~50:1, 1 :1 to 100:1, 2:1 to 5:1, 2:1 to 20:1, 2:1 to 50:1, 3:1 to 10:1, 3:1 to 30:1, 4:1 to 25:1, 5:1 to 10:1, 5:1 to 50:1, 10:1 to 50:1, 10:1 to 100:1, 40:1 to 80:1, 50:1 to 100:1, or 75:1 to 90:1, for example, about 1:100, about 1:75, about 1:50, about 1 1:25, about 1:10, about 1:5, about 1:2, about 1:1, about 3:2, about 2:1, about 5:2, about 3:1, about 7:2, about 4:1, about 5:1, about 6:1, about 7:1, about 8:1, about 9:1, about 10:1, about 15:1, about 20:1, about 25:1, about 30:1, about 40:1, about 50:1, about 60:1, about 70:1, about 80:1, about 90:1, or about 100:1).
[0044] In some embodiments, the system further includes a first reservoir in fluid communication with the first inlet, a second reservoir in fluid communication with the second outlet, a third reservoir in fluid communication with the third inlet and the third outlet, a fourth reservoir in fluid communication with the fourth inlet and the fourth outlet, and / or a fifth reservoir in fluid communication with a lumen of either the first electrode or the second electrode, e.g., either the first electrode or the second electrode has at least one additional inlet for fluid communication with the fifth reservoir. In some embodiments, the system further includes a fluid delivery source in fluid communication with the first inlet, the fluid delivery source configured to deliver the plurality of cells in liquid and / or suspension through the first lumen to the second outlet. In some embodiments, the device further includes a plurality of electroporation zones, e.g., each of the plurality of electroporation zones has a substantially uniform or non-uniform cross-sectional area.
[0045] The system may further include a controller operably coupled to the electric potential source to deliver voltage pulses to the first electrode and the second electrode to generate a potential difference between the first electrode and the second electrode, thus generating an electric field in the electroporation zone.
[0046] In some embodiments, the system further includes an outer structure including a housing configured to enclose the first electrode, the second electrode, and at least one electroporation zone of the device. The system may further include a first electrical input operably coupled to the first electrode and a second electrical input operably coupled to the second electrode. The housing may further include a thermal controller configured to increase the temperature of the device and / or the liquid in which the plurality of cells are suspended, the thermal controller being a heating element selected from the group consisting of a heat block, a liquid flow, a battery-powered heater, and a thin film heater. Additionally or alternatively, the housing may further include a thermal controller configured to decrease the temperature of the device and / or the liquid in which the plurality of cells are suspended, the thermal controller being a cooling element selected from the group consisting of a liquid flow, an evaporative cooler, and a Peltier device. In some embodiments, the electrical potential source is releasably connected to the first electrical input and the second electrical input of the outer structure, for example, the releasable connection between the first electrical input or the second electrical input and the electrical potential source is selected from the group consisting of a clamp, a clip, a spring, a sheath, a wire brush, a mechanical connection, an inductive connection, or combinations thereof. The outer structure and / or the housing may be integral to or releasably connected to the device.
[0047] In some embodiments, the system further includes a plurality of cell poration devices, e.g., having a plurality of exterior structures. In some embodiments, the housing is configured to energize the plurality of devices in parallel, in series, or offset in time, and the housing further includes a tray that houses the plurality of electroporation devices, the tray decorated with two grid electrodes, a first grid electrode being electrically isolated from a second grid electrode, an exterior of the first electrode of each of the plurality of devices being in releasable, operative contact with either a first spring-loaded electrode, a first mechanically connected electrode, or a first inductively connected electrode, and an exterior of the second electrode of each of the plurality of devices being in releasable, operative contact with either a second spring-loaded electrode, a second mechanically connected electrode, or a first inductively connected electrode. Each of the plurality of devices releasably enters the housing through an opening in the grid electrode, with either the first spring-loaded electrode, the first mechanically connected electrode, or the first inductively connected electrode of each device in operative contact with the first grid electrode, and either the second spring-loaded electrode, the second mechanically connected electrode, or the second inductively connected electrode of each device in operative contact with the second grid electrode, the grid electrodes being connected to a source of electrical potential. In some embodiments, the source of electrical potential delivers voltage pulses to the grid electrodes, such that the first grid electrode is energized with a particular applied voltage while the second grid electrode is energized with a particular applied voltage, and each of the plurality of devices is energized by the grid electrode with the same applied voltage pulse such that the magnitude of the electric field generated within each of the at least one electroporation zone of each device is substantially the same. In some embodiments, the potential source includes additional circuitry or programming configured to modulate the delivery of voltage pulses to the grid electrodes, such that each of the multiple devices may receive a different voltage to the grid electrodes, and the magnitude of the electric field generated within each of the at least one electroporation zone of each device may be different.
[0048] In another aspect, the invention provides a method of introducing a composition into a plurality of cells suspended in a flowing liquid using any of the devices or systems of the invention. In particular, the method of the invention provides a device comprising a first electrode comprising a first lumen comprising a first outlet, a first inlet, and a minimum cross-sectional dimension, a second electrode comprising a second outlet, a second inlet, and a second lumen comprising a minimum cross-sectional dimension, and an electroporation zone disposed between the first outlet and the second inlet, wherein the electroporation zone is greater than about 100 μm (e.g., 100 μm to 10 mm, 150 μm to 15 mm, 200 μm to 10 mm, 250 μm to 5 mm, 500 μm to 10 mm, 1 mm to 10 mm, 1 mm to 50 mm, 5 mm to 25 mm, or 20 mm to 50 mm). providing an electroporation zone having a substantially uniform cross-sectional area, the first outlet, the electroporation zone, and the second inlet being in fluid communication; generating an electric field in the electroporation zone by applying a potential difference between the first electrode and the second electrode; passing the plurality of cells and the composition through the electroporation zone, thereby permeabilizing the plurality of cells and introducing the composition into the plurality of cells. In some embodiments, passing the plurality of cells includes applying a fluid-driven positive pressure. In some embodiments, none of the first lumen, the second lumen, or the electroporation zone has a minimum cross-sectional dimension that temporarily compresses the cross-sectional dimension of any of the plurality of cells suspended in the liquid. Electroporation can be substantially non-thermally reversible electroporation, substantially non-thermally irreversible electroporation, or substantially thermally irreversible electroporation.In some embodiments, the flow rate of the liquid and / or plurality of cells in suspension delivered from the fluid delivery source from the first lumen to the electroporation zone is between 0.001 mL / min and 1,000 mL / min (e.g., 0.001 mL / min and 0.05 mL / min, 0.001 mL / min and 0.1 mL / min, 0.001 mL / min and 1 mL / min, 0.05 mL / min and 0.5 mL / min, 0.05 mL / min and 5 mL / min, 0.1 mL / min and 1 mL / min, 0.5 mL / min and 2 mL / min, 1 mL / min and 5 mL / min, 1 mL / min and 10mL / min, 1mL / min~100mL / min, 5mL / min~25mL / min, 5mL / min~150mL / min, 10mL / min~100mL / min, 15mL / min~150mL / min, 25mL / min~100mL / min, 25mL / min~200mL / min, 5 0mL / min~150mL / min, 50mL / min~250mL / min, 75mL / min~200mL / min, 75mL / min~350mL / min, 100mL / min~250mL / min, 100mL / min~400mL / min, 150mL / min~450mL / min, 200 mL / min to 500 mL / min, 250 mL / min to 700 mL / min, 300 mL / min to 1,000 mL / min, 400 mL / min to 750 mL / min, 500 mL / min to 1,000 mL / min, or 750 mL / min to 1,000 mL / min, for example, about 0.001 mL / min, about 0.01 mL / min, about 0.05 mL / min, about 0.1 mL / min, about 0.5 mL / min, about 1 mL / min, about 5 mL / min, about 10 mL / min, about 15 mL / min, about 20 mL / min, about 30 mL / min, about 40 mL / min, about 50 mL / min, about 6 0 mL / min, about 70 mL / min, about 80 mL / min, about 90 mL / min, about 100 mL / min, about 150 mL / min, about 200 mL / min, about 250 mL / min, about 300 mL / min, about 350 mL / min, about 400 mL / min, about 450 mL / min, about 500 mL / min, about 600 mL / min, about 700 mL / min, about 800 mL / min, about 900 mL / min, or about 1,000 mL / min), and the fluid delivery source is configured to deliver the liquid and / or the plurality of cells in suspension through the first lumen to the second outlet.
[0049] In some embodiments, the residence time in the electroporation zone of any of the plurality of cells suspended in liquid is between 0.5 ms and 50 ms (e.g., between 0.5 ms and 5 ms, between 1 ms and 10 ms, between 1 ms and 15 ms, between 5 ms and 15 ms, between 10 ms and 20 ms, between 15 ms and 25 ms, between 20 ms and 30 ms, between 25 ms and 35 ms, between 30 ms and 40 ms, between 35 ms and 45 ms, or between 40 ms and 50 ms, e.g., about 0.5 ms, about 0.6 ms, about 0.7 ms, about 0.8 ms, about 0.9 ms, about 1 ms, about 1. 5 ms, about 2 ms, about 2.5 ms, about 3 ms, about 3.5 ms, about 4 ms, about 4.5 ms, about 5 ms, about 5.5 ms, about 6 ms, about 6.5 ms, about 7 ms, about 7.5 ms, about 8 ms, about 8.5 ms, about 9 ms, about 9.5 ms, about 10 ms, about 10.5 ms, about 11 ms, about 11.5 ms, about 12 ms, about 12.5 ms, about 13 ms, about 13.5 ms, about 14 ms, about 14.5 ms, about 15 ms, about 20 ms, about 25 ms, about 30 ms, about 35 ms, about 40 ms, about 45 ms, or about 50 ms). In some embodiments, the dwell time is 5 to 20 ms (e.g., 6 to 18 ms, 8 to 15 ms, or 10 to 14 ms).
[0050] In some embodiments, upon exiting the second outlet of the device (e.g., within 48 hours after exiting the second outlet, e.g., within 24 hours after exiting the second outlet, e.g., 1 minute to 24 hours, 5 minutes to 24 hours, 10 minutes to 24 hours, 30 minutes to 24 hours, 1 hour to 24 hours, or 2 hours to 24 hours after exiting the second outlet), the phenotype of the plurality of cells is between 0% and about 25% (e.g., between about 0% and about 2.5%) relative to a baseline measurement of the cell phenotype. , about 1% to about 5%, about 1% to about 10%, about 5% to about 15%, about 10% to about 20%, about 15% to about 25%, or about 20% to about 25%, for example, about 1%, about 2%, about 3%, about 4%, about 5%, about 6%, about 7%, about 8%, about 9%, about 10%, about 11%, about 12%, about 13%, about 14%, about 15%, about 16%, about 17%, about 18%, about 19%, about 20%, about 21%, about 22%, about 23%, about 24%, or about 25%).
[0051] In some embodiments, upon exiting the second outlet of the device (e.g., within 48 hours after exiting the second outlet, e.g., within 24 hours after exiting the second outlet, e.g., 1 minute to 24 hours, 5 minutes to 24 hours, 10 minutes to 24 hours, 30 minutes to 24 hours, 1 hour to 24 hours, or 2 hours to 24 hours after exiting the second outlet), the phenotype of the plurality of cells is unchanged relative to the baseline measurement of the cell phenotype.
[0052] In some embodiments, the electric field is generated by a voltage pulse, which energizes a first electrode with a particular applied voltage while a second electrode is energized with the particular applied voltage, thus applying a potential difference between the first and second electrodes, the voltage pulses each ranging from -3 kV to 3 kV (e.g., -3 kV to 1 kV, -3 kV to -1.5 kV, -2 kV to 2 kV, -1.5 kV to 1.5 kV, -1.5 kV to 2.5 kV, -1 kV to 1 kV, -1 kV to 2 kV, -0.5 kV to 0.5 kV, -0.5 kV to 1.5 kV, -0.5 kV to 3 kV, -0.01kV~2kV, 0kV~1kV, 0kV~2kV, 0kV~3kV, 0.01kV~0.1kV, 0.01kV~1kV , 0.02kV~0.2kV, 0.03kV~0.3kV, 0.04kV~0.4kV, 0.05kV~0.5kV, 0.05kV~ 1.5kV, 0.06kV~0.6kV, 0.07kV~0.7kV, 0.08kV~0.8kV, 0.09kV~0.9kV, 0. 1kV~0.7kV, 0.1kV~1kV, 0.1kV~2kV, 0.1kV~3kV, 0.15kV~1.5kV, 0.2~0.6 kV, 0.2 kV to 2 kV, 0.25 kV to 2.5 kV, 0.3 kV to 3 kV, 0.5 kV to 1 kV, 0.5 kV to 3 kV, 0.6 kV to 1.5 kV, 0.7 kV to 1.8 kV, 0.8 kV to 2 kV, 0.9 kV to 3 kV, 1 kV to 2 kV, 1.5 kV to 2.5 kV, or 2 kV to 3 kV, for example, about -3 kV, about -2.5 kV, about -2 kV, about -1.5 kV, about -1 kV, about -0.5 kV, about -0.01 kV, about 0 kV, about 0.01 kV, about 0.02 kV, about 0.03 kV, about 0.04 kV, about 0.05 kV, about 0.06 kV, In some embodiments, the amplitude of the pulse width is about 0.07 kV, about 0.08 kV, about 0.09 kV, about 0.1 kV, about 0.2 kV, about 0.3 kV, about 0.4 kV, about 0.5 kV, about 0.6 kV, about 0.7 kV, about 0.8 kV, about 0.9 kV, about 1 kV, about 1.1 kV, about 1.2 kV, about 1.3 kV, about 1.4 kV, about 1.5 kV, about 1.6 kV, about 1.7 kV, about 1.8 kV, about 1.9 kV, about 2 kV, about 2.1 kV, about 2.2 kV, about 2.3 kV, about 2.4 kV, about 2.5 kV, about 2.6 kV, about 2.7 kV, about 2.8 kV, about 2.9 kV, or about 3 kV.In some embodiments, the first electrode is energized with a particular applied voltage while the second electrode is held at ground (e.g., 0 kV), thus applying a potential difference between the first and second electrodes. In some embodiments, the voltage pulse lasts for 0.01 ms to 1,000 ms (e.g., 0.01 ms to 0.1 ms, 0.01 ms to 1 ms, 0.01 ms to 10 ms, 0.05 ms to 0.5 ms, 0.05 ms to 1 ms, 0.1 ms to 1 ms, 0.1 ms to 5 ms, 0.1 ms to 500 ms, 0.5 ms to 2 ms, 1 ms to 5 ms, 1 ms to 10 ms, 1ms~25ms, 1ms~100ms, 1ms~1,000ms, 5ms~25ms, 5ms~150ms, 10ms~100ms, 15ms~150ms, 25ms~1 00ms, 25ms~200ms, 50ms~150ms, 50ms~250ms, 75ms~200ms, 75ms~350ms, 100ms~250ms, 100ms~4 00 ms, 150 ms to 450 ms, 200 ms to 500 ms, 250 ms to 700 ms, 300 ms to 1,000 ms, 400 ms to 750 ms, 500 ms to 1,000 ms, or 750 ms to 1,000 ms, for example, about 0.01 ms, about 0.05 ms, about 0.1 ms, about 0.5 ms, about 1 ms, about 5 ms, about 10 ms, about 15 ms, about 20 In some embodiments, the pulse width may be about 1,000 ms, about 2,000 ms, about 3,000 ms, about 4,000 ms, about 5,000 ms, about 6,000 ms, about 7,000 ms, about 8,000 ms, about 9,000 ms, or about 1,000 ms.In some embodiments, the voltage pulses are between 1 Hz and 50,000 Hz (e.g., 1 Hz to 10 Hz, 1 Hz to 100 Hz, 1 Hz to 1,000 Hz, 5 Hz to 20 Hz, 5 Hz to 2,000 Hz, 10 Hz to 50 Hz, 10 Hz to 100 Hz, 10 Hz to 1,000 Hz, 10 Hz to 10,000 Hz, 20 Hz to 50 Hz, 20 Hz to 100 Hz, 20 Hz to 2,000 Hz, 20 Hz to 20,000 Hz, 50 Hz to 500 Hz, 50 Hz to 1,000Hz, 50Hz~50,000Hz, 100Hz~200Hz, 100Hz~500Hz, 100Hz~1,000Hz, 100Hz~10,000Hz, 100Hz~50,000Hz, 200Hz~400H z, 200Hz~750Hz, 200Hz~2,000Hz, 500Hz~1,000Hz, 750Hz~1,500Hz, 750Hz~10,000Hz, 1,000Hz~2,000Hz, 1,000Hz~5,000 Hz, 1,000Hz to 10,000Hz, 1,000Hz to 50,000Hz, 5,000Hz to 10,000Hz, 5,000Hz to 20,000Hz, 5,000Hz to 50,000Hz, 10,000Hz to 15,000Hz, 10,000Hz to 25,000Hz, 10,000Hz to 50,000Hz, 20,000Hz to 30,000Hz, or 20,000 to 50,000Hz, for example, about 1Hz, about 5Hz, about 10Hz, about The first electrode and the second electrode are applied with a frequency of about 20 Hz, about 50 Hz, about 75 Hz, about 100 Hz, about 150 Hz, about 200 Hz, about 300 Hz, about 400 Hz, about 500 Hz, about 600 Hz, about 700 Hz, about 800 Hz, about 900 Hz, about 1,000 Hz, about 2,000 Hz, about 5,000 Hz, about 10,000 Hz, about 15,000 Hz, about 20,000 Hz, about 30,000 Hz, about 40,000 Hz, or about 50,000 Hz.
[0053] In some embodiments, the waveform of the voltage pulse is selected from the group consisting of DC, square, pulse, bipolar, sinusoidal, ramp, asymmetric bipolar, any, and any superposition or combination thereof. In some embodiments, the electric field resulting from the voltage pulse is between 1 V / cm and 50,000 V / cm (e.g., between 1 V / cm and 50 V / cm, between 1 V / cm and 500 V / cm, between 1 V / cm and 1,000 V / cm, between 1 V / cm and 20,000 V / cm, between 5 V / cm and 10,000 V / cm, between 25 V / cm and 200 V / cm, between 50 V / cm and 250 V / cm, between 50 V / cm and 500 V / cm, between 50 V / cm and 15,000 V / cm, between 100 V / cm and 1,000 V / cm, between 3 V / cm and 5 ...0 V / cm, between 3 V / cm and 500 V / cm, between 3 V / cm and 500 V / cm, between 3 V 00V / cm to 500V / cm, 500V / cm to 10,000V / cm, 1000V / cm to 25,000V / cm, 5,000V / cm to 25,000V / cm, 10,000V / cm to 20,000V / cm, 10,000V / cm to 50,000V / cm, for example, about 1V / cm, about 2V / cm, about 3V / cm, about 4V / cm, about 5V / cm, about 6V / cm, about 7V / cm, about 8V / cm, about 9V / cm, about 10V / cm, about 20V / cm, about 30V / cm, cm, approximately 40V / cm, approximately 50V / cm, approximately 60V / cm, approximately 70V / cm, approximately 80V / cm, approximately 90V / cm, approximately 100V / cm, approximately 150V / cm, approximately 200V / cm, approximately 250V / cm, approximately 300V / cm, approximately 350V / c m, approximately 400V / cm, approximately 450V / cm, approximately 500V / cm, approximately 550V / cm, approximately 600V / cm, approximately 650V / cm, approximately 700V / cm, approximately 750V / cm, approximately 800V / cm, approximately 900V / cm, approximately 1,000V / cm, approximately In some embodiments, the dielectric constant may be about 2,000 V / cm, about 3,000 V / cm, about 4,000 V / cm, about 5,000 V / cm, about 6,000 V / cm, about 7,000 V / cm, about 8,000 V / cm, about 9,000 V / cm, about 10,000 V / cm, about 15,000 V / cm, about 20,000 V / cm, about 25,000 V / cm, about 30,000 V / cm, about 35,000 V / cm, about 40,000 V / cm, about 45,000 V / cm, or about 50,000 V / cm.
[0054] In some embodiments, the duty cycle of the voltage pulses is between 0.001% and 100% (e.g., 0.001% to 0.1%, 0.001% to 10%, 0.01% to 1%, 0.01% to 100%, 0.1% to 5%, 0.1% to 99%, 1% to 10%, 1% to 97%, 2.5% to 20%, 5% to 25%, 5% to 40%, 10% to 25%, 10% to 50%, 10% to 95%, 15% to 60%, 15% to 85%, 20% to 40%, 30% to 50%, 40% to 60%, 40% to 75%, 50% to 85%, 50% to 100%, 75% to 100%, or 90% to 100%, for example, about 0.001%, about 0.002%, about 0.003%, about 0.004%, about 0.0 05%, approx. 0.006%, approx. 0.007%, approx. 0.008%, approx. 0.009%, approx. 0.01%, approx. 0.02%, approx. 0.03%, approx. 0.04%, approx. 0.05%, approx. 0.06%, approx. 0.07%, approx. 0.08%, approx. 0.09%, approx. 0.1%, approx. 0.2%, approx. 0.3%, approx. 0.4%, approx. 0.5%, approx. 0.6%, approx. 0.7%, approx. 0.8% , about 0.9%, about 1%, about 2%, about 3%, about 4%, about 5%, about 6%, about 7%, about 8%, about 9%, about 10%, about 15%, about 20%, about 25%, about 30%, about 35%, about 40%, about 45%, about 50%, about 55%, about 60%, about 65%, about 70%, about 75%, about 80%, about 85%, about 90%, about 95%, or about 100%).
[0055] In some embodiments, the liquid has a viscosity of 0.001 mS / cm to 500 mS / cm (e.g., 0.001 mS / cm to 0.05 mS / cm, 0.001 mS / cm to 0.1 mS / cm, 0.001 mS / cm to 1 mS / cm, 0.05 mS / cm to 0.5 mS / cm, 0.05 mS / cm to 5 mS / cm, 0.1 mS / cm to 1 mS / cm, 0.1 mS / cm to 100 mS / cm, 0.5 mS / cm to 2 mS / cm, 1 mS / cm to 5 mS / cm, 1 mS / cm ~10mS / cm, 1mS / cm~100mS / cm, 1mS / cm~500mS / cm, 5mS / cm~25mS / cm, 5mS / cm~150mS / cm, 10mS / cm~100mS / cm, 10mS / cm~250mS / cm, 15mS / cm~150mS / cm, 25mS / cm~100mS / cm, 25mS / cm~200mS / cm, 50mS / cm~150mS / cm, 50mS / cm~250mS / cm, 50mS / cm~500mS / cm, 75mS / cm to 200mS / cm, 75mS / cm to 350mS / cm, 100mS / cm to 250mS / cm, 100mS / cm to 400mS / cm, 100mS / cm to 500mS / cm, 150mS / cm to 450mS / cm, 200mS / cm to 500mS / cm, 300mS / cm to 500mS / cm, for example, about 0.001mS / cm, about 0.01mS / cm, about 0.05mS / cm, about 0.1mS / cm, about 0.5mS / cm, about 1 In some embodiments, the ion exchange polymer has a conductivity of about 100 mS / cm, about 5 mS / cm, about 10 mS / cm, about 15 mS / cm, about 20 mS / cm, about 30 mS / cm, about 40 mS / cm, about 50 mS / cm, about 60 mS / cm, about 70 mS / cm, about 80 mS / cm, about 90 mS / cm, about 100 mS / cm, about 150 mS / cm, about 200 mS / cm, about 250 mS / cm, about 300 mS / cm, about 350 mS / cm, about 400 mS / cm, about 450 mS / cm, or about 500 mS / cm.
[0056] In some embodiments, the temperature of the plurality of cells suspended in the liquid is between 0°C and 50°C (0°C to 5°C, 2°C to 15°C, 3°C to 30°C, 4°C to 10°C, 4°C to 25°C, 5°C to 30°C, 7°C to 35°C, 10°C to 25°C, 10°C to 40°C, 15°C to 50°C, 20°C to 40°C, 25°C to 50°C, or 35°C to 45°C, e.g., about 0°C, about 1°C, about 2°C, about 3°C, about 4°C, about 5°C, about 6°C, about 7°C, about 8°C, about 9°C, about 10°C, about 11°C, about 12°C, 13°C, 14°C, 15°C, 16°C, 17°C, 18°C, 19°C, 20°C, 21°C, 22°C, 23°C, 24°C, 25°C, 26°C, 27°C, 28°C, 29°C, 30°C, 31°C, 32°C, 33°C, 34°C, 35°C, 36°C, 37°C, 38°C, 39°C, 40°C, 41°C, 42°C, 43°C, 44°C, 45°C, 46°C, 47°C, 48°C, 49°C, or 50°C).
[0057] In some embodiments, the method further includes storing the plurality of cells suspended in the liquid in a collection buffer after perforation. In some embodiments, the cells are stored in a collection buffer at a concentration of 0.1% to 99.9% (e.g., 0.1% to 5%, 1% to 10%, 2.5% to 20%, 5% to 40%, 10% to 30%, 10% to 60%, 10% to 90%, 25% to 40%, 25% to 85%, 30% to 50%, 30% to 80%, 40% to 65%, 50% to 75%, 50% to 99.9%, 60% to 80%, 75% to 99.9%, or 85% to 99.9%, e.g., about 0.1%, about 0.15%, about 0.2%, about 0.25%, about 0.3%, about 0.35%, about 0.4%, about 0.5%, about 0.6%, about 0.7%, about 0.8%, about 0.9%, about 10%, about 11%, about 12%, about 13%, about 14%, about 15%, about 16%, about 17%, about 18%, about 19%, about 20%, about 21%, about 22%, about 23%, about 24%, about 25%, about 26%, about 27%, about 28%, about 29%, about 30%, about 31%, about 32%, about 33%, about 34%, about 35%, about 36%, about 37%, about 38%, about 39%, about 40%, about 41%, about 42%, about 43%, about 44%, about 45%, about 46%, about 47%, about 48%, about 49%, about 49%, about 49%, about 45%, about 0.5%, about 0.55%, about 0.6%, about 0.65%, about 0.7%, about 0.75%, about 0.8%, about 0.85%, about 0.9%, about 0.95%, about 1%, about 2%, about 3%, about 4%, about 5%, about 6%, about 7%, about 8%, about 9%, about 10%, about 15%, about 20%, about 25%, about 30%, about 35%, about 40%, about 45%, about 50%, about 55%, about 60%, about 65%, about 70%, about 75%, about 80%, about 85%, about 90%, about 95%, about 99%, or about 99.9%) after introduction of the composition.
[0058] In some embodiments, the composition comprises 0.1% to 99.9% (e.g., 0.1% to 5%, 1% to 10%, 2.5% to 20%, 5% to 40%, 10% to 30%, 10% to 60%, 10% to 90%, 25% to 40%, 25% to 85%, 30% to 50%, 30% to 80%, 40% to 65%, 50% to 75%, 50% to 99.9%, 60% to 80%, 75% to 99.9%, or 85% to 99.9%, e.g., about 0.1%, about 0.15%, about 0.2%, about 0.25%, about 0.3%, about 0.35%, about 0.4%, about 0.5%, about 0.6%, about 0.7%, about 0.8%, about 0.9%, about 10%, about 11%, about 12%, about 13%, about 14%, about 15%, about 16%, about 17%, about 18%, about 19%, about 20%, about 21%, about 22%, about 23%, about 24%, about 25%, about 26%, about 27%, about 28%, about 29%, about 30%, about 31%, about 32%, about 33%, about 34%, about 35%, about 36%, about 37%, about 38%, about 39%, about 40%, about 41%, about 42%, about 43%, about 44%, about 45%, about 46%, about 47%, about 48%, about 49%, about 49%, about 49%, about 49%, about 49%, about 49%, about 49%, about 49%, about 49%, about 49%, about 0.45%, about 0.5%, about 0.55%, about 0.6%, about 0.65%, about 0.7%, about 0.75%, about 0.8%, about 0.85%, about 0.9%, about 0.95%, about 1%, about 2%, about 3%, about 4%, about 5%, about 6%, about 7%, about 8%, about 9%, about 10%, about 15%, about 20%, about 25%, about 30%, about 35%, about 40%, about 45%, about 50%, about 55%, about 60%, about 65%, about 70%, about 75%, about 80%, about 85%, about 90%, about 95%, about 99%, or about 99.9%).
[0059] In some embodiments, any of the methods of the present invention comprises the steps of: 4 cells ~10 12 Cells (e.g., 10 4 cells ~10 5 cells, 10 4 cells ~10 6 cells, 10 4 cells ~10 7 cells, 5 x 10 4 cells ~5×10 5 cells, 10 5 cells ~10 6 cells, 10 5 cells ~10 7 cells, 10 5 cells ~10 10 cells, 2.5 x 10 5 cells ~10 6 cells, 5 x 10 5 cells ~5×10 6 cells, 10 6 cells ~10 7 cells, 10 6 cells ~10 8 cells, 10 6 cells ~10 12cells, 5 x 10 6 cells ~5×10 7 cells, 10 7 cells ~10 8 cells, 10 7 cells ~10 9 cells, 10 7 cells ~10 12 cells, 5 x 10 7 cells ~5×10 8 cells, 10 8 cells ~10 9 cells, 10 8 cells ~10 10 cells, 10 8 cells ~10 12 cells, 5 x 10 8 cells ~5×10 9 cells, 10 9 cells ~10 10 cells, 10 9 cells ~10 11 cells, 10 10 cells ~10 11 cells, 10 10 cells ~10 12 cells, or 10 11 cells ~10 12 Cells, e.g., about 10 4 cells, approximately 2.5 x 10 4 cells, approximately 5 x 10 4 cells, about 10 5 cells, approximately 2.5 x 10 5 cells, approximately 5 x 10 5 cells, about 10 6 cells, approximately 2.5 x 10 6 cells, approximately 5 x 10 6 cells, about 10 7 cells, approximately 2.5 x 10 7 cells, approximately 5 x 10 7 cells, about 10 8 cells, approximately 2.5 x 10 8 cells, approximately 5 x 10 8 cells, about 10 9 cells, approximately 2.5 x 10 9 cells, approximately 5 x 10 9 cells, about 10 10 cells, approximately 5 x 10 10 cells, about 10 11 cells, or about 10 12 Generate a cell harvest count (100 cells).
[0060] In some embodiments, the method comprises the step of: providing a concentration of from 0.1% to 100% (e.g., from 0.1% to 5%, from 1% to 10%, from 2.5% to 20%, from 5% to 40%, from 10% to 30%, from 10% to 60%, from 10% to 90%, from 25% to 40%, from 25% to 85%, from 30% to 50%, from 30% to 80%, from 40% to 65%, from 50% to 75%, from 50% to 100%, from 60% to 80%, from 75% to 100%, from 85% to 100%, e.g., about 0.1%, about 0.15%, about 0.2%, about 0.25%, about 0.3%, about 0.35%, about 0.4%, about In some embodiments, the method produces a cell recovery of about 0.45%, about 0.5%, about 0.55%, about 0.6%, about 0.65%, about 0.7%, about 0.75%, about 0.8%, about 0.85%, about 0.9%, about 0.95%, about 1%, about 2%, about 3%, about 4%, about 5%, about 6%, about 7%, about 8%, about 9%, about 10%, about 15%, about 20%, about 25%, about 30%, about 35%, about 40%, about 45%, about 50%, about 55%, about 60%, about 65%, about 70%, about 75%, about 80%, about 85%, about 90%, about 95%, or about 100%).In some embodiments, the method comprises the steps of: 150%, 90% to 250%, 100% to 200%, 100% to 400%, 150% to 300%, 200% to 500%, or 300% to 500%, for example, about 0.1%, about 0.15%, about 0.2%, about 0.25%, about 0.3%, about 0.35%, about 0.4%, about 0.45%, about 0.5%, about 0.55%, about 0.6%, about 0.65%, about 0.7%, about 0.75%, about 0.8%, about 0.85%, about 0.9%, About 0.95%, about 1%, about 2%, about 3%, about 4%, about 5%, about 6%, about 7%, about 8%, about 9%, about 10%, about 15%, about 20%, about 25%, about 30%, about 35%, about 40%, about 45%, about 50%, about 55%, about 60%, about 65%, about 70%, about 75%, about 80%, about 85%, about 90%, about 95%, about 99%, about 100%, about 150%, about 200%, about 210%, about 220%, about 230%, about 240%, about 250%, about 260%, about 270%, about 280%, about 290%, about 300%, about 310%, about 320%, about 330%, about 340%, about 350%, about 360%, about 370%, about 380%, about 390%, about 400%, about 410%, about 420%, about 430%, about 440%, about 450%, about 460%, about 470%, about 480%, about 490%, or about 500%).
[0061] In some embodiments, the composition comprises at least one compound selected from the group consisting of a therapeutic agent, a vitamin, a nanoparticle, a charged molecule, an uncharged molecule, an engineered nuclease, DNA, RNA, a CRISPR-Cas complex, a transcription activator-like effector nuclease (TALEN), a zinc finger nuclease (ZFN), a homing nuclease, a meganuclease (mn), a megaTAL, an enzyme, a transposon, a peptide, a protein, a virus, a polymer, a ribonucleoprotein (RNP), and a polysaccharide. In some embodiments, the composition comprises a concentration of from 0.0001 μg / mL to 1,000 μg / mL (e.g., from about 0.0001 μg / mL to about 0.001 μg / mL, from about 0.001 μg / mL to about 0.01 μg / mL, from about 0.001 μg / mL to about 5 μg / mL, from about 0.005 μg / mL to about 0.1 μg / mL, from about 0.01 μg / mL to about 0.1 μg / mL, from about 0.01 μg / mL to about 1 μg / mL, from about 0.1 μg / mL to about 1 μg / mL, , about 0.1μg / mL to about 5μg / mL, about 1μg / mL to about 10μg / mL, about 1μg / mL to about 50μg / mL, about 1μg / mL to about 100μg / mL, about 2.5μg / mL to about 15μg / mL, about 5μg / mL mL ~ approx. 25 μg / mL, approx. 5 μg / mL ~ approx. 50 μg / mL, approx. 5 μg / mL ~ approx. 500 μg / mL, approx. 7.5 μg / mL ~ approx. 75 μg / mL, approx. 10 μg / mL ~ approx. 100 μg / mL, approx. 10 μg / mL ~ approx. 1 ,000μg / mL, about 25μg / mL to about 50μg / mL, about 25μg / mL to about 250μg / mL, about 25μg / mL to about 500μg / mL, about 50μg / mL to about 100μg / mL, about 50μg / mL to about 250μg / mL, approximately 50μg / mL to approximately 750μg / mL, approximately 100μg / mL to approximately 300μg / mL, approximately 100μg / mL to approximately 1,000μg / mL, approximately 200μg / mL to approximately 400μg / mL, approximately 250μg / mL to about 500 μg / mL, about 350 μg / mL to about 500 μg / mL, about 400 μg / mL to about 1,000 μg / mL, about 500 μg / mL to about 750 μg / mL, about 650 μg / mL to about 1,000 μg / mL, or about 800 μg / mL to about 1,000 μg / mL, for example, about 0.0001 μg / mL, about 0.0005 μg / mL, about 0.001 μg / mL, about 0.005 μg / mL, about 0.01 μg / mL, about 0.02μg / mL, approximately 0.03μg / mL, approximately 0.04μg / mL, approximately 0.05μg / mL, approximately 0.06μg / mL, approximately 0.07μg / mL, approximately 0.08μg / mL, approximately 0.09μg / mL, approximately 0 .1μg / mL, approximately 0.2μg / mL, approximately 0.3μg / mL, approximately 0.4μg / mL, approximately 0.5μg / mL, approximately 0.6μg / mL, approximately 0.7μg / mL, approximately 0.8μg / mL, approximately 0.9μg / mL , about 1μg / mL, about 1.5μg / mL, about 2μg / mL, about 2.5μg / mL, about 3μg / mL, about 3.5μg / mL, about 4μg / mL, about 4.5μg / mL, about 5μg / mL, about 5.5μg / mL, approximately 6μg / mL, approximately 6.5μg / mL, approximately 7μg / mL, approximately 7.5μg / mL, approximately 8μg / mL, approximately 8.5μg / mL, approximately 9μg / mL, approximately 9.5μg / mL, approximately 10μg / mL, approximately 1 5μg / mL, approximately 20μg / mL, approximately 25μg / mL, approximately 30μg / mL, approximately 35μg / mL, approximately 40μg / mL, approximately 45μg / mL, approximately 50μg / mL, approximately 55μg / mL, approximately 60μg / mL , about 65μg / mL, about 70μg / mL, about 75μg / mL, about 80μg / mL, about 85μg / mL, about 90μg / mL, about 95μg / mL, about 100μg / mL, about 200μg / mL, about 25 The compound has a concentration in the liquid of about 0 μg / mL, about 300 μg / mL, about 350 μg / mL, about 400 μg / mL, about 450 μg / mL, about 500 μg / mL, about 550 μg / mL, about 600 μg / mL, about 650 μg / mL, about 700 μg / mL, about 750 μg / mL, about 800 μg / mL, about 850 μg / mL, about 900 μg / mL, about 950 μg / mL, or about 1,000 μg / mL.
[0062] In some embodiments, the plurality of cells suspended in the liquid comprises eukaryotic cells (e.g., animal cells, e.g., human cells), prokaryotic cells (e.g., bacterial cells), plant cells, and / or synthetic cells. The cells can be primary cells (e.g., primary human cells), cells from a cell line (e.g., a human cell line), cells in suspension, adherent cells, stem cells, blood cells (e.g., peripheral blood mononuclear cells (PBMCs)), and / or immune cells (e.g., leukocytes (e.g., innate immune cells or adaptive immune cells). In some embodiments, the cells (e.g., immune cells, e.g., T cells, B cells, natural killer cells, macrophages, monocytes, or antigen presenting cells) are unstimulated cells, stimulated cells, or activated cells. In some embodiments, the cells are adaptive immune cells and / or innate immune cells. In some embodiments, the plurality of cells are antigen presenting cells (APCs). The cells include primary human T cells, primary human macrophages, primary human monocytes, primary human NK cells, primary human monocytes, primary human NK cells, primary human induced pluripotent stem cells (iPSCs), ...
[0063] In another aspect, the invention provides a kit comprising any of the devices or systems described herein. For example, in one aspect, the invention provides a kit for electroporating a plurality of cells suspended in a liquid, the kit comprising a plurality of cell poration devices, each of the plurality of cell poration devices comprising a first electrode comprising a first outlet, a first inlet, and a first lumen comprising a minimum cross-sectional dimension, a second electrode comprising a second outlet, a second inlet, and a second lumen comprising a minimum cross-sectional dimension, and an electroporation zone disposed between the first outlet and the second inlet, the electroporation zone being greater than about 100 μm (e.g., 100 μm to 10 mm, 150 μm to 15 mm, 200 μm to 10 mm, 250 μm to 5 mm, 500 μm to 10 mm, 1 mm to 10 mm, 1 mm to 50 mm, 5 mm to 25 mm, or 20 mm to 50 mm, e.g., about 0.5 mm, about 1 and an electroporation zone having a minimum cross-sectional dimension of about 0.0 mm, about 1.5 mm, about 2 mm, about 5 mm, about 7 mm, about 10 mm, about 15 mm, about 25 mm, or about 50 mm, the electroporation zone having a substantially uniform cross-sectional area, and application of a potential difference to the first electrode and the second electrode generating an electric field within the electroporation zone; and a plurality of outer structures configured to enclose the plurality of cell perforation devices, each of the plurality of outer structures including a housing configured to enclose at least one of the first electrode, the second electrode, and the electroporation zone of the cell perforation device, a first electrical input operably coupled to the first electrode, and a second electrical input operably coupled to the second electrode. In some embodiments, the plurality of outer structures are integral to the plurality of cell perforation devices. In some embodiments, the plurality of outer structures are releasably connected to the plurality of cell perforation devices. In some embodiments, the housing further includes a thermal controller configured to increase the temperature of the at least one cell poration device, the thermal controller being a heating element selected from the group consisting of a heating block, a liquid flow, a battery-powered heater, and a thin film heater.In some embodiments, the housing further includes a thermal controller configured to reduce the temperature of the at least one cell perforation device, the thermal controller being a cooling element selected from the group consisting of a liquid flow, an evaporative cooler, and a Peltier device.
[0064] In another aspect, the present invention provides a kit for electroporating a plurality of cells suspended in a liquid, the kit comprising: a plurality of cell perforation devices, each of the plurality of cell perforation devices comprising the device of the above-mentioned embodiment; and a plurality of outer structures configured to enclose the plurality of cell perforation devices, each of the plurality of outer structures comprising a housing configured to enclose a first electrode, a second electrode, and an electroporation zone of at least one cell perforation device, a first electrical input operably coupled to the first electrode, and a second electrical input operably coupled to the second electrode. In some embodiments, the plurality of outer structures are integrated into the plurality of cell perforation devices. In some embodiments, the plurality of outer structures are releasably connected to the plurality of cell perforation devices. In some embodiments, the housing further comprises a thermal controller configured to increase the temperature of at least one cell perforation device, the thermal controller being a heating element selected from the group consisting of a heating block, a liquid flow, a battery-powered heater, and a thin film heater. In some embodiments, the housing further includes a thermal controller configured to reduce the temperature of the at least one cell perforation device, the thermal controller being a cooling element selected from the group consisting of a liquid flow, an evaporative cooler, and a Peltier device.
[0065] In another aspect, the invention provides a device for electroporating a plurality of cells suspended in a fluid, the device comprising: a first electrode having a first inlet and a first outlet, the lumen of the first electrode defining an entry zone, a second electrode having a second inlet and a second outlet, the lumen of the second electrode defining a withdrawal zone, and an electroporation zone, the electroporation zone fluidly connected to the first outlet of the first electrode and the second inlet of the second electrode, the electroporation zone having a substantially uniform cross-sectional dimension, and application of a potential difference to the first electrode and the second electrode generating an electric field within the electroporation zone, in which the plurality of cells suspended in the fluid are electroporated upon entering the electroporation zone.
[0066] In some embodiments, the device further includes one or more reservoirs, such as a first reservoir and a second reservoir, fluidly connected to a zone of the device, such as an entry zone or a recovery zone. For example, the first reservoir can be fluidly connected to the entry zone and the second reservoir can be fluidly connected to the recovery zone.
[0067] In certain embodiments, the cross-section of the electroporation zone is selected from the group consisting of a cylinder, an ellipse, a polygon, a star, a parallelogram, a trapezoid, and irregular.
[0068] In some cases, the cross-sectional dimension of the entry zone or the cross-sectional dimension of the recovery zone is between 0.01% and 100,000% of the cross-sectional dimension of the electroporation zone. For example, the cross-sectional dimension of the entry zone or the cross-sectional dimension of the recovery zone can be between about 0.01% and about 1000% of the cross-sectional dimension of the electroporation zone, such as between about 0.01% and about 1%, between about 0.1% and about 10%, between about 5% and about 25%, between about 10% and about 50%, between about 10% and about 1000%, between about 25% and about 75%, between about 25% and about 750%, or between about 50% and about 1000% of the cross-sectional dimension of the electroporation zone. Alternatively, the cross-sectional dimension of the entry zone or the cross-sectional dimension of the recovery zone can be about 100% to about 100,000% of the cross-sectional dimension of the electroporation zone, e.g., about 100% to about 1000%, about 500% to about 5,000%, about 1,000% to about 10,000%, about 5,000% to about 25,000%, about 10,000% to about 50,000%, about 25,000% to about 75,000%, or about 50,000% to about 100,000% of the cross-sectional dimension of the electroporation zone.
[0069] In some embodiments, the cross-sectional dimension of the electroporation zone is between 0.005 mm and 50 mm. In some embodiments, the length of the electroporation zone is between 0.005 mm and 50 mm. In certain embodiments, the length of the electroporation zone is between 0.005 mm and 25 mm. In some embodiments, the cross-sectional dimension of either the first electrode or the second electrode is between 0.1 mm and 500 mm. In certain embodiments, none of the entry zone, recovery zone, or electroporation zone reduces the cross-sectional dimension of any of the plurality of cells suspended in the fluid, e.g., cells can pass through the device without deformation.
[0070] In some embodiments, upon exiting the electroporation zone, the phenotype of the plurality of cells changes by between 0% and about 25% relative to a baseline measurement of the cell phenotype, In some embodiments, upon exiting the electroporation zone, the phenotype of the plurality of cells does not change.
[0071] In further embodiments, the device includes an outer structure having a housing configured to enclose the first electrode, the second electrode, and the electroporation zone of the device. In some embodiments, the outer structure is integral to the device. In certain embodiments, the outer structure is releasably connected to the device.
[0072] In another aspect, the invention provides a device for electroporating a plurality of cells suspended in a fluid, the device comprising: a first electrode having a first inlet and a first outlet, the lumen of the first electrode defining an entry zone; a second electrode having a second inlet and a second outlet, the lumen of the second electrode defining a recovery zone; and a third inlet and a third outlet, the third inlet and the third outlet intersecting the first electrode between the first inlet and the second outlet. a third inlet and a third outlet, a fourth inlet and a fourth outlet, the fourth inlet and the fourth outlet intersecting the second electrode between the second inlet and the second outlet, and an electroporation zone, the electroporation zone fluidly connected to the first outlet of the first electrode and the second inlet of the second electrode, the electroporation zone having a substantially uniform cross-sectional dimension, and application of a potential difference to the first electrode and the second electrode generating an electric field within the electroporation zone, in which a plurality of cells suspended in a fluid are electroporated upon entering the electroporation zone.
[0073] In some embodiments, the device further includes one or more reservoirs, such as a first reservoir and a second reservoir, fluidly connected to a zone of the device, such as an entry zone or a recovery zone. For example, the first reservoir can be fluidly connected to the entry zone and the second reservoir can be fluidly connected to the recovery zone. In certain embodiments, the device includes a third reservoir fluidly connected to a third inlet and a third outlet, and a fourth reservoir fluidly connected to a fourth inlet and a fourth outlet.
[0074] In certain embodiments, the cross-section of the electroporation zone is selected from the group consisting of a cylinder, an ellipse, a polygon, a star, a parallelogram, a trapezoid, and irregular.
[0075] In some cases, the cross-sectional dimension of the entry zone or the cross-sectional dimension of the recovery zone is between 0.01% and 100,000% of the cross-sectional dimension of the electroporation zone. For example, the cross-sectional dimension of the entry zone or the cross-sectional dimension of the recovery zone can be between about 0.01% and about 1,000% of the cross-sectional dimension of the electroporation zone, such as between about 0.01% and about 1%, between about 0.1% and about 10%, between about 5% and about 25%, between about 10% and about 50%, between about 10% and about 1,000%, between about 25% and about 75%, between about 25% and about 750%, or between about 50% and about 100% of the cross-sectional dimension of the electroporation zone. Alternatively, the cross-sectional dimension of the entry zone or the cross-sectional dimension of the recovery zone can be about 100% to about 100,000% of the cross-sectional dimension of the electroporation zone, e.g., about 100% to about 1000%, about 500% to about 5,000%, about 1,000% to about 10,000%, about 5,000% to about 25,000%, about 10,000% to about 50,000%, about 25,000% to about 75,000%, or about 50,000% to about 100,000% of the cross-sectional dimension of the electroporation zone.
[0076] In some embodiments, the cross-sectional dimension of the electroporation zone is between 0.005 mm and 50 mm. In some embodiments, the length of the electroporation zone is between 0.005 mm and 50 mm. In certain embodiments, the length of the electroporation zone is between 0.005 mm and 25 mm. In some embodiments, the cross-sectional dimension of either the first electrode or the second electrode is between 0.1 mm and 500 mm. In certain embodiments, none of the entry zone, recovery zone, or electroporation zone reduces the cross-sectional dimension of any of the plurality of cells suspended in the fluid, e.g., cells can pass through the device without deformation.
[0077] In certain embodiments, the first electrode and / or the second electrode are porous or are a conductive fluid (eg, liquid).
[0078] In some embodiments, upon exiting the electroporation zone, the phenotype of the plurality of cells changes by between 0% and about 25% relative to a baseline measurement of the cell phenotype, In some embodiments, upon exiting the electroporation zone, the phenotype of the plurality of cells does not change.
[0079] In further embodiments, the device includes an outer structure having a housing configured to enclose the first electrode, the second electrode, and the electroporation zone of the device. In some embodiments, the outer structure is integral to the device. In certain embodiments, the outer structure is releasably connected to the device.
[0080] In another aspect, the present invention provides a system for electroporating a plurality of cells suspended in a fluid, the system comprising a cell poration device including a first electrode having a first inlet and a first outlet, the lumen of the first electrode defining an entry zone, a second electrode having a second inlet and a second outlet, the lumen of the second electrode defining a recovery zone, and an electroporation zone, the electroporation zone being fluidly connected to the first outlet of the first electrode and the second inlet of the second electrode, the electroporation zone having a substantially uniform cross-sectional dimension, and application of a potential difference to the first electrode and the second electrode generating an electric field in the electroporation zone. The system further includes a potential source, the first electrode and the second electrode of the device being releasably connected to the potential source. In the system, the plurality of cells suspended in a fluid are electroporated upon entering the electroporation zone.
[0081] In some embodiments, upon exiting the electroporation zone, the phenotype of the plurality of cells changes by between 0% and about 25% relative to a baseline measurement of the cell phenotype, in some embodiments, upon exiting the electroporation zone, the phenotype of the plurality of cells does not change.
[0082] In further embodiments, the device includes an outer structure having a housing configured to enclose the first electrode, the second electrode, and the electroporation zone of the device. In some embodiments, the outer structure includes a first electrical input operably coupled to the first electrode and a second electrical input operably coupled to the second electrode. In some embodiments, the releasable connection between the first electrical input or the second electrical input and the source of electrical potential is selected from the group consisting of a clamp, a clip, a spring, a sheath, a wire brush, a mechanical connection, an inductive connection, or a combination thereof.
[0083] In some embodiments, the outer structure is integral to the device, hi certain embodiments, the outer structure is releasably connected to the device.
[0084] In some cases, the system induces reversible or irreversible electroporation. In certain embodiments, the electroporation is substantially non-thermally reversible electroporation, substantially non-thermally irreversible electroporation, or substantially thermally irreversible electroporation.
[0085] In some embodiments, the releasable connection between the device and the source of electrical potential is selected from the group consisting of a clamp, a clip, a spring, a sheath, a wire brush, a mechanical connection, an inductive connection, or combinations thereof, hi certain embodiments, the releasable connection between the device and the source of electrical potential is a spring.
[0086] In some embodiments, the device further includes one or more reservoirs, such as a first reservoir and a second reservoir, fluidly connected to a zone of the device, such as an entry zone or a recovery zone. For example, the first reservoir can be fluidly connected to the entry zone and the second reservoir can be fluidly connected to the recovery zone.
[0087] In certain embodiments, the cross-section of the electroporation zone is selected from the group consisting of a cylinder, an ellipse, a polygon, a star, a parallelogram, a trapezoid, and irregular.
[0088] In some cases, the cross-sectional dimension of the entry zone or the cross-sectional dimension of the recovery zone is between 0.01% and 100,000% of the cross-sectional dimension of the electroporation zone. For example, the cross-sectional dimension of the entry zone or the cross-sectional dimension of the recovery zone can be between about 0.01% and about 1000% of the cross-sectional dimension of the electroporation zone, such as between about 0.01% and about 1%, between about 0.1% and about 10%, between about 5% and about 25%, between about 10% and about 50%, between about 10% and about 1,000%, between about 25% and about 75%, between about 25% and about 750%, or between about 50% and about 100% of the cross-sectional dimension of the electroporation zone. Alternatively, the cross-sectional dimension of the entry zone or the cross-sectional dimension of the recovery zone can be about 100% to about 100,000% of the cross-sectional dimension of the electroporation zone, e.g., about 100% to about 1000%, about 500% to about 5,000%, about 1,000% to about 10,000%, about 5,000% to about 25,000%, about 10,000% to about 50,000%, about 25,000% to about 75,000%, or about 50,000% to about 100,000% of the cross-sectional dimension of the electroporation zone.
[0089] In some embodiments, the cross-sectional dimension of the electroporation zone is between 0.005 mm and 50 mm. In some embodiments, the length of the electroporation zone is between 0.005 mm and 50 mm. In certain embodiments, the length of the electroporation zone is between 0.005 mm and 25 mm. In some embodiments, the cross-sectional dimension of either the first electrode or the second electrode is between 0.1 mm and 500 mm. In certain embodiments, none of the entry zone, recovery zone, or electroporation zone reduces the cross-sectional dimension of any of the plurality of cells suspended in the fluid, e.g., cells can pass through the device without deformation.
[0090] In further embodiments, the system includes a fluid delivery source fluidly connected to the entry zone, the fluid delivery source configured to deliver a plurality of cells suspended in the fluid through the entry zone to the collection zone. In some embodiments, the delivery rate from the fluid delivery source is between 0.001 mL / min and 1,000 mL / min, e.g., 25 mL / min. In certain embodiments, the residence time of any of the plurality of cells suspended in the fluid is between 0.5 ms and 50 ms. In some embodiments, the conductivity of the fluid is between 0.001 mS / cm and 500 mS / cm, e.g., between 1 and 20 mS / cm.
[0091] In further embodiments, the system includes a controller operably coupled to the potential source to deliver a voltage pulse to the first electrode and the second electrode to generate a potential difference between the first electrode and the second electrode. In some embodiments, the voltage pulse has an amplitude of -3 kV to 3 kV, e.g., 0.01 kV to 3 kV, e.g., 0.2 to 0.6 kV. In some cases, the duty cycle of the electroporation is 0.001% to 100%, e.g., 10 to 95%. In some embodiments, the voltage pulse has a duration of 0.01 ms to 1,000 ms, e.g., 1 to 10 ms. In certain embodiments, the voltage pulse is applied to the first electrode and the second electrode at a frequency of 1 Hz to 50,000 Hz, e.g., 100 to 500 Hz. The waveform of the voltage pulse can be DC, square, pulse, bipolar, sinusoidal, ramp, asymmetric bipolar, any, and any superposition or combination thereof. In certain embodiments, the electric field resulting from the voltage pulse has a magnitude between 1 V / cm and 50,000 V / cm, for example between 100 and 1,000 V / cm.
[0092] In further embodiments, the system includes a housing (e.g., a housing structure) configured to accommodate the electroporation device described herein. In further instances, the housing (e.g., a housing structure) includes a thermal controller configured to increase or decrease the temperature of the housing or any component of the system. In some embodiments, the thermal controller is a heating element, such as a heating block, liquid flow, a battery-powered heater, or a thin film heater. In other embodiments, the thermal controller is a cooling element, such as a liquid flow, an evaporative cooler, or a thermoelectric, such as a Peltier device.
[0093] In further embodiments, the system includes multiple cell perforation devices, for example in series or in parallel. In certain embodiments, the system includes multiple outer structures for multiple cell perforation devices.
[0094] In a related aspect, the invention provides a system for electroporating a plurality of cells suspended in a fluid, the system comprising: a first electrode having a first inlet and a first outlet, the lumen of the first electrode defining an entry zone; a second electrode having a second inlet and a second outlet, the lumen of the second electrode defining a recovery zone; and a third inlet and a third outlet, the third inlet and the third outlet intersecting the first electrode between the first inlet and the second outlet. and a cell poration device including an inlet and a third outlet, a fourth inlet and a fourth outlet, the fourth inlet and the fourth outlet intersecting the second electrode between the second inlet and the second outlet, and an electroporation zone, the electroporation zone fluidly connected to the first outlet of the first electrode and the second inlet of the second electrode, the electroporation zone having a substantially uniform cross-sectional dimension, and application of a potential difference to the first electrode and the second electrode generating an electric field within the electroporation zone, in which a plurality of cells suspended in a fluid are electroporated upon entering the electroporation zone.
[0095] In some embodiments, upon exiting the electroporation zone, the phenotype of the plurality of cells changes by between 0% and about 25% relative to a baseline measurement of the cell phenotype, In some embodiments, upon exiting the electroporation zone, the phenotype of the plurality of cells does not change.
[0096] In further embodiments, the device includes an outer structure having a housing (e.g., a housing structure) configured to enclose the first electrode, the second electrode, and the electroporation zone of the device. In some embodiments, the outer structure includes a first electrical input operably coupled to the first electrode and a second electrical input operably coupled to the second electrode. In some embodiments, the releasable connection between the first electrical input or the second electrical input and the source of electrical potential is selected from the group consisting of a clamp, a clip, a spring, a sheath, a wire brush, a mechanical connection, an inductive connection, or a combination thereof.
[0097] In some embodiments, the outer structure is integral to the device, hi certain embodiments, the outer structure is releasably connected to the device.
[0098] In some cases, the system induces reversible or irreversible electroporation. In certain embodiments, the electroporation is substantially non-thermally reversible electroporation, substantially non-thermally irreversible electroporation, or substantially thermally irreversible electroporation.
[0099] In some embodiments, the releasable connection between the device and the source of electrical potential is selected from the group consisting of a clamp, a clip, a spring, a sheath, a wire brush, a mechanical connection, an inductive connection, or combinations thereof, hi certain embodiments, the releasable connection between the device and the source of electrical potential is a spring.
[0100] In some embodiments, the device further comprises one or more reservoirs, e.g., a first reservoir and a second reservoir, fluidly connected to a zone of the device, e.g., an entry zone or a recovery zone. For example, the first reservoir can be fluidly connected to the entry zone and the second reservoir can be fluidly connected to the recovery zone.
[0101] In certain embodiments, the cross-section of the electroporation zone is selected from the group consisting of a cylinder, an ellipse, a polygon, a star, a parallelogram, a trapezoid, and irregular.
[0102] In some cases, the cross-sectional dimension of the entry zone or the cross-sectional dimension of the recovery zone is between 0.01% and 100,000% of the cross-sectional dimension of the electroporation zone. For example, the cross-sectional dimension of the entry zone or the cross-sectional dimension of the recovery zone can be between about 0.01% and about 1000% of the cross-sectional dimension of the electroporation zone, such as between about 0.01% and about 1%, between about 0.1% and about 10%, between about 5% and about 25%, between about 10% and about 50%, between about 10% and about 1,000%, between about 25% and about 75%, between about 25% and about 750%, or between about 50% and about 100% of the cross-sectional dimension of the electroporation zone. Alternatively, the cross-sectional dimension of the entry zone or the cross-sectional dimension of the recovery zone can be about 100% to about 100,000% of the cross-sectional dimension of the electroporation zone, e.g., about 100% to about 1000%, about 500% to about 5,000%, about 1,000% to about 10,000%, about 5,000% to about 25,000%, about 10,000% to about 50,000%, about 25,000% to about 75,000%, or about 50,000% to about 100,000% of the cross-sectional dimension of the electroporation zone.
[0103] In some embodiments, the cross-sectional dimension of the electroporation zone is between 0.005 mm and 50 mm. In some embodiments, the length of the electroporation zone is between 0.005 mm and 50 mm. In certain embodiments, the length of the electroporation zone is between 0.005 mm and 25 mm. In some embodiments, the cross-sectional dimension of either the first electrode or the second electrode is between 0.01 mm and 500 mm. In certain embodiments, none of the entry zone, recovery zone, or electroporation zone reduces the cross-sectional dimension of any of the plurality of cells suspended in the fluid, e.g., cells can pass through the device without deformation.
[0104] In further embodiments, the system includes a fluid delivery source fluidly connected to the entry zone, the fluid delivery source configured to deliver a plurality of cells suspended in the fluid through the entry zone to the collection zone. In some embodiments, the delivery rate from the fluid delivery source is between 0.001 mL / min and 1,000 mL / min, e.g., 25 mL / min. In certain embodiments, the residence time of any of the plurality of cells suspended in the fluid is between 0.5 ms and 50 ms. In some embodiments, the conductivity of the fluid is between 0.001 mS / cm and 500 mS / cm, e.g., between 1 mS / cm and 20 mS / cm.
[0105] In further embodiments, the system includes a controller operably coupled to the potential source to deliver a voltage pulse to the first electrode and the second electrode to generate a potential difference between the first electrode and the second electrode. In some embodiments, the voltage pulse has an amplitude of -3 kV to 3 kV, e.g., 0.01 kV to 3 kV, e.g., 0.2 to 0.6 kV. In some cases, the duty cycle of the electroporation is 0.001% to 100%, e.g., 10 to 95%. In some embodiments, the voltage pulse has a duration of 0.01 ms to 1,000 ms, e.g., 1 to 10 ms. In certain embodiments, the voltage pulse is applied to the first electrode and the second electrode at a frequency of 1 Hz to 50,000 Hz, e.g., 100 to 500 Hz. The waveform of the voltage pulse can be DC, square, pulse, bipolar, sinusoidal, ramp, asymmetric bipolar, any, and any superposition or combination thereof. In certain embodiments, the electric field generated from the voltage pulse has a magnitude between 1 V / cm and 50,000 V / cm, for example between 100 V / cm and 1,000 V / cm.
[0106] In further embodiments, the system includes a housing (e.g., a housing structure) configured to accommodate the electroporation device described herein. In further instances, the housing structure includes a thermal controller configured to increase or decrease the temperature of the housing or any component of the system. In some embodiments, the thermal controller is a heating element, such as a heating block, liquid flow, a battery-powered heater, or a thin film heater. In other embodiments, the thermal controller is a cooling element, such as a liquid flow, an evaporative cooler, or a thermoelectric, such as a Peltier device.
[0107] In further embodiments, the system includes multiple cell perforation devices, for example in series or in parallel. In certain embodiments, the system includes multiple outer structures for multiple cell perforation devices.
[0108] In another aspect, the invention provides a method of introducing a composition into at least a portion of a plurality of cells suspended in a fluid, the method comprising the steps of: a. providing a device, the device including a first electrode having a first inlet and a first outlet, the lumen of the first electrode defining an entry zone; a second electrode having a second inlet and a second outlet, the lumen of the second electrode defining a withdrawal zone; and an electroporation zone, the electroporation zone fluidly connected to the first outlet of the first electrode and the second inlet of the second electrode, wherein application of a potential difference to the first electrode and the second electrode creates an electric field in the electroporation zone; b. generating an electric field in the electroporation zone by energizing the first electrode and the second electrode to generate a potential difference between the first electrode and the second electrode; and c. passing the plurality of cells suspended in the fluid with the composition through the electric field in the electroporation zone of the device. In the method, flow of a plurality of cells suspended in a fluid, along with a composition, through an electric field in an electroporation zone introduces the composition into at least a portion of the plurality of cells by increasing the temporary permeability of the plurality of cells.
[0109] In further embodiments, the method includes assessing the health of a portion of the plurality of cells suspended in the fluid. In certain embodiments, the assessing includes measuring the viability of the portion of the plurality of cells suspended in the fluid. In some embodiments, the assessing includes measuring the transfection efficiency of the portion of the plurality of cells suspended in the fluid. In some embodiments, the assessing includes measuring the cell recovery of the portion of the plurality of cells suspended in the fluid. In certain embodiments, the assessing includes flow cytometry analysis of cell surface marker expression.
[0110] In some cases, upon exiting the electroporation zone of the device, the phenotype of the plurality of cells changes by between 0% and about 25% relative to a baseline measurement of the cell phenotype. In some cases, upon exiting the electroporation zone of the device, the phenotype of the plurality of cells does not change.
[0111] In some cases, the method induces reversible or irreversible electroporation. In certain embodiments, the electroporation is substantially non-thermally reversible electroporation, substantially non-thermally irreversible electroporation, or substantially thermally irreversible electroporation.
[0112] In some embodiments, cells suspended in a fluid with a composition are passed through an electric field in the electroporation zone of the device by applying positive pressure, for example, a pump, for example a syringe pump or a peristaltic pump.
[0113] In certain embodiments, the cells of the plurality of cells in the sample can be mammalian cells, eukaryotic organisms, human cells, animal cells, plant cells, synthetic cells, primary cells, cell lines, suspension cells, adherent cells, unstimulated cells, stimulated cells, activated cells, immune cells, stem cells, blood cells, red blood cells, T cells, B cells, neutrophils, dendritic cells, antigen presenting cells (APCs), natural killer (NK) cells, monocytes, macrophages, or peripheral blood mononuclear cells (PBMCs), human embryonic kidney cells, such as HEK-293 cells, or Chinese hamster ovary (CHO) cells. In certain embodiments, the plurality of cells comprises Jurkat cells. In certain embodiments, the plurality of cells comprises primary human T cells. In certain embodiments, the plurality of cells comprises THP-1 cells. In certain embodiments, the plurality of cells comprises primary human macrophages. In certain embodiments, the plurality of cells comprises primary human monocytes. In certain embodiments, the plurality of cells comprises natural killer (NK) cells. In certain embodiments, the plurality of cells comprises Chinese hamster ovary cells. In certain embodiments, the plurality of cells comprises human embryonic kidney cells. In certain embodiments, the plurality of cells comprises B cells. In certain embodiments, the plurality of cells comprises primary human T cells. In certain embodiments, the plurality of cells comprises primary human monocytes. In certain embodiments, the plurality of cells comprises primary human macrophages. In certain embodiments, the plurality of cells comprises embryonic stem cells (ESCs), mesenchymal stem cells (MSCs), or hematopoietic stem cells (HSCs). In certain embodiments, the plurality of cells comprises primary human induced pluripotent stem cells (iPSCs).
[0114] In some cases, the composition comprises at least one compound selected from the group consisting of a therapeutic agent, a vitamin, a nanoparticle, a charged therapeutic agent, a nanoparticle, a charged molecule, e.g., an ion in solution, an uncharged molecule, a nucleic acid, e.g., DNA or RNA, a CRISPR-Cas complex, a protein, a polymer, a ribonucleoprotein (RNP), an engineered nuclease, a transcription activator-like effector nuclease (TALEN), a zinc finger nuclease (ZFN), a homing nuclease, a meganuclease (MN), a megaTAL, an enzyme, a peptide, a transposon, or a polysaccharide, e.g., a dextran, e.g., dextran sulfate. Compositions that can be delivered to cells in suspension include nucleic acids (e.g., oligonucleotides, mRNA, or DNA), antibodies (or antibody fragments, e.g., bispecific fragments, trispecific fragments, Fab, F(ab')2, or single chain variable fragments (scFv)), amino acids, polypeptides (e.g., peptides or proteins), cells, bacteria, gene therapy drugs, genomically engineered therapeutic drugs, epigenetically engineered therapeutic drugs, carbohydrates, chemical drugs, contrast agents, magnetic particles, polymeric beads, metal nanoparticles, metal microparticles, quantum dots, antioxidants, antibiotics, hormones, nucleoproteins, polysaccharides, glycoproteins, lipoproteins, steroids, analgesics, local anesthetics, anti-inflammatory agents, antimicrobial agents, chemotherapeutic agents, exosomes, outer membrane vesicles, vaccines, viruses, bacteriophages, adjuvants, vitamins, minerals, organelles, and combinations thereof. In certain embodiments, the composition is a nucleic acid (e.g., oligonucleotides, mRNA, or DNA). In certain embodiments, the composition is an antibody. In certain embodiments, the composition is a polypeptide (e.g., a peptide or protein).
[0115] In certain embodiments, the composition comprises a concentration of from 0.0001 μg / mL to 1,000 μg / mL (e.g., from about 0.0001 μg / mL to about 0.001 μg / mL, from about 0.001 μg / mL to about 0.01 μg / mL, from about 0.001 μg / mL to about 5 μg / mL, from about 0.005 μg / mL to about 0.1 μg / mL, from about 0.01 μg / mL to about 0.1 μg / mL, from about 0.01 μg / mL to about 1 μg / mL, from about 0.1 μg / mL to about 1 μg / mL, from about 0.1 μg / mL to about 5 μg / mL, from about 1 μg / mL to about 10 μg / mL, from about 1 μg / mL to about 50 μg / mL, from about 1 μg / mL to about 50 μg / mL, / mL~about 100μg / mL, about 2.5μg / mL~about 15μg / mL, about 5μg / mL~about 25μg / mL, about 5μg / mL~about 50μg / mL, about 5μg / mL~about 500μg / mL, about 7.5μg / mL~about 75μg / mL, about 10μg / mL~about 100μg / mL, Approximately 10μg / mL to approximately 1,000μg / mL, approximately 25μg / mL to approximately 50μg / mL, approximately 25μg / mL to approximately 250μg / mL, approximately 25μg / mL to approximately 500μg / mL, approximately 50μg / mL to approximately 100μg / mL, approximately 50μg / mL to approximately 250μg / mL, approximately 50μg / mL about 0.0001 μg / mL, about 0.0005 μg / mL, about 0. ... .005μg / mL, approximately 0.01μg / mL, approximately 0.02μg / mL, approximately 0.03μg / mL, approximately 0.04μg / mL, approximately 0.05μg / mL, approximately 0.06μg / mL, approximately 0.07μg / mL, approximately 0.08μg / mL, approximately 0.09μg / mL, approximately 0.1μg / mL, approximately 0.2 μg / mL, approximately 0.3 μg / mL, approximately 0.4 μg / mL, approximately 0.5 μg / mL, approximately 0.6 μg / mL, approximately 0.7 μg / mL, approximately 0.8 μg / mL, approximately 0.9 μg / mL, approximately 1 μg / mL, approximately 1.5 μg / mL, approximately 2 μg / mL, approximately 2.5 μg / mL, approximately 3 μg / mL, approximately 3.5μg / mL, approximately 4μg / mL, approximately 4.5μg / mL, approximately 5μg / mL, approximately 5.5μg / mL, approximately 6μg / mL, approximately 6.5μg / mL, approximately 7μg / mL, approximately 7.5μg / mL, approximately 8μg / mL, approximately 8.5μg / mL, approximately 9μg / mL, approximately 9.5μg / mL, approximately 10 μg / mL, approximately 15 μg / mL, approximately 20 μg / mL, approximately 25 μg / mL, approximately 30 μg / mL, approximately 35 μg / mL, approximately 40 μg / mL, approximately 45 μg / mL, approximately 50 μg / mL, approximately 55 μg / mL, approximately 60 μg / mL, approximately 65 μg / mL, approximately 70 μg / mL, approximately 75 μg / mL, about 80 μg / mL, about 85 μg / mL, about 90 μg / mL, about 95 μg / mL, about 100 μg / mL, about 200 μg / mL, about 250 μg / mL, about 300 μg / mL, about 350 μg / mL, about 400 μg / mL, about 450 μg / mL, about 500 μg / mL, about 550 μg / mL, about 600 μg / mL, about 650 μg / mL, about 700 μg / mL, about 750 μg / mL, about 800 μg / mL, about 850 μg / mL, about 900 μg / mL, about 950 μg / mL, or about 1,000 μg / mL).
[0116] In some embodiments, the device further comprises one or more reservoirs, e.g., a first reservoir and a second reservoir, fluidly connected to a zone of the device, e.g., an entry zone or a recovery zone. For example, the first reservoir can be fluidly connected to the entry zone and the second reservoir can be fluidly connected to the recovery zone.
[0117] In some embodiments, the electroporation zone of the device has a uniform cross-sectional dimension. In other embodiments, the electroporation zone of the device has a non-uniform cross-sectional dimension. In further embodiments, the device further comprises a plurality of electroporation zones, each of the plurality of electroporation zones may have a uniform or non-uniform cross-section. In certain embodiments, the cross-section of the electroporation zone is selected from the group consisting of a cylinder, an ellipse, a polygon, a star, a parallelogram, a trapezoid, and an irregular shape.
[0118] In some cases, the cross-sectional dimension of the entry zone or the cross-sectional dimension of the recovery zone is between 0.01% and 100,000% of the cross-sectional dimension of the electroporation zone. For example, the cross-sectional dimension of the entry zone or the cross-sectional dimension of the recovery zone can be between about 0.01% and about 100% of the cross-sectional dimension of the electroporation zone, such as between about 0.01% and about 1%, between about 0.1% and about 10%, between about 5% and about 25%, between about 10% and about 50%, between about 25% and about 75%, or between about 50% and about 100% of the cross-sectional dimension of the electroporation zone. Alternatively, the cross-sectional dimension of the entry zone or the cross-sectional dimension of the recovery zone can be about 100% to about 100,000% of the cross-sectional dimension of the electroporation zone, e.g., about 100% to about 1000%, about 500% to about 5,000%, about 1,000% to about 10,000%, about 5,000% to about 25,000%, about 10,000% to about 50,000%, about 25,000% to about 75,000%, or about 50,000% to about 100,000% of the cross-sectional dimension of the electroporation zone.
[0119] In some embodiments, the cross-sectional dimension of the electroporation zone is between 0.005 mm and 50 mm. In some embodiments, the length of the electroporation zone is between 0.005 mm and 50 mm. In some embodiments, the length of the electroporation zone is between 0.005 mm and 25 mm. In some embodiments, the cross-sectional dimension of either the first electrode or the second electrode is between 0.1 mm and 500 mm. In certain embodiments, none of the entry zone, recovery zone, or electroporation zone reduces the cross-sectional dimension of any of the plurality of cells suspended in the fluid, e.g., cells can pass through the device without deformation.
[0120] In further embodiments, the device includes an outer structure having a housing configured to enclose the first electrode, the second electrode, and the electroporation zone of the device. In some embodiments, the outer structure includes a first electrical input operably coupled to the first electrode and a second electrical input operably coupled to the second electrode. In some embodiments, the outer structure is integral to the device. In certain embodiments, the outer structure is releasably connected to the device.
[0121] In some embodiments, the delivery rate from the fluid delivery source is between 0.001 mL / min and 1,000 mL / min, e.g., between 20 and 30 mL / min, e.g., 25 mL / min. In certain embodiments, the residence time of any of the plurality of cells suspended in the fluid is between 0.5 ms and 50 ms. In some embodiments, the conductivity of the fluid is between 0.001 mS / cm and 500 mS / cm, e.g., between 1 and 20 mS / cm.
[0122] In further embodiments, the method includes a controller operably coupled to the potential source to deliver a voltage pulse to the first electrode and the second electrode to generate a potential difference between the first electrode and the second electrode. In some embodiments, the voltage pulse has an amplitude of -3 kV to 3 kV, e.g., 0.2 to 0.6 kV. In some cases, the duty cycle of the electroporation is 0.001% to 100%, e.g., 10% to 95%. In some embodiments, the voltage pulse has a duration of 0.01 ms to 1,000 ms, e.g., 1 ms to 10 ms. In certain embodiments, the voltage pulse is applied to the first electrode and the second electrode at a frequency of 1 Hz to 50,000 Hz, e.g., 100 to 500 Hz. The waveform of the voltage pulse can be DC, square, pulse, bipolar, sinusoidal, ramp, asymmetric bipolar, any, and any superposition or combination thereof. In certain embodiments, the electric field generated from the voltage pulse has a magnitude between 1 V / cm and 50,000 V / cm, for example between 100 V / cm and 1,000 V / cm.
[0123] In further embodiments, the method includes a housing structure configured to house the electroporation device described herein. In further instances, the housing structure includes a thermal controller configured to increase or decrease the temperature of the housing or any component of the system. In some embodiments, the thermal controller is a heating element, e.g., a heating block, liquid flow, a battery-powered heater, or a thin film heater. In other embodiments, the thermal controller is a cooling element, e.g., liquid flow, an evaporative cooler, or a thermoelectric, e.g., a Peltier device. In certain embodiments, the temperature of the plurality of cells suspended in the fluid is between 0°C and 50°C.
[0124] In further embodiments, the device comprises multiple cell perforation devices, for example in series or parallel. In certain embodiments, the device comprises multiple outer structures for multiple devices.
[0125] In some cases, the method further comprises storing the plurality of cells suspended in the fluid in a recovery buffer after poration. In certain embodiments, the electroporated cells have a viability of 0.1%-99.9%, e.g., 25%-85%, after introduction of the composition. In other embodiments, the efficiency of introduction of the composition to the cells is 0.1-99.9%, e.g., 25%-85%. In certain embodiments, the cell recovery rate is 0.1%-100%. In certain embodiments, the cell recovery yield is 0.1%-500%. In some embodiments, the number of recovered cells (e.g., viable cells) is 10 4 ~10 12 It is.
[0126] In another aspect, the invention provides a kit for electroporating a plurality of cells suspended in a fluid, the kit comprising a plurality of cell poration devices as described herein, a plurality of outer structures as described herein, and a transfection buffer.
[0127] In some embodiments, the outer structure is integral to the multiple cell-perforation devices. In certain embodiments, the outer structure is releasably connected to the multiple cell-perforation devices.
[0128] This application contains at least one color printed drawing. Copies of this patent application including color drawing(s) will be provided by the Office upon payment of the necessary fee. [Brief description of the drawings]
[0129] [Figure 1A-1C] 1A-1C are schematic diagrams of an embodiment of a single electroporation device of the present invention. FIG 1A shows a schematic diagram of the operation of a device of the present invention. FIG 1B shows a schematic diagram of the components of the present invention. FIG 1C shows a photograph of the embodiment of the device of the present invention shown in FIG 1B. [Figure 2A-2B] 2A-2B are exemplary schematic diagrams of a housing for parallel delivery of electrical energy to an embodiment of an electroporation device of the present invention. FIG. 2A shows an isometric view of a housing with an electrical grid concept used to energize 96 electroporation devices of the present invention in parallel. FIG. 2B shows a close-up view of the interface between a single electroporation device of the present invention and a housing with an electrical grid that uses spring-loaded electrodes to securely hold the first and second electrodes of each electroporation device against the housing's electrical grid. [Figure 3A-3B] 3A-B are bar graphs of the optimization of fluid flow rate (mL / min) for electroporation of Jurkat cells (1×107 cells / mL) using the device of the present invention. Harvested cells were cultured in RPMI with 10% FBS at 37° C. for 24 hours prior to flow cytometer analysis using an LSR II HTS (BD Bioscience). FIG. 3A shows the viability of Jurkat cells assessed using 7-AAD exclusion dye. FIG. 3B shows the transfection efficiency of Jurkat cells assessed using GFP expression. [Figure 4A-4D]Figures 4A-4D are illustrations of flow rate simulations along the active zone of the device. Figure 4A is a 3D model representing a liquid volumetric flow rate of 10 mL per minute. Figure 4C is a 3D model representing a liquid volumetric flow rate of 100 mL per minute. Figures 4B and 4D are 2D models corresponding to Figures 4A and 4C, respectively. [Figure 5A-5B] 5A-5B are bar graphs for optimization of the electric field in the electroporation zone of the device of the present invention for electroporation of Jurkat cells. Harvested cells were cultured in RPMI with 10% FBS at 37° C. for 24 hours prior to flow cytometer analysis using an LSR II HTS (BD Bioscience). FIG. 5A shows the viability of Jurkat cells assessed using 7-AAD exclusion dye. FIG. 5B shows the transfection efficiency of Jurkat cells assessed using GFP expression. [Figure 6A-6B] 6A-6B are bar graphs showing the effect of temperature on transfection of Jurkat cells using the device of the present invention. "RT" in these figures represents room temperature. Harvested cells were cultured in RPMI with 10% FBS at 37°C for 24 hours prior to flow cytometer analysis using an LSR II HTS (BD Bioscience). FIG. 6A shows viability of Jurkat cells assessed using 7-AAD exclusion dye. FIG. 6B shows transfection efficiency of Jurkat cells assessed using GFP expression. [Figure 7A-7D] Figures 7A-7D are illustrations of simulations showing the electric field distribution along the active zone of the device. Figure 7A shows the electric field distribution map of the device with an applied voltage of 225V. Figure 7B is a longitudinal cross-section of the 2D model of Figure 7A. Figure 7C shows the electric field distribution map of the device with an applied voltage of 275V. Figure 7D is a longitudinal cross-section of the 2D model of Figure 7C. [Figure 8A-8D]Figures 8A-8D are illustrations of a simulation showing the effect of temperature distribution along the active zone of the device. Figure 8A shows a temperature distribution map of the liquid in the active zone of the device at time = 0 ms. Figure 8B shows a temperature distribution map of the liquid in the active zone of the device at time = 100 ms. Figure 8C shows a temperature distribution map of the liquid in the active zone of the device at time = 200 ms. Figure 8D shows a temperature distribution map of the liquid in the active zone of the device at time = 300 ms. [Figure 9A-9B] 9A-9B are bar graphs showing optimization of voltage pulse duration and pulse number for electroporation of Jurkat cells using the device of the present invention. Harvested cells were cultured in RPMI with 10% FBS at 37° C. for 24 hours prior to flow cytometer analysis using an LSR II HTS (BD Bioscience). FIG. 8A shows viability of Jurkat cells assessed using 7-AAD exclusion dye. FIG. 9B shows transfection efficiency of Jurkat cells assessed using 7GFP expression. [Figure 10A-10B] 10A-10B are bar graphs showing optimization of sample volume for electroporation of Jurkat cells using the device of the present invention. Harvested cells were cultured in RPMI with 10% FBS at 37° C. for 24 hours prior to flow cytometer analysis using an LSR II HTS (BD Bioscience). FIG. 10A shows viability of Jurkat cells assessed using 7-AAD exclusion dye. FIG. 10B shows transfection efficiency of Jurkat cells assessed using GFP expression. [Figure 11A-11B]11A-11B are bar graphs showing optimization of electroporation zone diameter for electroporation of Jurkat cells using the device of the present invention. Electroporation was performed at a fixed voltage with variable flow rates to substantially match the total cell residence time across different channel dimensions. Harvested cells were cultured in RPMI with 10% FBS at 37° C. for 24 hours prior to flow cytometer analysis using an LSR II HTS (BD Bioscience). FIG. 11A shows viability of Jurkat cells assessed using 7-AAD exclusion dye. FIG. 11B shows transfection efficiency of Jurkat cells assessed using GFP expression. [Figure 12A] 12A-12L show bar graphs illustrating the effect of selected voltage pulse waveforms for electroporation of Jurkat cells using a device of the invention and exemplary waveform shapes. Harvested cells were cultured in RPMI with 10% FBS at 37° C. for 24 hours prior to flow cytometer analysis using an LSR II HTS (BD Bioscience). FIG. 12A shows the viability of Jurkat cells assessed using 7-AAD exclusion dye. [Figure 12B] FIG. 12B shows transfection efficiency of Jurkat cells assessed using GFP expression. [Figure 12C] FIG. 12C shows a direct current (DC) always-on waveform. [Figure 12D] FIG. 12D shows a square wave waveform with a 50% duty cycle that includes an offset. [Figure 12E] FIG. 12E shows a 75% asymmetric ramp waveform. [Figure 12F] FIG. 12F shows a pulse waveform with a 95% duty cycle. [Figure 12G] FIG. 12G shows a square wave waveform with a 75% duty cycle including an offset. [Figure 12H] FIG. 12H shows a sine waveform. [Figure 12I] FIG. 12I shows a 25% asymmetric ramp waveform. [Figure 12J]FIG. 12J shows a square wave waveform with a 25% duty cycle including an offset. [Figure 12K] FIG. 12K shows a bipolar square wave waveform with no offset. [Figure 12L] FIG. 12L shows a symmetric ramp waveform. [Figure 13A] 13A-B are bar graphs comparing transfection efficiency and resulting cell viability of Jurkat cells using a device of the present invention and a commercially available cell transfection instrument. Jurkat cell viability assessed using 7-AAD exclusion dye, and transfection efficiency of Jurkat cells assessed using GFP expression. Figure 13A shows the results of a transfection experiment performed using published parameters for Jurkat cell transfection (sample in 100 μL tip; 3 pulses / 10 ms / 450 V / cm). [Figure 13B] FIG. 13B is a duplicate experiment of FIG. 13A showing reproducibility in experiments performed using optimized parameters for the device of the present invention compared to published parameters for Jurkat cell transfection. [Figure 13C] Figure 13C shows a workflow diagram of Cas9 ribonucleoprotein array library screening, which uses a commercially available single-stranded sgRNA array library to anneal purified Cas9 protein to form an array Cas9 ribonucleoprotein library.Using the device of the present invention, Cas9 ribonucleoprotein array library screening leads to the identification of gene targets for future immunotherapy research using plate-based analysis.In addition, Cas9 ribonucleoprotein pool library screening can be used to carry out the assays required to identify gene targets for future therapies. [Figure 14A-14B]14A-B are bar graphs showing the viability and efficiency of delivery of FITC-dextran to primary human T cells using a device of the invention that uses variable molecular weight dextran polymers to assess any size constraints for dextran delivery. Recovered cells were cultured in RPMI with 10% FBS at 37° C. for 24 hours prior to flow cytometer analysis using an LSR II HTS (BD Bioscience). FIG. 14A shows the viability of primary human T cells assessed using 7-AAD exclusion dye. FIG. 14B shows the transfection efficiency of primary human T cells assessed using GFP expression. [Figure 15A-15B] 15A-B are bar graphs comparing transfection efficiency and viability in THP-1 monocytes using the device of the present invention with a commercially available cell transfection instrument (NEON®) using a published transfection protocol for THP-1 monocytes. Harvested cells were cultured in RPMI with 10% FBS at 37° C. for 24 hours prior to flow cytometer analysis using an LSR II HTS (BD Bioscience). FIG. 15A shows the viability of THP-1 monocytes assessed using 7-AAD exclusion dye. FIG. 15B shows the transfection efficiency of THP-1 monocytes assessed using GFP expression. [Figure 16A-16B] 16A-B are bar graphs comparing transfection efficiency and viability in primary human monocytes using the device of the present invention with a commercially available cell transfection instrument using a published transfection protocol for primary human monocytes. Primary human monocytes were isolated from peripheral blood using negative selection. Harvested cells were cultured in RPMI with 10% FBS at 37° C. for 24 hours prior to flow cytometer analysis using an LSR II HTS (BD Bioscience). FIG. 16A shows the viability of primary human monocytes assessed using 7-AAD exclusion dye. FIG. 16B shows the transfection efficiency of primary human monocytes assessed using GFP expression. [Figure 17A-17B]Figures 17A-B are bar graphs comparing transfection efficiency and viability in the NK-92 cell line using the device of the present invention with a commercially available cell transfection instrument using a published transfection protocol for the NK-92 cell line. After electroporation, cells were cultured in complete aMEM (aMEM with 25% serum 0.2 mM inositol 0.02 folic acid 0.1 mM mercaptoethanol) for 24 hours at 37°C prior to flow cytometer analysis using an iQue (Intellicyt). Figure 17A shows viability assessed using 7-AAD exclusion dye. Figure 17B shows transfection efficiency assessed by GFP expression. [Figure 18A-18B] Figures 18A-B are bar graphs comparing transfection efficiency and viability in the NK-92MI cell line using the device of the present invention with a commercially available cell transfection instrument using a published transfection protocol for the NK-92MI cell line. After electroporation, cells were cultured in complete aMEM (aMEM with 25% serum 0.2 mM inositol 0.02 folic acid 0.1 mM mercaptoethanol) for 24 hours at 37°C prior to flow cytometer analysis using an iQue (Intellicyt). Figure 18A shows viability assessed using 7-AAD exclusion dye. Figure 18B shows transfection efficiency assessed by GFP expression. [Figure 19A] 19A-19F are bar graphs comparing T cells (FIGS. 19A-19C) and primary human monocytes electroporated and transfected with SIRPα custom mRNA using the device of the present invention compared to non-electroporated cells (FIGS. 19D-19F). T cells expanded on day 11 were transfected with 20 μg of SIRPα mRNA and assessed for overexpression at 24 hours. FIG. 19A is a representative graph of viability measured as 7AAD negative cells. Monocytes isolated from PBMCs were transfected with 20 μg of SIRPα mRNA and assessed for overexpression at 24 hours. Graphs are mean ± SEM. [Figure 19B]19A-19F are bar graphs comparing T cells (FIGS. 19A-19C) and primary human monocytes electroporated and transfected with SIRPα custom mRNA using a device of the invention compared to non-electroporated cells (FIGS. 19D-19F). T cells expanded on day 11 were transfected with 20 μg of SIRPα mRNA and assessed for overexpression at 24 hours. FIG. 19B is a representative graph of transfection efficiency measured as SIRPα positive cells. Monocytes isolated from PBMCs were transfected with 20 μg of SIRPα mRNA and assessed for overexpression at 24 hours. Graphs are mean ± SEM. [Figure 19C] 19A-19F are bar graphs comparing T cells (FIGS. 19A-19C) and primary human monocytes (FIGS. 19D-19F) electroporated and transfected with SIRPα custom mRNA using a device of the invention compared to non-electroporated cells. T cells expanded on day 11 were transfected with 20 μg of SIRPα mRNA and assessed for overexpression at 24 hours. FIG. 19C is a representative graph of SIRPα expression measured as mean fluorescence intensity (MFI). Monocytes isolated from PBMCs were transfected with 20 μg of SIRPα mRNA and assessed for overexpression at 24 hours. Graphs are mean ± SEM. [Figure 19D] 19A-19F are bar graphs comparing T cells (FIGS. 19A-19C) and primary human monocytes electroporated and transfected with SIRPα custom mRNA using a device of the invention compared to non-electroporated cells (FIGS. 19D-19F). T cells expanded on day 11 were transfected with 20 μg SIRPα mRNA and assessed for overexpression at 24 hours. FIG. 19D is a representative graph of viability measured as 7AAD negative cells. Graphs are mean±SEM. [Figure 19E]19A-19F are bar graphs comparing T cells (FIGS. 19A-19C) and primary human monocytes (FIGS. 19D-19F) electroporated and transfected with SIRPα custom mRNA using a device of the invention compared to non-electroporated cells. T cells expanded on day 11 were transfected with 20 μg SIRPα mRNA and assessed for overexpression at 24 hours. FIG. 19E is a representative graph of transfection efficiency measured as SIRPα positive cells. Graphs are mean±SEM. [Figure 19F] 19A-19F are bar graphs comparing T cells (FIGS. 19A-19C) and primary human monocytes (FIGS. 19D-19F) electroporated and transfected with SIRPα custom mRNA using a device of the invention compared to non-electroporated cells. T cells expanded on day 11 were transfected with 20 μg SIRPα mRNA and assessed for overexpression at 24 hours. FIG. 19F is a representative graph of SIRPα expression measured as mean fluorescence intensity (MFI). Graphs are mean ± SEM. [Figures 20A-20D] 20A-D are bar graphs showing delivery of GFP nRMA to human primary naive T cells. 20A shows cells recovered. 20B shows naive T cell efficiency. 20C shows naive T cell viability. 20D shows total yield. Naive T cells were transfected with 10 μg of commercial GFP mRNA and assessed for expression at 24 hours. Representative graphs of counts, viability, efficiency, and yield are shown. Graphs are mean ± SEM. [Figure 21A-21B]Figures 21A-B are FACS plots showing that electroporation does not change the phenotype of human primary naive T cells. Figure 21A shows untreated cells. Figure 21B shows electroporated cells. Naive T cells were transfected with 10 μg of commercial GFP mRNA and then stained for CD45RA and CD45RO at 24 hours as shown in the dot plots. The CD45RA / CD45RO phenotype is equivalent between untreated and Flowfect™ electroporated naive T cells. [Figure 22] Figure 22 is a kinetic plot showing proliferation of naive T cells using the device of the present invention compared to untreated cells. Electroporation does not alter proliferation of human primary naive T cells. Naive T cells were transfected with 10 μg of commercial GFP mRNA and then expanded with soluble CD3 / CD28 activator. Cell counts were taken 1, 4, and 6 days after activation. Proliferation rates are equivalent between untreated and electroporated naive T cells. [Figures 23A-23C]
[0036] Figure 23 shows an exemplary embodiment of an electroporation device of the present invention integrated into an electronic discharge device configured to simultaneously energize and electroporate multiple cell samples. Figure 23A shows a top isometric view of the electronic discharge device. Figure 23B shows a side view of a device of the present invention installed in the electronic discharge device, showing how electrical contact is made within the system using pogo pin style electrical contacts. Figure 23C shows a side view of the complete electronic discharge device. [Fig. 23D-23F]FIG. 23D shows an exemplary embodiment of an electroporation device of the present invention integrated into an electronic discharge device configured to simultaneously energize and electroporate multiple cell samples. FIG. 23D shows a top isometric view of an alternative embodiment of an electronic discharge device. FIG. 23E shows a side view of a device of the present invention installed in an electronic discharge device, showing how electrical contact is made in the system using flexible spring-loaded electrical contacts. FIG. 23F shows a top view of an electronic discharge device configured to simultaneously energize and electroporate multiple cell samples. [Fig. 24A-24B] 24A-B show an embodiment of a temperature-controlled electroporation device that uses a thermal liquid for temperature control. FIG 24A shows a schematic diagram of the components of a temperature-controlled electroporation device. FIG 24B shows a side view of the temperature-controlled electroporation device, showing the device in an external frame. [Fig. 25A-25B] Figures 25A-B show an embodiment of a fluidic chip-based electroporation device configured to accept industry standard pipette tips for sample introduction. Figure 25A shows an embodiment of a fluidic chip incorporating embedded electrodes and fluidic channels. Figure 25B shows a schematic diagram of the components of the fluidic chip-based electroporation device. [Figure 26A-26B] Figures 26A-B show an embodiment of a continuous flow electroporation device. Figure 26A shows a cutaway schematic of the components of the continuous flow electroporation device. Figure 26B shows an exterior view with transparency to show the components of the continuous flow electroporation device. [Figure 27A] Figures 27A-F show simulated electric fields generated using computational modeling of an embodiment of a helical electrode: Figure 27A shows the simulated electric field of a helical electrode shown along all three Cartesian axes. [Figure 27B] FIG. 27B shows the simulated electric field of the helical electrode shown from a cross section along the Z axis. [Figure 27C] FIG. 27C shows the simulated electric field of a spiral electrode along the XY axis shown from four different positions along the Z axis. [Figure 27D] FIG. 27D shows the simulated electric field of a spiral electrode along the XY axis shown from four different positions along the Z axis. [Figure 27E] FIG. 27E shows the simulated electric field of a spiral electrode along the XY axis shown from four different positions along the Z axis. [Figure 27F] FIG. 27F shows the simulated electric field of a spiral electrode along the XY axis shown from four different positions along the Z axis. [Figures 28A-28C] Figures 28A-C show an embodiment of a two-part electroporation device of the present invention configured for manufacturing scalability. Figure 28A shows a top isometric 3D rendering of an embodiment of a two-part electroporation device of the present invention. Figure 28B shows a vertical cross-section of the embodiment depicted in Figure 28A showing how the two components fit together. Figure 28C shows the same view of the embodiment depicted in Figure 28B with the dimensions of the device (in mm) superimposed. [Figure 29A-29B] 29A-B show an embodiment of a two-part electroporation device of the present invention including an embedded electrode with an interface for a liquid handling cannula. FIG. 29A shows a top isometric 3D rendering of an embodiment of a two-part electroporation device of the present invention with an embedded electrode. FIG. 29B shows a vertical cross section of the embodiment depicted in FIG. 29A showing the location of the embedded electrode relative to the electroporation zone of the device of the present invention. [Fig. 30A-30B] Figures 30A-30B show an embodiment of an outer housing of the invention configured to house multiple devices, liquid handling components, a controller, and optional electrical components of the invention. Figure 30A shows an embodiment of an outer housing of the invention having a user interface. Figure 30B shows an embodiment of a device of the invention connected to a liquid dispensing manifold and a sample plate. [Diagram 31]FIG. 31 shows a comparison of traditional (using the commercially available Lonza NUCLEOFECTOR 4D™ electroporation system, bottom) and flow cytometry gating strategies employed (using the device and system of the present invention, top) for post-transfection analysis for cell counting, viability, transfection efficiency, and detection of surface / intracellular markers. [Fig. 32A-32B] 32A-B are bar graphs showing the viability and efficiency from delivery of GFP-encoding plasmid DNA into CHO-K1 cells using a device of the present invention 24 hours after electroporation. Figure 32A shows the viability of CHO-K1 cells. Figure 32B shows the transfection efficiency of CHO-K1 cells assessed using GFP expression. [Fig. 33A-33D] 33A-33D are bar graphs showing the viability and efficiency from delivery of GFP-encoding plasmid DNA into HEK-293T cells using a device of the present invention 24 and 48 hours after electroporation. FIG. 33A shows the viability of HEK-293T cells 24 hours after electroporation. FIG. 33B shows the transfection efficiency of HEK-293T cells assessed using GFP expression 24 hours after electroporation. FIG. 33C shows the viability of HEK-293T cells 48 hours after electroporation. FIG. 33D shows the transfection efficiency of HEK-293T cells assessed using GFP expression 48 hours after electroporation. [Fig. 34A-34B] 34A-B show the collected GFP fluorescence signals of Chinese Hamster Ovary (CHO-K1) cells before (FIG. 34A) and after (FIG. 34B) electroporation using the device and system of the present invention. GFP fluorescence images were captured using an ECHO Revolve microscope equipped with a 10x objective. [Fig. 35A-35B] 35A-B show the collected GFP fluorescence signals of HEK-293T cells before (FIG. 35A) and after (FIG. 35B) electroporation using the device and system of the present invention. GFP fluorescence images were captured using an ECHO Revolve microscope equipped with a 10x objective. [Fig. 36A-36D]
[00136] Figures 36A-D are bar graphs showing total cell count, viability, efficiency, and relative live positive transfected cells following electroporation to deliver 40 kD FITC dextran to primary human T cells using the commercially available NEON® transfection system and the device of the present invention. Figure 36A shows total cell count following electroporation. Figure 36B shows viability of primary human T cells. Figure 36C shows efficiency of delivery into primary human T cells. Figure 36D shows relative live positive transfected cell population. [Figure 37] FIG. 37 is a bar graph showing a comparison of the relative live positive transfected cell population following delivery of GFP plasmid into primary human T cells between the NEON® Transfection System and a device of the present invention. [Fig. 38A-38D] 38A-D are bar graphs showing recovery, viability, efficiency, and yield of delivery of mRNA to 9-day-old primary human T cells. Electroporation was performed using two commercially available transfection systems (Lonza NUCLEOFECTOR 4D™ and Thermo Fisher NEON®) and the device of the present invention. Either 1 million (106 cells / mL) or 5 million (5×106 cells / mL) were electroporated in 100 μL containing 10 μg of mRNA encoding EGFP. Analysis by flow cytometry was performed 24 hours after electroporation. Cell counts are normalized to 1 million cells input and yields are normalized to results collected using the device of the present invention. FIG. 38A shows recovery at both cell densities. FIG. 38B shows viability at both cell densities. FIG. 38C shows efficiency at both cell densities. FIG. 38D shows the yield at both cell densities. [Fig. 39A-39D]Figures 39A-D are line graphs showing recovery, viability, efficiency, and MFI of delivery of Cas9 ribonucleoprotein complex (RNP) targeting CXCR3 in primary human T cells. Cas9 RNP was formulated with commercially available Cas9 protein and two commercial sources of sgRNA. Analysis by flow cytometry was performed 24-72 hours after electroporation. Figure 39A shows cell recovery. Figure 39B shows viability. Figure 39C shows efficiency. Figure 39D shows total yield of targeted KO cells expanded up to 72 hours after electroporation. [Fig. 40A-40B] 40A-B are bar graphs showing viable cell counts for GFP expression from THP-1 cells and FITC-labeled dextran delivery to NK-92MI cells for electroporation using a commercial NEON® transfection system and a device of the present invention. FIG. 40A shows viable cell counts for GFP expression for THP-1 cells. FIG. 40B shows viable cell counts for FITC-labeled dextran delivery to NK-92MI cells. [Figure 41A-41B] 41A-B are bar graphs showing a comparison of the resulting viability and efficiency of GFP mRNA delivery to THP-1 monocytes using the commercial NEON® transfection system and the device of the present invention. FIG. 41A shows the viability of THP-1 monocytes assessed 24 hours after transfection. FIG. 41B shows the transfection efficiency THP-1 monocytes assessed using GFP expression 24 hours after electroporation. [Fig. 42A-42C] 42A-C are bar graphs showing the viability, efficiency, and yield of GFP mRNA delivery into THP-1 monocytes using a device of the invention with a control sample of non-electroporated cells. FIG. 42A shows the viability of transfected cells assessed 24-72 hours after electroporation. FIG. 42B shows the efficiency of GFP mRNA uptake assessed 24-72 hours after electroporation. FIG. 42C shows the yield of transfected cells assessed 24-72 hours after electroporation. [Fig. 43A-43B]43A-B are bar graphs showing the viability and efficiency of GFP mRNA delivery into LPS-activated THP-1 cells using a device of the invention. FIG. 43A shows the viability of LPS-activated THP-1 cells assessed 24 hours after transfection. FIG. 43B shows the transfection efficiency of LPS-activated THP-1 cells assessed using GFP expression 24 hours after electroporation. [Fig. 44A-44D] Figures 44A-D are bar graphs showing the viability and efficiency of delivery of 40 kD FITC dextran and GFP mRNA into primary peripheral blood monocytes using a device of the invention. Figure 44A shows the viability of primary peripheral blood monocytes transfected with FITC dextran. Figure 44B shows the transfection efficiency of primary peripheral blood monocytes transfected with FITC dextran. Figure 44C shows the viability of primary peripheral blood monocytes transfected with GFP mRNA. Figure 44B shows the transfection efficiency of primary peripheral blood monocytes transfected with GFP mRNA. [Fig. 45A-45B] Figures 45A-B are bar graphs showing CD80 and CD86 expression in primary peripheral blood monocytes transfected with GFP upon LPS stimulation using a device of the invention. CD80 and CD86 expression was measured 24 and 96 hours after electroporation. Figure 45A shows expression of the activation marker CD80. Figure 45B shows expression of the lineage marker CD86. [Figures 46A-46C] Figures 46A-C are bar graphs showing macrophage phenotype, viability, and GFP expression of primary peripheral blood monocytes transfected with GFP mRNA using a device of the invention differentiated into macrophages over days 4-8. Figure 46A shows macrophage phenotype assessed by flow cytometry analysis of FSC and SSC. Figure 46B shows the viability of transfected macrophages. Figure 46C shows the percent GFP expression of transfected macrophages. [Fig. 47A-47D]Figures 47A-D are bar graphs showing the viability and efficiency of delivery of 40 kD FITC dextran and GFP mRNA to peripheral blood differentiated macrophages using the device of the present invention. Figure 47A shows the viability of peripheral blood differentiated macrophages transfected with FITC dextran. Figure 47B shows the transfection efficiency of peripheral blood differentiated macrophages transfected with FITC dextran. Figure 47C shows the viability of peripheral blood differentiated macrophages transfected with GFP mRNA. Figure 47D shows the transfection efficiency of peripheral blood differentiated macrophages transfected with GFP mRNA. [Fig. 48A-48B] Figures 48A-B are bar graphs showing the ability of peripheral blood differentiated macrophages to polarize into M1 and M2 macrophages after transfection with GFP mRNA using a device of the invention. Figure 48A shows M1 polarized macrophages, with M1 polarization upon IFNg+LPS stimulation indicated by increased CD86 expression. Figure 48B shows M2 polarization, with IL-4 stimulation indicated by CD206 expression. [Figures 49A-49C] Figures 49A-C are bar graphs showing the viability, efficiency, and viable cell counts of primary human monocytes transfected with FITC-dextran using the commercial NEON® transfection system and the device of the present invention. Figure 49A shows the viability of primary human monocytes. Figure 49B shows the efficiency of delivery of FITC-dextran into primary human monocytes. Figure 49C shows the viable cell counts of transfected primary human monocytes. [Fig. 50A-50D]
[0036] Figures 50A-50D are bar graphs comparing the recovery, viability, efficiency, and yield of DNA transfection into Jurkat cells at various cell densities using the single channel and continuous flow devices of the present invention. Figure 50A shows the recovery of transfected Jurkat cells. Figure 50B shows the viability of transfected Jurkat cells. Figure 50C shows the efficiency of DNA transfection into Jurkat cells. Figure 50D shows the yield of transfected Jurkat cells. [Fig. 51A-51B] 51A-51B are bar graphs comparing GFP and FITC yields of transfected Jurkat cells using single channel and continuous flow devices of the present invention. Figure 51A shows the GFP yield of transfected Jurkat cells. Figure 51B shows the FITC yield of transfected Jurkat cells. [Fig. 52A-52D] Figures 52A-D are bar graphs showing the delivery of FITC-dextran into high cell density suspensions using a continuous flow device of the present invention. Analysis by flow cytometry was performed 24 hours after electroporation. Figure 52A shows the total cell counts recovered per million cells input. Figure 52B shows the viability of transfected Jurkat cells. Figure 52C shows the efficiency of FITC-dextran transfection into Jurkat cells. Figure 52D shows the FITC yield of transfected Jurkat cells. [Fig. 53A-53D]53A-D are bar graphs showing the recovery, viability, efficiency, and yield of mRNA transfection into Jurkat cells at a cell number of 100 million cells using various amounts of mRNA and various cell concentrations in a continuous flow device of the present invention. Analysis by flow cytometry was performed 24 hours after electroporation. FIG. 53A shows the number of Jurkat cells recovered at different concentrations of mRNA and cell concentrations. FIG. 53B shows the viability of transfected Jurkat cells at different concentrations of mRNA and cell concentrations. FIG. 53C shows the efficiency of mRNA transfection into Jurkat cells at different concentrations of mRNA and cell concentrations. FIG. 53D shows the yield of transfected Jurkat cells at different concentrations of mRNA and cell concentrations. [Figure 54] Figure 54 shows flow cytometry analysis of untreated and electroporated T cells comparing the commercial Lonza NUCLEOFECTOR 4D™ transfection system with the device of the present invention. The top panel shows FSC / SSC total cell plots and the bottom panel shows viability staining. Dead cell populations are indicated with red arrows and red boxes. There is also a morphology shift in Lonza NUCLEOFECTOR 4D™ transfected cells at 24 hours compared to untreated cells, indicating a phenotypic change occurs during electroporation with the Lonza platform. [Figure 55] FIG. 55 shows a bar graph of total cell yield from electroporation of 50 million primary T cells with either FITC-dextran or EGFP mRNA using the commercial Lonza LV transfection system and the continuous flow device of the present invention. [Fig. 56A-56B] 56A-B are bar graphs showing the viability and efficiency of delivery of FITC-dextran into a suspension of 1 billion THP-1 cells using a continuous flow device of the present invention over a period of up to 72 hours of electroporation. Figure 56A shows the viability of THP-1 cells. Figure 56B shows the efficiency of FITC-dextran delivery into THP-1 cells. [Figure 57]Figure 57 is a bar graph showing the yield of recoverable live FITC-dextran transfected cells starting from a suspension of 1 billion THP-1 cells using the continuous flow device of the present invention. The yield was followed for a period of up to 72 hours after electroporation culture and represents approximately 50% of the input number of cells. Analysis by flow cytometry was performed 4 hours, 24 hours, 48 hours, and 72 hours after electroporation. [Fig. 58A-58D]
[0036] Figures 58A-D are bar graphs comparing waveform shapes and waveform voltages with respect to total cell count, viability, efficiency, and yield of FITC-dextran transfection into Jurkat cells using a device of the present invention. Figure 58A shows the number of Jurkat cells recovered at different waveform shapes and voltages. Figure 58B shows the viability of transfected Jurkat cells at different waveform shapes and voltages. Figure 58C shows the efficiency of FITC-dextran transfection into Jurkat cells at different waveform shapes and voltages. Figure 58D shows the yield of transfected Jurkat cells at different waveform shapes and voltages. [Fig. 59A-59D]
[00136] Figures 59A-D are bar graphs comparing waveform maximum voltages and duty cycles with respect to total cell count, viability, efficiency, and yield of FITC-dextran transfection into primary T cells using a device of the present invention. Figure 59A shows the number of primary T cells recovered at different waveform maximum voltages and duty cycles. Figure 59B shows the viability of transfected primary T cells at different waveform maximum voltages and duty cycles. Figure 59C shows the efficiency of FITC-dextran transfection into primary T cells at different waveform maximum voltages and duty cycles. Figure 59D shows the yield of transfected primary T cells at different waveform maximum voltages and duty cycles. [Fig. 60A-60D]
[0036] Figures 60A-D are bar graphs comparing waveform maximum voltages and duty cycles with respect to total cell count, viability, efficiency, and yield of mRNA transfection into primary T cells using a device of the present invention. Figure 60A shows the number of primary T cells recovered at different waveform maximum voltages and duty cycles. Figure 60B shows the viability of transfected primary T cells at different waveform maximum voltages and duty cycles. Figure 60C shows the efficiency of mRNA transfection into primary T cells at different waveform maximum voltages and duty cycles. Figure 60D shows the yield of transfected primary T cells at different waveform maximum voltages and duty cycles. [Figure 61] Figure 61 is a bar graph showing the efficiency of delivery of CD3 / CD28 Dynabeads into a suspension of 1 million primary human T cells using a device of the invention. Electroporation was performed with or without Dynabeads, and incorporation of Dynabeads was performed for 5 minutes or overnight. Analysis by flow cytometry was performed 24 hours after electroporation. [Fig. 62A-62B] Figures 62A-B show embodiments of outer structures configured to encapsulate electrodes of a device of the invention. Figure 62A shows an outer structure configured with latches and clamshell-type hinges for encapsulating a device of the invention. Figure 62B shows the outer structure of Figure 62A with a device of the invention placed within a corresponding internal recess of the outer structure. [Fig. 63A-63B] Figures 63A-B are bar graphs showing the viability and efficiency of delivery of FITC-dextran into THP-1 monocytes using a device of the invention, both with and without an outer structure covering the electrodes of the device. Analysis by flow cytometry was performed 24 hours after electroporation. Figure 63A shows the viability of THP-1 monocytes. Figure 63B shows the efficiency of transfection of THP-1 monocytes. [Fig. 64A-64B]Figures 64A-B are bar graphs showing the viability and efficiency of delivery of FITC-dextran into THP-1 monocytes using devices of the invention made from different polymer resins. Figure 64A shows the viability of transfected THP-1 monocytes. Figure 64B shows the efficiency of transfection of FITC-dextran into THP-1 monocytes. [Fig. 65A-65B]
[00136] Figures 65A-B are bar graphs comparing the viability and efficiency of delivery of both DNA and mRNA encoding GFP into Jurkat cells using a manually operated device of the invention or on an automated fluid handling platform. Figure 65A shows the viability of transfected Jurkat cells. Figure 65B shows the efficiency of transfection of DNA and mRNA encoding GFP into Jurkat cells. [Fig. 66A-66E]
[00136] Figures 66A-E are bar graphs and dot plots comparing the viability and efficiency of delivery of multiple mRNAs encoding both GFP and mCherry either in parallel (on the same day) or in series (2 days apart) into T cells using a manually operated device of the invention or on an automated fluid handling platform. Figure 66A shows T cell viability 24 hours after electroporation of delivery of multiple mRNAs encoding mCherry. Figure 66B shows GFP efficiency 24 hours after electroporation. Figure 66C shows mCherry efficiency 24 hours after electroporation. Figure 66D shows dual GFP and mCherry efficiency 24 hours after electroporation. Figure 66E shows dot plots of both GFP (x-axis) and mCherry (y-axis) expression at 24 hours. [Fig. 67A-67B]Figures 67A-B are bar graphs demonstrating the efficiency of delivery of mRNA into peripheral blood mononuclear cells (PBMCs) using the device of the present invention. These experiments were performed using commercially provided mRNA encoding GFP, followed by identification of specific cell populations by phenotypic staining of surface receptors. Figure 67A shows the efficiency in a T cell subpopulation. Figure 67B shows the efficiency in a non-T cell population derived from PBMCs. Analysis by flow cytometry was performed 24 hours after electroporation. [Figure 68] FIG. 68 is a photograph of an embodiment of a system of the present invention having a reservoir (bag) in fluid communication with a first inlet and a reservoir (bag) in fluid communication with a second outlet. [Figures 69A-69C] Figure 69A is a set of photomicrographs showing eGFP-mRNA expression using a device of the present invention versus an untreated control. Figure 69B is a bar graph showing the percentage of live cells. Figure 69C is a bar graph showing the percentage of GFP+ cells. [Fig. 70A-70D] Figure 70A is a bar graph showing total NK cell recovery. Figure 70B is a bar graph showing viability. Figure 70C is a bar graph showing transfection efficiency. Figure 70D is a bar graph showing GFP+ cell yield. DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS
[0130] When values are described as ranges, it is understood that such disclosure includes all possible subranges within such ranges, as well as disclosure of specific numerical values that fall within such ranges, whether or not a specific numerical value or specific subrange is explicitly stated.
[0131] As used herein, the term "about" refers to + / - 10% of the recited value.
[0132] As used herein, the term "plurality" refers to two or more.
[0133] As used herein, the term "substantially uniform" refers to a variation of + / - 5%.
[0134] As used herein, the term "minimum cross-sectional dimension" refers to the smallest length of a straight line that passes through the geometric center of the cross-section of the lumen and intersects the inner wall of the lumen twice in the same plane of the cross-section.
[0135] The term "cross-sectional area" refers to a cross-sectional area (eg, along a plane perpendicular to the longitudinal axis or direction of flow), unless otherwise specified.
[0136] As used herein, the term "fluidically connected" refers to a direct connection between at least two device elements, e.g., an electroporation device, a reservoir, etc., that allows fluid to move between such device elements without passing through an intervening element.
[0137] As used herein, the term "fluid communication" refers to an indirect connection between at least two device elements, e.g., an electroporation zone, a reservoir, etc., that allows fluid to move between such device elements, e.g., through an intervening element (e.g., through an intervening tube, an intervening channel, etc.). For example, in embodiments in which fluid flows from the lumen of a first electrode, through the electroporation zone, and into the lumen of a second electrode, the first electrode is in fluid communication with the second electrode.
[0138] As used herein, the term "lumen" refers to the internal cavity of the electrode of the device of the present invention that allows fluid to pass through. Some or all of the electrode lumen may be conductive or non-conductive. For example, the electrode lumen may enclose a C-shaped conductive element that does not completely surround the lumen. In other embodiments, the electrode is substantially entirely composed of a conductive material that transmits electric current. When a potential difference is applied to the first and second electrodes of the device of the present invention, the electric field that may be generated in the lumen of either the first or second electrode is not high enough to cause cell electroporation in the lumen.
[0139] As used herein, the term "entry zone" includes the lumen of the first electrode of the device of the present invention through which a fluid and a plurality of cells suspended in the fluid may pass prior to electroporation. The entry zone may further include an additional reservoir in fluid communication with the lumen of the first electrode of the device of the present invention. When a potential difference is applied to the first and second electrodes of the device of the present invention, the electric field that may be generated within the entry zone of the device of the present invention is not high enough to cause cell electroporation.
[0140] As used herein, the term "recovery zone" includes the lumen of the second electrode of the device of the present invention through which the fluid and a plurality of cells suspended in the fluid may pass after electroporation. The recovery zone may further include an additional reservoir in fluid communication with the lumen of the second electrode of the device of the present invention. When a potential difference is applied to the first and second electrodes of the device of the present invention, the electric field that may be generated within the recovery zone of the device of the present invention is not high enough to cause cell electroporation.
[0141] The present invention provides devices, systems, and methods for transfection of cells, such as primary T cells, with electroporation in larger volumes, higher transfection efficiency, higher throughput, higher recovery, higher yield, and higher cell viability compared to traditional cuvette-based electroporation approaches or commercially available electroporation instruments. In particular, systems and methods are provided that can perform electroporation in a flow-through mode, in a continuous mode, or using multiple electroporation devices of the present invention to increase throughput and cell numbers.
[0142] device In general, the device of the present invention is configured to be a flow-through device that can interface with existing liquid handling, pumping, or fluid transport equipment, such as a conventional pipette tip robot or large-scale liquid handling system, to provide continuous electroporation of cells suspended in a fluid. The device of the present invention typically features three distinct regions: a first electrode having a first inlet and a first outlet, the lumen of the first electrode defining an entry zone; a second electrode having a second inlet and a second outlet, the lumen of the second electrode defining a recovery zone; and an electroporation zone fluidly connected to the first outlet of the first electrode and the second inlet of the second electrode. An example of an embodiment of the device of the present invention is shown in FIG. 1A, in which the first electrode and the second electrode are fluidly connected by the electroporation zone therebetween. When a potential difference is applied to the first and second electrodes, a local electric field is generated in the space between the two electrodes, e.g., the electroporation zone, and cells exposed to the electric field are electroporated. An individual device of the invention may include two electrodes, as shown in Figures 1A-1C, or alternatively, an individual device of the invention may include three or more electrodes defining multiple electroporation zones, thus allowing multiple electroporations of cells suspended in a fluid. A device of the invention may include multiple electroporation zones between the first and second electrodes, allowing cells to be subjected to different electric fields, e.g., caused by the different geometries of each of the multiple electroporation zones, while flowing in a single device or multiple devices.
[0143] In some cases, the first and second electrodes may be conductive wires, hollow cylinders, conductive thin films, metal foams, mesh electrodes, liquid diffusion membranes, conductive liquids, or any combination thereof, and may be included in the device. The electrodes may be aligned parallel to the fluid flow axis of the device, or aligned perpendicular to the fluid flow axis of the device. For example, the first and second electrodes may be hollow cylindrical electrodes arranged parallel to the axis of fluid flow in the device, such as in the device of Figures 1A-1C, such that fluid flows through the electrodes. In alternative examples, the first and / or second electrodes may be made of a porous conductor, such as a metal mesh, with pores aligned with respect to the fluid flow axis of the device. In alternative examples, the first and / or second electrodes may be a conductive fluid, such as a liquid. In some cases, the first and second electrodes may be configured as a helix, such as a double helix, of a solid conductor, such as a wire, around the electroporation zone. In this configuration, the cross-sectional dimensions of the electroporation zone remain substantially uniform, but the first and second electrodes vary in position along the length of the electroporation zone. The first and second electrodes are in fluid communication with the electroporation zone, but the electric field generated when a potential difference is applied to the electrodes rotates as cells suspended in the fluid move through the device of the invention. In certain embodiments, the first and second electrodes are embedded in the device of the invention and have active areas disposed at or near a fluid connection to the electroporation zone, such that a fluid carrying cells in suspension contacts a portion of the electrode where an electric field is generated within the electroporation zone.
[0144] When configured to be a hollow cylindrical electrode, the electrode has a diameter of about 0.1 mm to about 5 mm, e.g., about 0.1 mm to about 1 mm, about 0.5 mm to about 1.5 mm, about 1 mm to about 2 mm, about 1.5 mm to about 2.5 mm, about 2 mm to about 3 mm, about 2.5 mm to about 3.5 mm, about 3 mm to about 4 mm, about 3.5 mm to about 4.5 mm, or about 4 mm to about 5 mm, e.g., about 0.1 mm, about 0.2 mm, about 0.3 mm, about 0.4 mm, about 0.5 mm, about 0.6 mm, about 0.7 mm, about 0.8 mm, about 0.9 mm, about 1 mm, about 1.1 mm, about 1.2 mm, about 1.3 mm, about 1.4 mm, or about 1.5 mm. m, about 1.5 mm, about 1.6 mm, about 1.7 mm, about 1.8 mm, about 1.9 mm, about 2 mm, about 2.1 mm, about 2.2 mm, about 2.3 mm, about 2.4 mm, about 2.5 mm, about 2.6 mm, about 2.7 mm, about 2.8 mm, about 2.9 mm, about 3 mm, about 3.1 mm, about 3.2 mm, about 3.3 mm, about 3.4 mm, about 3.5 mm, about 3.6 mm, about 3.7 mm, about 3.8 mm, about 3.9 mm, about 4 mm, about 4.1 mm, about 4.2 mm, about 4.3 mm, about 4.4 mm, about 4.5 mm, about 4.6 mm, about 4.7 mm, about 4.8 mm, about 4.9 mm, or about 5 mm. An exemplary electrode outer diameter is 1.3 mm, which corresponds to a 16 gauge electrode.
[0145] In some embodiments, when the device of the present invention is configured to include a hollow cylindrical electrode, the lumen of the electrode, e.g., the first electrode or the second electrode, may include a zone that is not exposed to the electric field of the electroporation zone, e.g., an entry zone or a withdrawal zone. As shown in FIG. 1A, the entry zone may be the lumen of the first electrode immediately before the entrance to the electroporation zone where the cells in suspension are located to be electroporated with the composition delivered into the cells. The withdrawal zone may be the lumen of the second electrode immediately after the exit to the electroporation zone where the cells with the delivered composition are moved so that the pores in the cell membrane can close, thus ensuring that the delivered composition remains inside the cells. In this configuration, the first electrode is energized and the second electrode is held at ground, and as the cells pass through the lumen of the first electrode and toward the lumen of the second electrode, a local electric field is created in the electroporation zone, thus electroporating the cells passing through the device.
[0146] The electroporation zone fluidly connects the first and second electrodes of the device of the present invention, and when the electrodes are energized, it is subjected to a local electric field between the first and second electrodes. The cross-sectional shape of the electroporation zone can be any suitable shape that allows cells to pass through the electroporation zone and the electric field within the electroporation zone. The cross-sectional shape can be, for example, circular, elliptical, or polygonal, such as a square, rectangle, triangle, n-gon (e.g., a regular or irregular polygon having 4, 5, 6, 7, 8, 9, 10, or more sides), star, parallelogram, trapezoid, or irregular, such as an oval, or curved shape. In some cases, the electroporation zone is a channel that has a substantially uniform cross-sectional dimension along the length of the channel, for example, the electroporation zone can have a circular cross-section, with a diameter that is constant from the fluid connection to the entry zone to the fluid connection to the recovery zone. In this configuration, the resulting electric field is more uniform, thus allowing for more predictable electric field exposure of cells suspended in the fluid. Alternatively, the cross-sectional dimension of the electroporation zone may vary along its length. For example, the cross-sectional dimension of the electroporation zone may either increase or decrease along its length, or may have two or more dimensional changes along its length, for example, the cross-sectional dimension, e.g., the diameter, may increase or decrease by at least 1%, 5%, 10%, 20%, 30%, 40%, 50%, 60%, 70%, 80%, 90%, or 100%, or up to 1%, 5%, 10%, 20%, 30%, 40%, 50%, 60%, 70%, 80%, 90%, or 100%. In this configuration, the electroporation zone may have a truncated cone-shaped cross-section, with the diameter increasing from the top opening to the bottom opening, or decreasing from the top opening to the bottom opening. In some cases, a device of the invention may include multiple electroporation zones fluidly connected in series, each having either a uniform or non-uniform cross-section, and each may have a different cross-sectional shape. As a non-limiting example, a device of the invention may include multiple serially connected electroporation zones, each of the multiple electroporation zones having a cylindrical cross-section with a different cross-sectional dimension, e.g., each having a different diameter.
[0147] In some embodiments, the cross-sectional dimension of the electroporation zone is from about 0.005 mm to about 50 mm, e.g., from about 0.005 mm to about 0.05 mm, from about 0.01 mm to about 0.1 mm, from about 0.05 mm to about 0.5 mm, from about 0.1 mm to about 1 mm, from about 0.5 mm to about 2 mm, from about 1 mm to about 5 mm, from about 3 mm to about 7 mm, from about 5 mm to about 10 mm, from about 7 mm to about 12 mm, from about 10 mm to about 15 mm, from about 13 mm to about 18 mm, from about 1 5 mm to about 20 mm, about 22 mm to about 30 mm, about 25 mm to about 35 mm, about 30 mm to about 40 mm, about 35 mm to about 45 mm, or about 40 mm to about 50 mm, for example, about 0.005 mm, about 0.006, about 0.007 mm, about 0.008 mm, about 0.009 mm, about 0.01 mm, about 0.02 mm, about 0.03 mm, about 0.04 mm, about 0.05 mm, about 0.06 mm, about 0.07 mm, about 0.08 mm, about 0.09mm, approximately 0.1mm, approximately 0.2mm, approximately 0.3mm, approximately 0.4mm, approximately 0.5mm, approximately 0.6mm, approximately 0.7mm, approximately 0.8mm, approximately 0.9mm, approximately 1mm, approximately 2mm, approximately 3mm, approximately 4mm, approximately 5 mm, approximately 6mm, approximately 7mm, approximately 8mm, approximately 9mm, approximately 10mm, approximately 11mm, approximately 12mm, approximately 13mm, approximately 14mm, approximately 15mm, approximately 16mm, approximately 17mm, approximately 18mm, approximately 19mm, approximately 20mm, approximately 21m The diameter of the electroporation zone may be about 22 mm, about 23 mm, about 24 mm, about 25 mm, about 26 mm, about 27 mm, about 28 mm, about 29 mm, about 30 mm, about 31 mm, about 32 mm, about 33 mm, about 34 mm, about 35 mm, about 36 mm, about 37 mm, about 38 mm, about 39 mm, about 40 mm, about 41 mm, about 42 mm, about 43 mm, about 44 mm, about 45 mm, about 46 mm, about 47 mm, about 48 mm, about 49 mm, or about 50 mm. Generally, the diameter of the electroporation zone is sized such that the electroporation zone does not have a constriction that contacts the cell to deform the cell membrane with the channel wall, e.g., cell poration is not induced by mechanical deformation due to squeezing of the cell, e.g., cells can pass freely through the electroporation zone.
[0148] In some cases, the length of the electroporation zone is about 0.005 mm to about 50 mm, e.g., about 0.005 mm to about 0.05 mm, about 0.01 mm to about 0.1 mm, about 0.05 mm to about 0.5 mm, about 0.1 mm to about 1 mm, about 0.5 mm to about 2 mm, about 1 mm to about 5 mm, about 3 mm to about 7 mm, about 5 mm to about 10 mm, about 7 mm to about 12 mm, about 10 mm to about 15 mm, about 13 mm to about 18 mm, about 15 mm ~ about 20 mm, about 22 mm to about 30 mm, about 25 mm to about 35 mm, about 30 mm to about 40 mm, about 35 mm to about 45 mm, or about 40 mm to about 50 mm, for example, about 0.005 mm, about 0.006, about 0.007 mm, about 0.008 mm, about 0.009 mm, about 0.01 mm, about 0.02 mm, about 0.03 mm, about 0.04 mm, about 0.05 mm, about 0.06 mm, about 0.07 mm, about 0.08 mm, about 0. 09mm, approximately 0.1mm, approximately 0.2mm, approximately 0.3mm, approximately 0.4mm, approximately 0.5mm, approximately 0.6mm, approximately 0.7mm, approximately 0.8mm, approximately 0.9mm, approximately 1mm, approximately 2mm, approximately 3mm, approximately 4mm, approximately 5mm , about 6mm, about 7mm, about 8mm, about 9mm, about 10mm, about 11mm, about 12mm, about 13mm, about 14mm, about 15mm, about 16mm, about 17mm, about 18mm, about 19mm, about 20mm, about 21mm , about 22 mm, about 23 mm, about 24 mm, about 25 mm, about 26 mm, about 27 mm, about 28 mm, about 29 mm, about 30 mm, about 31 mm, about 32 mm, about 33 mm, about 34 mm, about 35 mm, about 36 mm, about 37 mm, about 38 mm, about 39 mm, about 40 mm, about 41 mm, about 42 mm, about 43 mm, about 44 mm, about 45 mm, about 46 mm, about 47 mm, about 48 mm, about 49 mm, or about 50 mm.
[0149] The cross-sectional dimension of the entry zone and / or the recovery zone, independently, can be substantially the same as the cross-sectional dimension of the electroporation zone. Alternatively, the entry zone and / or the recovery zone, independently, can be smaller or larger than the cross-sectional dimension of the electroporation zone. For example, when the cross-sectional dimension of the entry zone and / or recovery zone is independently configured to be smaller than the cross-sectional dimension of the electroporation zone, the cross-sectional dimension of the entry zone and / or recovery zone may be smaller than about 0.01% to about 100%, about 0.01% to about 1%, about 0.1% to about 10%, about 5% to about 25%, about 10% to about 50%, about 25% to about 75%, or about 50% to about 100%, e.g., about 0.01%, about 0.02%, about 0.03%, about 0.04%, about 0.05%, about 0.06%, about 0.07%, about 0.08%, about 0.09%, about 0.1%, Approximately 0.15%, approximately 0.2%, approximately 0.25%, approximately 0.3%, approximately 0.35%, approximately 0.4%, approximately 0.45%, approximately 0.5%, approximately 0.55%, approximately 0.6%, approximately 0.65%, approximately 0.7%, approximately 0.75%, approximately 0.8%, approximately 0.85%, approximately 0.9%, approximately 0.95%, approximately 1%, approximately 2%, approximately 3%, approximately 4% , about 5%, about 6%, about 7%, about 8%, about 9%, about 10%, about 15%, about 20%, about 25%, about 30%, about 35%, about 40%, about 45%, about 50%, about 55%, about 60%, about 65%, about 70%, about 75%, about 80%, about 85%, about 90%, about 95%, or about 100%.
[0150] Alternatively, when the cross-sectional dimension of the entry zone and / or recovery zone is independently configured to be larger than the cross-sectional dimension of the electroporation zone, the cross-sectional dimension of the entry zone and / or recovery zone may be about 100% to about 100,000%, e.g., about 100% to about 1000%, about 500% to about 5,000%, about 1,000% to about 10,000%, about 5,000% to about 25,000%, about 10,000% to about 50,000%, about 25,000% to about 75,000%, or about 50,000% to about 100,000%, e.g., about 100%, about 200%, about 300%, about 400%, about 500%, about 600%, approx. 700%, approx. 800%, approx. 900%, approx. 1,000%, approx. 2,000%, approx. 3,000%, approx. 4,000%, approx. 5,000%, approx. 6,000%, approx. 7,000%, approx. 8,000%, approx. 9,000%, approx. 10,000%, approx. 15,000%, approx. 20,000%, approx. 25,000%, approx. 30,000 %, about 35,000%, about 40,000%, about 45,000%, about 50,000%, about 55,000%, about 60,000%, about 65,000%, about 70,000%, about 75,000%, about 80,000%, about 85,000%, about 90,000%, about 95,000%, or about 100,000%.
[0151] The device of the present invention may also include one or more reservoirs for fluidic reagents, such as buffer solutions, or samples, such as suspensions of cells, and compositions to be introduced to the cells. For example, the device of the present invention may include a reservoir for cells suspended in fluid to flow into the electroporation zone in the first electrode, and / or a reservoir for holding the electroporated cells. Similarly, there may be reservoirs for liquid flow in additional components of the device, such as additional inlets across the first or second electrodes. A single reservoir may also be connected to multiple devices of the present invention, for example, when the same liquid is introduced into two or more individual devices of the present invention configured to electroporate cells in parallel or in series. Alternatively, the device of the present invention may be configured to mate with a liquid source, which may be an external reservoir, such as a vial, tube, or pouch. Similarly, the device may be configured to mate with a separate component that houses a reservoir. The reservoir can be of any suitable size to hold, for example, 10 mL to 5000 mL, e.g., 10 mL to 3000 mL, 25 mL to 100 mL, 100 mL to 1000 mL, 40 mL to 300 mL, 1 mL to 100 mL, or 10 mL to 500 mL. If multiple reservoirs are present, each reservoir may have the same size or different sizes.
[0152] In addition to the components discussed above, the device of the present invention may include additional components. For example, the first and second electrodes of the device of the present invention may include one or more additional fluid inlets to allow the introduction of non-sample fluids, such as buffer solutions, into appropriate regions of the device. For example, the recovery zone of the device of the present invention may include additional inlets and outlets to circulate a recovery buffer to aid in the closure of pores opened in the cell membrane from the electroporation process.
[0153] Systems and Kits One or more electroporation devices of the present invention may be combined with various external components, such as power sources, pumps, reservoirs (e.g., bags), controllers, reagents, fluids, and / or samples, in the form of a system. In some embodiments, a system of the present invention includes a plurality of devices of the present invention and an electrical potential source releasably connected to a first electrode and a second electrode of the device(s) of the present invention. In this configuration, the device(s) of the present invention are connected to the electrical potential source, the first electrode is energized, and the second electrode is held at ground. This creates a localized electric field in the electroporation zone, thus electroporating cells passing through the device(s). Electroporation systems incorporating devices of the present invention may induce either reversible or irreversible electroporation in cells passing through the devices and systems of the present invention. For example, the devices and systems of the present invention may induce substantially non-thermal reversible electroporation, substantially non-thermal irreversible electroporation, or substantially thermal irreversible electroporation on cells suspended in a fluid.
[0154] In some cases, the releasable connections to the first and second electrodes may include any practical electromechanical connection that can maintain consistent electrical contact between a potential source and the first and second electrodes. Exemplary electrical connections include, but are not limited to, clamps, clips, such as alligator clips, springs, such as leaf springs, external sheaths or sleeves, wire brushes, flexible conductors, pogo pins, mechanical connections, inductive connections, or combinations thereof. Other types of electrical connections are known in the art. For example, spring-type electrodes may be integrated into a conductive platform as shown in Figures 2A-2B. In the embodiment shown in Figures 2A-2B, the device of the present invention is inserted into a housing that incorporates two conductive grids, electrically isolated from each other, on a base that contains respective openings for receiving the device of the present invention. The device of the present invention may be placed within the openings of the conductive grid such that the first and second electrodes of the device can contact the conductive grid. In particular, the conductive grid includes a spring-loaded electrode, e.g., an electrode connected to a spring, such that when a device of the invention is placed within an opening in the conductive grid, the spring-loaded electrode displaces and compresses the spring (thereby providing an additional restoring force to the first and second electrodes of the device of the invention), thus ensuring electrical contact between the device of the invention and the source of electrical potential.
[0155] The electric potential source is configured to deliver an applied voltage to one or more electrodes to provide a potential difference between the electrodes and thus establish a uniform electric field within the electroporation zone. In some cases, such as in a two-electrode electroporation circuit, the applied voltage is delivered to a first electrode and a second electrode is held at ground. Without wishing to be bound by any particular theory, the applied voltage delivered to the electrodes is delivered at a particular amplitude, a particular frequency, a particular pulse shape, a particular duration, a particular number of pulses applied, and a particular duty cycle. These parameters, coupled with the geometry of the electroporation zone, deliver a particular electric field within the electroporation zone to which cells suspended in the fluid will be subjected. The electrical parameters described herein may be optimized for a particular cell line and / or composition delivered to a particular cell line. The application of the electric potential to the electrodes of the device(s) of the present invention may be initiated and / or controlled by a controller, e.g., a computer having programming, operably coupled to the electric potential source.
[0156] The geometry of the device of the present invention, e.g., the cross-sectional shape and dimensions of the electroporation zone, together with the potential parameters described herein, control the shape and strength of the resulting electric field in the electroporation zone. Typically, a device having an electroporation zone with a uniform cross-section will exhibit a uniform electric field along the length of the electroporation zone. To modulate the resulting electric field in the electroporation zone, the electroporation zone can include multiple different cross-sectional dimensions and / or different cross-sectional shapes along the length of the electroporation zone. As a non-limiting example, the device of the present invention can include multiple serially connected electroporation zones, each of the multiple electroporation zones having a circular cross-section with a different cross-sectional dimension, e.g., each having a different diameter. In this configuration, each of the circular cross-sections of the electroporation zone with different diameters will act as an independent electroporation zone, and each will induce a different electric field per change in dimension at the same applied voltage, e.g., a constant DC voltage.
[0157] In some cases, a device of the invention may include multiple electroporation zones fluidly connected in series, each having either a uniform or non-uniform cross-section, and each may have a different cross-sectional shape. Alternatively, a system of the invention may include multiple devices of the invention in a parallel configuration, each device operating independently of one another to increase the overall throughput of electroporation.
[0158] In some cases, the amplitude of the applied voltage is about -3 kV to 3 kV, e.g., 0.01 kV to about 3 kV, e.g., about 0.01 kV to about 0.1 kV, about 0.02 kV to about 0.2 kV, about 0.03 kV to about 0.3 kV, about 0.04 kV to about 0.4 kV, about 0.05 kV to about 0.5 kV, about 0.06 kV to about 0.6 kV, about 0.07 kV, about 0.7 kV, about 0.08 kV to about 0.8 kV, about 0.09 kV to about 0.9 kV, about 0.1 kV to about 1 kV, about 0.15 kV to about 1.5 kV, about 0.2 kV to about 2 kV, about 0.25 kV to about 2.5 kV, or about 0.3 kV to about 3 kV, for example, about 0.01 to about 1 kV, about 0.1 kV to about 0.7 kV, or about 0.2 to about 0 .6 kV, for example, about 0.01 kV, about 0.02 kV, about 0.03 kV, about 0.04 kV, about 0.05 kV, about 0.06 kV, about 0.07 kV, about 0.08 kV, about 0.09 kV, about 0.1 kV, about 0.2 kV, about 0.3 kV, about 0.4 kV, about 0.5 kV, about 0.6 kV, about 0.7 kV, about 0.8 kV, about 0.9 kV, about 1 kV, about 1.1 kV, about 1.2 kV, about 1.3 kV, about 1.4 kV, about 1.5 kV, about 1.6 kV, about 1.7 kV, about 1.8 kV, about 1.9 kV, about 2 kV, about 2.1 kV, about 2.2 kV, about 2.3 kV, about 2.4 kV, about 2.5 kV, about 2.6 kV, about 2.7 kV, about 2.8 kV, about 2.9 kV, or about 3 kV.
[0159] In some cases, the frequency of the applied voltage is about 1 Hz to about 50,000 Hz, e.g., about 1 Hz to about 1,000 Hz, about 100 Hz to about 5,000 Hz, about 500 Hz to about 10,000 Hz, about 1000 Hz to about 25,000 Hz, or about 5,000 Hz to about 50,000 Hz, e.g., about 10 Hz to about 1000 Hz, about 500 Hz to about 750 Hz, or about 100 Hz to about 500 Hz, e.g., about 1 Hz, about 2 Hz, about 3 Hz, about 4 Hz, about 5 Hz, about 6 Hz, about 7 Hz, about 8 Hz, about 9 Hz, about 10 Hz, about 20 Hz, about 30 Hz, about 40 Hz, about 50 Hz, about 60 Hz. , about 70 Hz, about 80 Hz, about 90 Hz, about 100 Hz, about 200 Hz, about 300 Hz, about 400 Hz, about 500 Hz, about 600 Hz, about 700 Hz, about 800 Hz, about 900 Hz, about 1,000 Hz, about 2,000 Hz, about 3,000 Hz, about 4,000 Hz, about 5,000 Hz, about 6,000 Hz, about 7,000 Hz, about 8,000 Hz, about 9,000 Hz, about 10,000 Hz, about 15,000 Hz, about 20,000 Hz, about 25,000 Hz, about 30,000 Hz, about 35,000 Hz, about 40,000 Hz, about 45,000 Hz, or about 50,000 Hz.
[0160] In some embodiments, the shape, e.g., waveform, of the applied pulse can be a square wave, a pulse, a bipolar wave, a sine wave, a ramp, an asymmetric bipolar wave, or any. Other voltage waveforms are known in the art. The selected waveform can be applied in any practical voltage pattern, including, but not limited to, high voltage-low voltage, low voltage-high voltage, direct current (DC), alternating current (AC), unipolar, positive (+) polarity only, negative (-) polarity only, (+) / (-) polarity, (-) / (+) polarity, or any superposition or combination thereof. One skilled in the art can understand that these pulse parameters are dependent on any electrical properties of the cell line and of the composition being delivered to the cells.
[0161] The applied voltage pulse may be about 0.01 ms to about 1,000 ms, for example, about 0.01 ms to about 1 ms, about 0.1 ms to about 10 ms, about 1 ms to about 50 ms, about 10 ms to about 100 ms, about 25 ms to about 200 ms, about 50 ms to about 400 ms, about 100 ms to about 600 ms, about 300 ms to about 800 ms, or about 500 ms to about 1,000 ms. 00 ms, for example, about 0.01 ms to 100 ms, about 0.1 ms to about 50 ms, or about 1 ms to about 10 ms, for example, about 0.01 ms, about 0.02 ms, about 0.03 ms, about 0.04 ms, about 0.05 ms, about 0.06 ms, about 0.07 ms, about 0.08 ms, about 0.09 ms, about 0.1 ms, about 0.2 ms, about 0.3 ms, about 0 In some embodiments, the electroporation zone may be delivered for a duration of about 0.4 ms, about 0.5 ms, about 0.6 ms, about 0.7 ms, about 0.8 ms, about 0.9 ms, about 1 ms, about 2 ms, about 3 ms, about 4 ms, about 5 ms, about 6 ms, about 7 ms, about 8 ms, about 9 ms, about 10 ms, about 20 ms, about 30 ms, about 40 ms, about 50 ms, about 60 ms, about 70 ms, about 80 ms, about 90 ms, about 100 ms, about 150 ms, about 200 ms, about 250 ms, about 300 ms, about 350 ms, about 400 ms, about 450 ms, about 500 ms, about 550 ms, about 600 ms, about 650 ms, about 700 ms, about 750 ms, about 800 ms, about 850 ms, about 900 ms, about 950 ms, or about 1,000 ms.
[0162] In some cases, the number of applied voltage pulses delivered can be from 0 to about 1000 or more, e.g., 1 or more, 2 or more, 3 or more, 4 or more, 5 or more, 10 or more, or 100 or more, e.g., 1-4, 2-5, 3-6, 4-7, 5-8, 6-9, or 7-10, e.g., from about 0.01 to about 1,0 ... About 1, about 0.1 to about 10, about 1 to about 50, about 10 to about 100, about 25 to about 200, about 50 to about 400, about 100 to about 600, about 300 to about 800, or about 500 to about 1,000, for example, about 0.01 to 100, about 0.1 to about 50, or about 1 to about 10, for example, about 0.01, about 0.02, about 0.03, about .04 pieces, about 0.05 pieces, about 0.06 pieces, about 0.07 pieces, about 0.07 pieces, about 0.08 pieces, about 0.09 pieces, about 0.1 pieces, about 0.2 pieces, about 0.3 pieces, about 0.4 pieces, about 0.5 pieces , about 0.6 pieces, about 0.7 pieces, about 0.8 pieces, about 0.9 pieces, about 1 piece, about 2 pieces, about 3 pieces, about 4 pieces, about 5 pieces, about 6 pieces, about 7 pieces, about 8 pieces, about 9 pieces, about 10 pieces, about 20 pieces, about 30 pieces, about The number of nucleic acids may be about 40, about 50, about 60, about 70, about 80, about 90, about 100, about 150, about 200, about 250, about 300, about 350, about 400, about 450, about 500, about 550, about 600, about 650, about 700, about 750, about 800, about 850, about 900, about 950, or about 1,000.
[0163] The pulse of applied voltage may, in some cases, be between about 0.001% and about 100%, e.g., between about 0.001% and about 0.1%, between about 0.01% and about 1%, between about 0.1% and about 5%, between about 1% and about 10%, between about 2.5% and about 20%, between about 5% and about 40%, between about 10% and about 60%, between about 30% and about 80%, or between about 50% and about 10%. 00%, for example, about 0.01% to 100%, about 0.1% to about 99%, about 1% to about 97%, or about 10% to about 95%, for example, about 0.001%, about 0.002%, about 0.003%, about 0.004%, about 0.005%, about 0.006%, about 0.007%, about 0.008%, about 0.009%, about 0.0 1%, about 0.02%, about 0.03%, about 0.04%, about 0.05%, about 0.06%, about 0.07%, about 0.08%, about 0.09%, about 0.1%, about 0.2%, about 0.3%, about 0.4%, about 0.5%, about 0.6%, about 0.7%, about 0.8%, about 0.9%, about 1%, about 2%, about 3%, about 4%, about 5%, It may be delivered at a duty cycle of about 6%, about 7%, about 8%, about 9%, about 10%, about 15%, about 20%, about 25%, about 30%, about 35%, about 40%, about 45%, about 50%, about 55%, about 60%, about 65%, about 70%, about 75%, about 80%, about 85%, about 90%, about 95%, or about 100%.
[0164] The device(s) of the invention, when the electrodes are connected to a source of electrical potential and energized, generate a localized electric field in the electroporation zone that electroporates cells passing through. In some cases, the electric field generated in the electroporation zone is from about 2 V / cm to about 50,000 V / cm, e.g., from about 2 V / cm to about 1,000 V / cm, from about 100 V / cm to about 5,000 V / cm, from about 500 V / cm to about 10,000 V / cm, from about 1000 V / cm to about 25,000 V / cm, or from about 5,000 V / cm to about 50,000 V / cm, e.g., about 2 V / cm to about 20,000 V / cm, about 5 V / cm to about 10,000 V / cm, or about 100 V / cm to about 1,000 V / cm, for example, about 2 V / cm, about 3 V / cm, about 4 V / cm, about 5 V / cm, about 6 V / cm, about 7 V / cm, about 8 V / cm, about 9 V / cm, about 10 V / cm, about 20 V / cm, about 30 V / cm, about 40 V / cm, about 50 V / cm, about 60 V / cm, cm, approx. 70V / cm, approx. 80V / cm, approx. 90V / cm, approx. 100V / cm, approx. 200V / cm, approx. 300V / cm, approx. 400V / cm, approx. 500V / cm, approx. 600V / cm, approx. 700V / cm, approx. 800V / cm, approx. 900V / cm, approx. 1,000V / cm, approx. 2,000V / cm, approx. 3,000V / cm, approx. 4,000V / cm, approx. 5,000V / cm, The dielectric constant may be about 6,000 V / cm, about 7,000 V / cm, about 8,000 V / cm, about 9,000 V / cm, about 10,000 V / cm, about 15,000 V / cm, about 20,000 V / cm, about 25,000 V / cm, about 30,000 V / cm, about 35,000 V / cm, about 40,000 V / cm, about 45,000 V / cm, or about 50,000 V / cm.
[0165] The system of the present invention typically includes a fluid delivery source configured to deliver a plurality of cells suspended in a fluid through a first electrode, e.g., an entry zone, to a second electrode, e.g., a recovery zone. The fluid delivery source typically includes a pump, including, but not limited to, a syringe pump, a micropump, or a peristaltic pump. Alternatively, the fluid can be delivered by displacement of a working fluid to a reservoir of the fluid to be delivered, or by air displacement. Other fluid delivery sources are known in the art. In some embodiments, the fluid delivery source is configured to flow the cells suspended in the fluid by application of a positive pressure. While not wishing to be bound by any particular theory, the flow rate at which the cells in suspension flow through the device of the present invention, and the particular geometry of the electroporation zone of the device of the present invention, will determine the residence time of the cells in the electric field in the electroporation zone.
[0166] In some cases, the volumetric flow rate of the fluid delivered from the fluid delivery source is about 0.001 mL / min to about 1,000 mL / min, e.g., about 0.001 mL / min to about 0.1 mL / min, about 0.01 mL / min to about 1 mL / min, about 0.1 mL / min to about 10 mL / min, about 1 mL / min to about 50 mL / min, about 10 mL / min to about 100 mL / min, about 25 mL / min to about 200 mL / min, about 50 mL / min to about 400 mL / min, about 100 mL / min to about 600 mL / min, about 300 mL / min to about 800 mL / min, or about 500 mL / min to about 600 mL / min. About 1,000 mL / min, for example, about 0.001 mL / min, about 0.002 mL / min, about 0.003 mL / min, about 0.004 mL / min, about 0.005 mL / min, about 0.006 mL / min, about 0.007 mL / min, about 0.008 mL / min, about 0.009 mL / min, about 0.01 mL / min, about 0.02 mL / min, about 0.03 mL / min, about 0.04 mL / min, about 0.05 mL / min, about 0.06 mL / min, about 0.07 mL / min, about 0.08 mL / min, about 0.09 mL / min, about 0.1 mL / min, about 0.2 mL / min, about 0.3 mL / min, approx. 0.4mL / min, approx. 0.5mL / min, approx. 0.6mL / min, approx. 0.7mL / min, approx. 0.8mL / min, approx. 0.9mL / min, approx. 1mL / min, approx. 2mL / min, approx. 3mL / min, approx. 4mL / min, approx. 5mL / min, approx. 6mL / min, approx. 7mL / min, approx. 8mL / min 9 mL / min, 10 mL / min, 15 mL / min, 20 mL / min, 25 mL / min, 30 mL / min, 35 mL / min, 40 mL / min, 45 mL / min, 50 mL / min, 55 mL / min, 60 mL / min, 65 mL / min, 70 mL / min, The system has a volumetric flow rate of about 75 mL / min, about 80 mL / min, about 85 mL / min, about 90 mL / min, about 95 mL / min, about 100 mL / min, about 150 mL / min, about 200 mL / min, about 250 mL / min, about 300 mL / min, about 350 mL / min, about 400 mL / min, about 450 mL / min, about 500 mL / min, about 550 mL / min, about 600 mL / min, about 650 mL / min, about 700 mL / min, about 750 mL / min, about 800 mL / min, about 850 mL / min, about 900 mL / min, about 950 mL / min, or about 1,000 mL / min.In certain embodiments, the flow rate is between 10 mL / min and about 100 mL / min, e.g., about 10 mL / min, 20 mL / min, 30 mL / min, 40 mL / min, 50 mL / min, 60 mL / min, 70 mL / min, 80 mL / min, 90 mL / min, or 100 mL / min.
[0167] The residence time of cells in the electroporation zone of the device of the present invention is about 0.5 ms to about 50 ms, for example, about 0.5 ms to about 5 ms, about 1 ms to about 10 ms, about 5 ms to about 15 ms, about 10 ms to about 20 ms, about 15 ms to about 25 ms, about 20 ms to about 30 ms, about 25 ms to about 35 ms, about 30 ms to about 40 ms, about 35 ms to about 45 ms, or about 40 ms to about 50 ms, for example, about 0.5 ms, about 0.6 ms, about 0.7 ms, about 0.8 ms, about 0.9 ms, about 1 ms, about 1.5 ms, about 2 ms, or about 3 ms. s, about 2.5 ms, about 3 ms, about 3.5 ms, about 4 ms, about 4.5 ms, about 5 ms, about 5.5 ms, about 6 ms, about 6.5 ms, about 7 ms, about 7.5 ms, about 8 ms, about 8.5 ms, about 9 ms, about 9.5 ms, about 10 ms, about 10.5 ms, about 11 ms, about 11.5 ms, about 12 ms, about 12.5 ms, about 13 ms, about 13.5 ms, about 14 ms, about 14.5 ms, about 15 ms, about 20 ms, about 25 ms, about 30 ms, about 35 ms, about 40 ms, about 45 ms, or about 50 ms. In some embodiments, the dwell time is 5 to 20 ms (e.g., 6 to 18 ms, 8 to 15 ms, or 5 to 14 ms).
[0168] The systems of the invention typically feature a housing that contains and supports the device(s) of the invention and any necessary electrical connections, e.g., electrode connections. The housing can be configured to hold and energize a single device of the invention, or alternatively, to hold and energize multiple devices of the invention simultaneously. For example, in the embodiment of the system of the invention shown in Figures 2A-2B, the housing is configured as a rack that can receive and energize 96 individual devices of the invention operating in parallel. The housing can include a thermal controller that can regulate the temperature of the device of the invention or thermoregulate a component of the system, e.g., a fluid, e.g., a buffer or a suspension containing cells, during electroporation. The thermal controller can be configured to heat the device of the invention, or a component of the system of these devices, cool the device of the invention, or a component of the system of these devices, or perform both operations. When configured to heat the devices of the invention, or components of the systems of these devices, suitable thermal controllers include, but are not limited to, heating blocks or mantles, liquid heating, e.g., immersion or circulating fluid baths, battery-operated heaters, or resistive heaters, e.g., thin film heaters, e.g., heat tapes. When configured to cool the devices of the invention, or components of the systems of these devices, suitable thermal controllers include, but are not limited to, liquid cooling, e.g., immersion or circulating fluid baths, evaporative coolers, or thermoelectric coolers, e.g., Peltier coolers. For example, when implemented with liquid cooling, the devices of the invention, or a housing configured to hold the devices of the invention, may be in direct contact with tubes that circulate the cooled fluid, or may be surrounded by a cooling jacket that includes tubes that circulate the cooled fluid. Other heating and cooling elements are known in the art.
[0169] The system of the present invention may include one or more outer structures configured to cover the electrodes of one or more devices of the present invention, e.g., to reduce end user exposure to active electrical connections. Typically, a device of the present invention (e.g., Flowfect™ device) includes one outer structure that covers the electrodes and electroporation zone of the device. The outer structure may be a non-conductive material, e.g., a non-conductive polymer, that includes structural features for electromechanically engaging portions of the device, e.g., the electrodes or the electroporation zone. The outer structure may include one or more recesses, notches, or similar openings in the structure for accommodating the device. The outer structure may be configured to be a component that can be removed from the device. For example, the outer structure may appear as two separate components connected by a hinge, e.g., a living hinge, so that the outer structure can be folded onto the device of the present invention. Alternatively, the outer structure may be one or more separate parts that can be connected together to form a single structure using suitable mating features. In these embodiments, the outer structure can be secured to the device of the present invention using any suitable fastener, such as a snap, latch, button, or clip, which can be integrated into the outer structure or externally connected to the outer structure. Other suitable fastener types are known in the art. In some embodiments, the outer structure includes one or more alignment features, such as a pin, divot, groove, or tab, that ensure proper alignment of one or more parts of the outer structure. In some cases, the outer structure is configured to be permanently connected to the device of the present invention.
[0170] In any of the embodiments of the outer structure described herein, the outer structure provides an electrical connection between an external potential source and the electrodes of the device of the invention. For example, the outer structure may include one or more electrical inputs for electrical connections, such as spades, banana plugs, or bayonets, e.g., BNC connectors, that facilitate electrical connection between a potential source and the electrodes of the device of the invention inside the outer structure.
[0171] The device and external structure of the present invention may be combined in a kit with additional external components such as reagents, e.g., buffers, e.g., transfection buffers or harvest buffers, and / or samples. In some cases, the transfection buffer comprises a composition suitable for cell electroporation. In some cases, the transfection buffer comprises a suitable concentration of one or more salts (e.g., potassium chloride, sodium chloride, potassium phosphate, potassium dihydrogen phosphate) or sugars (e.g., dextrose or myo-inositol), or any combination thereof, at a concentration of 0.1-200 mM (e.g., 0.1-1.0 mM, 1.0 mM-10 mM, or 10 mM-100 mM).
[0172] method The present invention features a method for introducing a composition, e.g., transfection, into at least a portion of a plurality of cells suspended in a fluid using the electroporation device described herein. The method described herein can be used to greatly increase the throughput of delivery of compositions to cell types, which is often considered a bottleneck in the research field of genetic engineering and the therapeutic field of genetically modified cell therapy. In particular, the method described herein significantly increases the number of recovered cells, transfection efficiency, and cell viability after transfection by applying to more cell types than typical transfection methods, e.g., lentiviral transfection, or commercially available cell transfection instruments, e.g., NEON® transfection system (Thermo Fisher, Carlsbad, CA) or NUCLEOFECTOR 4D (Lonza, Switzerland).
[0173] As described herein, a composition is introduced into at least a portion of a plurality of cells suspended in a fluid by passing a fluid having suspended cells, which also contains a composition to be introduced into the cells, through a device of the present invention, e.g., an electroporation device. The composition and cells suspended in a fluid can be delivered through the device of the present invention by applying positive pressure, e.g., from a pump connected to a fluid source, e.g., a peristaltic pump, a digital pipette, or an automated liquid handling source. The composition and cells suspended in a fluid move from a first electrode, e.g., including an entry zone, to an electroporation zone fluidly connected to the first electrode, and then to a recovery zone fluidly connected to the electroporation zone. As the composition and cells suspended in a fluid flow through the first electrode to the electroporation zone, a potential difference is applied to the first electrode and the second electrode, producing cells, thus exposing the cells to an electric field in the electroporation zone. Exposure of the cells to the generated electric field increases the temporary permeability of the plurality of cells, thus introducing the composition into at least a portion of the plurality of cells.
[0174] In some instances of the methods, the phenotype of the cells may or may not be altered relative to a baseline measurement of the cell phenotype upon exiting the electroporation zone of the device of the invention. In some cases, the phenotype of the cells is altered by between 0% and about 25%, e.g., between about 0% and about 2.5%, between about 1% and about 5%, between about 1% and about 10%, between about 5% and about 15%, between about 10% and about 20%, between about 15% and about 25%, or between about 20% and about 25%, e.g., about 1%, about 2%, about 3%, about 4%, about 5%, about 6%, about 7%, about 8%, about 9%, about 10%, about 11%, about 12%, about 13%, about 14%, about 15%, about 16%, about 17%, about 18%, about 19%, about 20%, about 21%, about 22%, about 23%, about 24%, or about 25%, relative to a baseline measurement of the cell phenotype upon exiting the electroporation zone of a device of the invention. In certain cases, the phenotype of a plurality of cells is unchanged upon exiting the electroporation zone. For example, the baseline or control measurements for establishing cell phenotype can be measurements of the expression of cell surface markers on cells that are not transfected using the device of the present invention. The corresponding identical measurements of the expression of the same cell markers on cells that are transfected using the device of the present invention can be used to evaluate changes in cell phenotype. To ensure that cell phenotype is minimally or not changed after electroporation, cell phenotype is evaluated by flow cytometry analysis of cell surface marker expression. Examples of cell surface markers to be evaluated include, but are not limited to, CD3, CD4, CD8, CD19, CD45RA, CD45RO, CD28, CD44, CD69, CD80, CD86, CD206, IL-2 receptor, CTLA4, OX40, PD-1, and TIM3. Cell morphology is evaluated using bright field or fluorescent microscopy to confirm the lack of phenotypic change after electroporation.
[0175] In some cases, after introducing the composition into at least a portion of the plurality of cells, the plurality of cells is stored in a collection buffer. The collection buffer is configured to facilitate eventual closure of pores formed in the plurality of cells. The collection buffer typically comprises a cell culture medium that may contain other components for cell nutrition and growth, such as serum, minerals, etc. One skilled in the art can understand that the selection of the collection buffer depends on the cell type to be subjected to electroporation.
[0176] In some embodiments of the methods described herein, the volume of fluid having suspended cells and a composition to be introduced to the cells that is flowed through the electroporation zone of a device of the invention is from about 0.001 mL to about 2000 mL, from about 0.001 mL to about 1000 mL, e.g., from 0.001 mL to about 1000 mL, e.g., from about 0.001 mL to about 0.1 mL, from about 0.01 mL to about 1 mL, from about 0.1 mL to about 5 mL, from about 1 mL to about 10 mL, from about 2.5 mL to about 20 mL. , about 5 mL to about 40 mL, about 10 mL to about 60 mL, about 30 mL to about 80 mL, about 50 mL to about 200 mL, about 100 mL to about 500 mL, or 250 mL to about 750 mL, or about 500 mL to about 1000 mL, for example, about 0.01 mL to 100 mL, about 0.1 mL to about 99 mL, about 1 mL to about 97 mL, or about 10 mL to about 95 mL, for example, about 0.0025 mL to about 10 mL, about 0.01 mL to about 1 mL, or about 0.025 mL to about 0.1 mL, e.g., about 0.001 mL, about 0.0025 mL, about 0.005 mL, about 0.0075 mL, about 0.01 mL, about 0.025 mL, about 0.05 mL, about 0.075 mL, about 0.1 mL, about 0.25 mL, about 0.5 mL, About 0.75mL, about 1mL, about 2mL, about 3mL, about 4mL, about 5mL, about 6mL, about 7mL, about 8mL, about 9mL, about 10mL, about 15mL, about 20mL, about 25mL, about 30mL, about 35mL, about 40mL, about 45mL, It can be about 50 mL, about 55 mL, about 60 mL, about 65 mL, about 70 mL, about 75 mL, about 80 mL, about 85 mL, about 90 mL, about 95 mL, about 100 mL, about 150 mL, about 200 mL, about 250 mL, about 300 mL, about 350 mL, about 400 mL, about 450 mL, about 500 mL, about 550 mL, about 600 mL, about 650 mL, about 700 mL, about 750 mL, about 800 mL, about 850 mL, about 900 mL, about 950 mL, or about 1000 mL.
[0177] In certain embodiments, the electrical conductivity of the fluid in which the cells are suspended can affect the electroporation of the cells in suspension and therefore the delivery of compositions to those cells. The electrical conductivity of the fluid having the suspended cells can be from about 0.001 mS to about 500 mS, e.g., from about 0.001 mS to about 0.1 mS, from about 0.01 mS to about 1 mS, from about 0.1 mS to about 10 mS, from about 1 mS to about 50 mS, from about 10 mS to about 100 mS, from about 25 mS to about 200 mS, from about 50 mS to about 400 mS, or from about 100 mS to about 500 mS, e.g., about 0.01 mS about 0.001 mS, about 0.002 mS, about 0.003 mS, about 0.004 mS, about 0.005 mS, about 0.006 mS, about 0.007 mS, about 0.008 mS, about 0.009 mS, about 0.01 mS, about 0.02 mS, about 0.03 mS, about 0.04 mS, about 0.05 mS, about 0 .06mS, approx. 0.07mS, approx. 0.08mS, approx. 0.09mS, approx. 0.1mS, approx. 0.2mS, approx. 0.3mS, approx. 0.4mS, approx. 0.5mS, approx. 0.6mS, approx. 0.7mS, approx. 0.8mS, approx. 0.9mS, approx. 1mS, approx. 2mS, approx. 3mS, approx. 4mS, approx. 5mS, approx. 6mS, approx. 7mS, approx. 8mS, approx. 9mS, approx. 10mS, approx. 15mS, approx. 20mS, approx. 25 In one embodiment, the infusion time may be about 100 mS, about 200 mS, about 250 mS, about 300 mS, about 350 mS, about 40 mS, about 45 mS, about 50 mS, about 55 mS, about 60 mS, about 65 mS, about 70 mS, about 75 mS, about 80 mS, about 85 mS, about 90 mS, about 95 mS, about 100 mS, about 150 mS, about 200 mS, about 250 mS, about 300 mS, about 350 mS, about 400 mS, about 450 mS, or about 500 mS.
[0178] The methods of the invention can deliver compositions to a variety of cell types, including, but not limited to, mammalian cells, eukaryotic, prokaryotic, synthetic cells, human cells, animal cells, plant cells, primary cells, cell lines, suspension cells, adherent cells, unstimulated cells, stimulated cells, or activated cells immune cells, stem cells (e.g., primary human induced pluripotent stem cells, e.g., iPSCs, embryonic stem cells, e.g., ESCs, mesenchymal stem cells, e.g., MSCs, or hematopoietic stem cells, e.g., HSCs), blood cells (e.g., red blood cells), T cells (e.g., primary human T cells), B cells, antigen presenting cells (APCs), natural killer (NK) cells (e.g., primary human NK cells), monocytes (e.g., primary human monocytes), macrophages (e.g., primary human macrophages), and peripheral blood mononuclear cells (PBMCs), neutrophils, dendritic cells, human embryonic kidney (e.g., HEK-293) cells, or Chinese hamster ovary (e.g., CHO-K1) cells. The typical number of cells that can be electroporated is approximately 10 4 cells ~ about 10 12 Cells, (e.g., about 10 4 cells ~ about 10 5 cells, about 10 4 cells ~ about 10 6 cells, about 10 4 cells ~ about 10 7 cells, approximately 5 x 10 4 Cells ~ approx. 5 x 10 5 cells, about 10 5 cells ~ about 10 6 cells, about 10 5 cells ~ about 10 7 cells, approximately 2.5 x 10 5 cells ~ about 10 6 cells, approximately 5 x 10 5 Cells ~ approx. 5 x 10 6 cells, about 10 6 cells ~ about 10 7 cells, about 10 6 cells ~ about 10 8 cells, about 10 6 cells ~ about 10 12 cells, approximately 5 x 10 6 Cells ~ approx. 5 x 10 7 cells, about 10 7 cells ~ about 10 8 cells, about 10 7 cells ~ about 10 9 cells, about 107 cells ~ about 10 12 cells, approximately 5 x 10 7 Cells ~ approx. 5 x 10 8 cells, about 10 8 cells ~ about 10 9 cells, about 10 8 cells ~ about 10 10 cells, about 10 8 cells ~ about 10 12 cells, approximately 5 x 10 8 Cells ~ approx. 5 x 10 9 cells, about 10 9 cells ~ about 10 10 cells, about 10 9 cells ~ about 10 11 cells, about 10 10 cells ~ about 10 11 cells, about 10 10 cells ~ about 10 12 cells, or about 10 11 cells ~ about 10 12 Cells, e.g., about 10 4 cells, approximately 2.5 x 10 4 cells, approximately 5 x 10 4 cells, about 10 5 cells, approximately 2.5 x 10 5 cells, approximately 5 x 10 5 cells, about 10 6 cells, approximately 2.5 x 10 6 cells, approximately 5 x 10 6 cells, about 10 7 cells, approximately 2.5 x 10 7 cells, approximately 5 x 10 7 cells, about 10 8 cells, approximately 2.5 x 10 8 cells, approximately 5 x 10 8 cells, about 10 9 cells, approximately 2.5 x 10 9 cells, approximately 5 x 10 9 cells, about 10 10 cells, approximately 5 x 10 10 cells, about 10 11 cells, or about 10 12 The present invention may be directed to a method for detecting a cell.
[0179] about 10 4 cells ~ about 10 12The cell concentration to achieve a cell poration rate, i.e., the number of cells per mL of fluid, is typically about 10 3 cells / mL~about 10 11 Cells / mL, e.g., about 10 3 cells / mL~about 10 4 cells / mL, approximately 5×10 3 cells / mL ~ approx. 5×10 4 cells / mL, approximately 10 5 cells / mL~about 10 5 cells / mL, approximately 5×10 5 cells / mL ~ approx. 5×10 6 cells / mL, approximately 10 6 cells / mL~about 10 7 cells / mL, approximately 5×10 6 cells / mL ~ approx. 5×10 7 cells / mL, approximately 10 7 cells / mL~about 10 8 cells / mL, approximately 5×10 7 cells / mL ~ approx. 5×10 8 cells / mL, approximately 10 8 cells / mL~about 10 9 cells / mL, approximately 5×10 8 cells / mL ~ approx. 5×10 9 cells / mL, approximately 10 9 cells / mL~about 10 9 cells / mL, approximately 5×10 9 cells / mL ~ approx. 5×10 10 cells / mL, or approximately 10 10 cells / mL~about 10 11 Cells / mL, e.g., about 10 3 cells / mL, approximately 5×10 3 cells / mL, approximately 10 4 cells / mL, approximately 5×10 4 cells / mL, approximately 10 5 cells / mL, approximately 5×10 5 cells / mL, approximately 10 6 cells / mL, approximately 5×10 6 cells / mL, approximately 10 7 cells / mL, approximately 5×10 7 cells / mL, approximately 10 8 cells / mL, approximately 5×10 8 cells / mL, approximately 10 9 cells / mL, approximately 5×109 cells / mL, approximately 10 10 cells / mL, approximately 5×10 10 cells / mL, or approximately 10 11 cells / mL.
[0180] The method of the present invention described herein can deliver any composition to cells suspended in fluid.The composition that can be delivered to cells includes, but is not limited to, therapeutic agents, vitamins, nanoparticles, charged molecules, such as ions in solution, uncharged molecules, nucleic acids, such as DNA or RNA, CRISPR-Cas complexes, proteins, polymers, ribonucleoproteins (RNPs), engineered nucleases, transcription activator-like effector nucleases (TALENs), zinc finger nucleases (ZFNs), homing nucleases, meganucleases (MNs), megaTALs, enzymes, peptides, transposons, or polysaccharides, such as dextran, such as dextran sulfate. Exemplary compositions that can be delivered to cells in suspension include nucleic acids, oligonucleotides, antibodies (or antibody fragments, e.g., bispecific fragments, trispecific fragments, Fab, F(ab')2, or single chain variable fragments (scFv)), amino acids, peptides, proteins, gene therapy drugs, genomically engineered therapeutic drugs, epigenetically engineered therapeutic drugs, carbohydrates, chemical drugs, contrast agents, magnetic particles, polymeric beads, metal nanoparticles, metal microparticles, quantum dots, antioxidants, antibiotics, hormones, nucleoproteins, polysaccharides, glycoproteins, lipoproteins, steroids, anti-inflammatory agents, antimicrobial agents, chemotherapeutic agents, exosomes, outer membrane vesicles, vaccines, viruses, bacterial phages, adjuvants, minerals, and combinations thereof. The composition delivered may include a single compound, such as the compounds described herein. Alternatively, the composition delivered may include multiple compounds or components that target different genes.
[0181] Typical concentrations of the composition in the fluid are from about 0.0001 μg / mL to about 1000 μg / mL, (e.g., from about 0.0001 μg / mL to about 0.001 μg / mL, from about 0.001 μg / mL to about 0.01 μg / mL, from about 0.001 μg / mL to about 5 μg / mL, from about 0.005 μg / mL to about 0.1 μg / mL, from about 0.01 μg / mL to about 0.1 μg / mL, from about 0.01 μg / mL to about 1 μg / mL, from about 0.1 μg / mL to about 1 μg / mL, from about 0.1 μg / mL to about 5 μg / mL, from about 1 μg / mL to about 10 μg / mL, from about 1 μg / mL to about 50 μg / mL, from about 1μg / mL to about 100μg / mL, about 2.5μg / mL to about 15μg / mL, about 5μg / mL to about 25μg / mL, about 5μg / mL to about 50μg / mL, about 5μg / mL to about 500μg / mL, about 7.5μg / mL to about 75μg / mL, about 10μg / mL to about 100μg / mL mL, about 10 μg / mL to about 1,000 μg / mL, about 25 μg / mL to about 50 μg / mL, about 25 μg / mL to about 250 μg / mL, about 25 μg / mL to about 500 μg / mL, about 50 μg / mL to about 100 μg / mL, about 50 μg / mL to about 250 μg / mL, about 50 μg / mL mL to about 750 μg / mL, about 100 μg / mL to about 300 μg / mL, about 100 μg / mL to about 1,000 μg / mL, about 200 μg / mL to about 400 μg / mL, about 250 μg / mL to about 500 μg / mL, about 350 μg / mL to about 500 μg / mL, about 400 μg / mL to about 1,000 μg / mL, about 500 μg / mL to about 750 μg / mL, about 650 μg / mL to about 1,000 μg / mL, or about 800 μg / mL to about 1,000 μg / mL, for example, about 0.0001 μg / mL, about 0.0005 μg / mL, about 0.001 μg / mL, about 0.005μg / mL, approximately 0.01μg / mL, approximately 0.02μg / mL, approximately 0.03μg / mL, approximately 0.04μg / mL, approximately 0.05μg / mL, approximately 0.06μg / mL, approximately 0.07μg / mL, approximately 0.08μg / mL, approximately 0.09μg / mL, approximately 0.1μg / mL, approximately 0. 2μg / mL, approximately 0.3μg / mL, approximately 0.4μg / mL, approximately 0.5μg / mL, approximately 0.6μg / mL, approximately 0.7μg / mL, approximately 0.8μg / mL, approximately 0.9μg / mL, approximately 1μg / mL, approximately 1.5μg / mL, approximately 2μg / mL, approximately 2.5μg / mL, approximately 3μg / mL, approximately 3.5μg / mL, approximately 4μg / mL, approximately 4.5μg / mL, approximately 5μg / mL, approximately 5.5μg / mL, approximately 6μg / mL, approximately 6.5μg / mL, approximately 7μg / mL, approximately 7.5μg / mL, approximately 8μg / mL, approximately 8.5μg / mL, approximately 9μg / mL, approximately 9.5μg / mL, approximately 1 0μg / mL, approximately 15μg / mL, approximately 20μg / mL, approximately 25μg / mL, approximately 30μg / mL, approximately 35μg / mL, approximately 40μg / mL, approximately 45μg / mL, approximately 50μg / mL, approximately 55μg / mL, approximately 60μg / mL, approximately 65μg / mL, approximately 70μg / mL, approximately 7 The concentration of the glycerol in the solution may be about 5 μg / mL, about 80 μg / mL, about 85 μg / mL, about 90 μg / mL, about 95 μg / mL, about 100 μg / mL, about 200 μg / mL, about 250 μg / mL, about 300 μg / mL, about 350 μg / mL, about 400 μg / mL, about 450 μg / mL, about 500 μg / mL, about 550 μg / mL, about 600 μg / mL, about 650 μg / mL, about 700 μg / mL, about 750 μg / mL, about 800 μg / mL, about 850 μg / mL, about 900 μg / mL, about 950 μg / mL, or about 1,000 μg / mL).
[0182] In some cases, the temperature of the fluid with the suspended cells and composition is controlled using a thermal controller integrated into the housing supporting the device(s) of the invention. The temperature of the fluid is controlled to reduce the effects of Joule heating resulting from the electric field generated within the electroporation zone, since too high a temperature can impair cell viability after electroporation. The temperature of the fluid can be between about 0°C and about 50°C, e.g., between about 0°C and about 10°C, between about 1°C and about 5°C, between about 2°C and about 15°C, between about 3°C and about 20°C, between about 4°C and about 25°C, between about 5°C and about 30°C, between about 7°C and about 35°C, between about 9°C and about 40°C, between about 10°C and about 43°C, between about 15°C and about 50°C, between about 20°C and about 40°C, between about 25°C and about 50°C, or between about 35°C and about 45°C, e.g. ...0°C and about 43°C, between about 10°C and about 43°C, between about 10°C and about 43°C, between about 10°C and about 43°C, between about 10°C and about 43°C, between about 10°C and about 43°C, between about 10°C and about 43°C, between about 10°C and about 43° For example, about 0°C, about 1°C, about 2°C, about 3°C, about 4°C, about 5°C, about 6°C, about 7°C, about 8°C, about 9°C, about 10°C, about 11°C, about 12°C, about 13°C, about 14°C, about 15°C, about 16°C, about 17°C, about 18°C, about 19°C, about 20°C, about 21°C, about 22°C, about 23°C, about 24°C, about 25°C, about 26°C, about 27°C, about 28°C, about 29°C, about 30°C The temperature may be about 31°C, about 32°C, about 33°C, about 34°C, about 35°C, about 36°C, about 37°C, about 38°C, about 39°C, about 40°C, about 41°C, about 42°C, about 43°C, about 44°C, about 45°C, about 46°C, about 47°C, about 48°C, about 49°C, or about 50°C.
[0183] Cells transfected using the methods of the present invention are more efficiently transfected and have higher viability than using typical transfection methods, such as lentiviral transfection, or commercially available cell transfection instruments, such as the NEON® Transfection System (Thermo Fisher, Carlsbad, Calif.) or NUCLEOFECTOR 4D (Lonza, Switzerland). For example, for the methods described herein, the transfection efficiency, i.e., the efficiency of successfully delivering a composition to a cell, may be about 0.1% to about 99.9%, e.g., about 0.1% to about 5%, about 1% to about 10%, about 2.5% to about 20%, about 5% to about 40%, about 10% to about 60%, about 30% to about 80%, or about 50% to about 99.9%, e.g., about 10% to about 90%, about 25% to about 85%, e.g., about 0.1%, about 0.15%, about 0.2%, about 0.25%, about 0.3%, about 0.35%, about 0.4%, about 0.5%, about 0.6%, about 0.7%, about 0.8%, about 0.9%, about 10% to about 12%, about 13% to about 14%, about 15% to about 16%, about 17% to about 18%, about 19% to about 20%, about 21% to about 22%, about 22% to about 24%, about 25% to about 26%, about 27% to about 28%, about 29% to about 30%, about 31% to about 32%, about 33% to about 34%, about 35% to about 36%, about 37% to about 38%, about 39% to about 40%, about 40 ... The concentration of the ion exchange polymer may be about 0.4%, about 0.45%, about 0.5%, about 0.55%, about 0.6%, about 0.65%, about 0.7%, about 0.75%, about 0.8%, about 0.85%, about 0.9%, about 0.95%, about 1%, about 2%, about 3%, about 4%, about 5%, about 6%, about 7%, about 8%, about 9%, about 10%, about 15%, about 20%, about 25%, about 30%, about 35%, about 40%, about 45%, about 50%, about 55%, about 60%, about 65%, about 70%, about 75%, about 80%, about 85%, about 90%, about 95%, or about 99.9%.
[0184] The cell viability, i.e., the number or percentage of cells that survived electroporation, of cells suspended in a fluid after having a composition introduced using the methods of the invention described herein is between about 0.1% and about 99.9%, e.g., between about 0.1% and about 5%, between about 1% and about 10%, between about 2.5% and about 20%, between about 5% and about 40%, between about 10% and about 60%, between about 30% and about 80%, or between about 50% and about 99.9%, e.g., between about 10% and about 90%, between about 25% and about 85%, e.g., about 0.1%, about 0.15%, about 0.2%, about 0.25%, about 0.3%. , about 0.35%, about 0.4%, about 0.45%, about 0.5%, about 0.55%, about 0.6%, about 0.65%, about 0.7%, about 0.75%, about 0.8%, about 0.85%, about 0.9%, about 0.95%, about 1%, about 2%, about 3%, about 4%, about 5%, about 6%, about 7%, about 8%, about 9%, about 10%, about 15%, about 20%, about 25%, about 30%, about 35%, about 40%, about 45%, about 50%, about 55%, about 60%, about 65%, about 70%, about 75%, about 80%, about 85%, about 90%, about 95%, or about 99.9%.
[0185] The number of cells recovered, i.e., the number of viable cells recovered after electroporation, was approximately 10 4 cells ~ about 10 12 Cells, e.g., about 10 4 cells ~ about 10 5 cells, about 10 4 cells ~ about 10 6 cells, about 10 4 cells ~ about 10 7 cells, approximately 5 x 10 4 Cells ~ approx. 5 x 10 5 cells, about 10 5 cells ~ about 10 6 cells, about 10 5 cells ~ about 10 7 cells, approximately 2.5 x 10 5 cells ~ about 10 6 cells, approximately 5 x 10 5 Cells ~ approx. 5 x 10 6 cells, about 10 6 cells ~ about 10 7 cells, about 10 6 cells ~ about 10 8 cells, about 10 6 cells ~ about 10 12cells, approximately 5 x 10 6 Cells ~ approx. 5 x 10 7 cells, about 10 7 cells ~ about 10 8 cells, about 10 7 cells ~ about 10 9 cells, about 10 7 cells ~ about 10 12 cells, approximately 5 x 10 7 Cells ~ approx. 5 x 10 8 cells, about 10 8 cells ~ about 10 9 cells, about 10 8 cells ~ about 10 10 cells, about 10 8 cells ~ about 10 12 cells, approximately 5 x 10 8 Cells ~ approx. 5 x 10 9 cells, about 10 9 cells ~ about 10 10 cells, about 10 9 cells ~ about 10 11 cells, about 10 10 cells ~ about 10 11 cells, about 10 10 cells ~ about 10 12 cells, or about 10 11 cells ~ about 10 12 Cells, e.g., about 10 4 cells, approximately 2.5 x 10 4 cells, approximately 5 x 10 4 cells, about 10 5 cells, approximately 2.5 x 10 5 cells, approximately 5 x 10 5 cells, about 10 6 cells, approximately 2.5 x 10 6 cells, approximately 5 x 10 6 cells, about 10 7 cells, approximately 2.5 x 10 7 cells, approximately 5 x 10 7 cells, about 10 8 cells, approximately 2.5 x 10 8 cells, approximately 5 x 10 8 cells, about 10 9 cells, approximately 2.5 x 10 9 cells, approximately 5 x 10 9 cells, about 10 10 cells, approximately 5 x 10 10 cells, about 10 11 cells, or about 1012 It may be a cell.
[0186] The recovery yield, i.e., the percentage of live engineered cells collected after electroporation, may be from about 0.1% to about 500%, e.g., from about 0.1% to about 5%, from about 1% to about 10%, from about 2.5% to about 20%, from about 5% to about 40%, from about 10% to about 60%, from about 30% to about 80%, from about 50% to about 99.9%, from about 75% to about 150%, from about 100% to about 200%, from about 150% to about 250%, from about 200% to about 300%, from about 250% to about 350%, from about 300% to about 400%, from about 400% to about 500%, from about 500% to about 600%, from about 600% to about 800%, from about 750% to about 150%, from about 100% to about 200%, from about 150% to about 250%, from about 200% to about 300%, from about 250% to about 350%, from about 300% to about 400%, from about 400% to about 500%, from about 500% to about 600%, from about 500% to about 99.9%, from about 75% to about 150%, from about 100% to about 200%, from about 150% to about 250%, from about 200% to about 300%, from about 300% to about 400%, from about 400% to about 500%, from about 500% to about 600%, from about 500% to about 99.9%, from about 75% to about 150%, from about 100 % to about 400%, about 350% to about 450%, or about 400% to about 500%, for example, about 0.1%, about 0.15%, about 0.2%, about 0.25%, about 0.3%, about 0.35%, about 0.4%, about 0.45%, about 0.5%, about 0.55%, about 0.6%, about 0.65%, about 0.7%, about 0.75%, about 0.8%, about 0.85%, about 0.9%, about 0.95%, about 1%, about 2%, about 3%, about 4%, about 5%, about 6%, about 7%, about 8%, about 9%, about 10%, about 15%, about 20%, about 25%, about 30%, about 35%, about 40%, about 45%, about 50%, about 55%, about 60%, about 65%, about 70%, about 75%, about 80%, about 85%, about 90%, about 95%, about 99.9%, about 100%, about 110%, about 120%, about 130%, about 140%, about 150%, about 160%, about 170%, about 180%, about 190%, about 200%, about 210%, about The concentration may be about 220%, about 230%, about 240%, about 250%, about 260%, about 270%, about 280%, about 290%, about 300%, about 310%, about 320%, about 330%, about 340%, about 350%, about 360%, about 370%, about 380%, about 390%, about 400%, about 410%, about 420%, about 430%, about 440%, about 450%, about 460%, about 470%, about 480%, about 490%, or about 500%.
[0187] One of skill in the art will appreciate that optimal conditions may vary depending on cell type or other factors. For each new cell type, the following parameters can be adjusted as necessary: waveform, electric field, pulse duration, buffer exposure time, buffer temperature, and post-electroporation conditions. EXAMPLES
[0188] Example 1 - Device and system Continuous flow electroporation devices and associated systems have been designed and manufactured to enhance or maximize throughput in cell engineering and / or accelerate biological discovery by allowing multiple devices to be used in parallel to enhance or maximize the number of cell electroporation events that occur in a fixed time window. The electroporation devices are configured to be compatible with current automated fluid handling systems, e.g., pipette tip based dispensers, robotic fluid pumps, etc.
[0189] FIG. 1A shows a schematic diagram of an exemplary embodiment of an electroporation device, shown in this configuration as a pipette tip. FIG. 1A shows a close-up view of the active area of the device, including the electroporation zone. This device provides continuous flow genetic manipulation of both eukaryotic and prokaryotic cells in a platform that can be easily automated through integration with liquid handling robots. In the device of FIGS. 1A-1C, the active area of the device includes three distinct zones: an entry zone, an electroporation zone, and a recovery zone. In the embodiment shown in FIGS. 1A-1C, the composition to be introduced into the cells and the cells to be transfected are placed in the entry zone. The cells and composition are passed through the electroporation zone, and the transfected cells are dispensed into a buffer for storage in the recovery zone. Thus, the space between the entry zone and the recovery zone is the electroporation zone, and all three zones are in fluid communication (e.g., fluidly connected) such that there is one flow path through the device.
[0190] In the embodiment shown in FIG. 1A, the entry and recovery zones are fabricated from hollow electrodes made of a suitable material, such as stainless steel, with the entry zone electrode acting as the current carrying electrode and the recovery zone electrode acting as the ground electrode, thus completing a circuit while allowing an electric field to develop between the two electrodes (in combination with the conductivity of the fluid carrying the cells and compositions).
[0191] The electroporation device of the present invention is designed to meet the requirements of injection molding and insert molding manufacturing techniques, both of which are inherently scalable, and is shown in Figures 1B and 1C. In Figures 1B and 1C, the device body is integrated with an electroporation zone located between commercial stainless steel electrodes where the electric field is active. The electroporation zone geometry was modified to exhibit a substantially uniform cross-section, resulting in more predictable electric field exposure during the dwell time of the electroporation sample. Using current production methods, such as 3D printing, approximately 100 devices can be manufactured per day, which is scalable to more than 10,000 devices per day using more robust large-scale production methods, such as injection molding and insert molding.
[0192] The housing can be configured to energize multiple electroporation devices, for example, 96 electroporation devices in an industry standard 96-well pipette tip tray with grid electrodes, in parallel to simultaneously energize all of the electroporation devices with the same applied voltage pulse so that the electric field in each electroporation device is the same. A single power source can be used to deliver the electrical energy. Therefore, a mechanism for distributing power to each electroporation device may be required. One way to implement this is shown in FIG. 2A, with an exploded view in FIG. 2B. This design features spring-loaded electrodes that enter the housing of 96 individual electroporation devices, with the first and second electrodes of each electroporation device physically contacting the electrical grid of the housing. Each of the spring-loaded electrodes is connected in parallel to the electrical grid of the housing, which is connected to a power source by a single set of leads. The housing is reusable so that when connected to a power source, it can facilitate the genetic modification of up to 96 discrete samples simultaneously. The power supply may include additional circuitry or programming configured to modulate the pulse delivery so that each individual device of the invention, for example 96 individual devices, receives a different voltage or different waveform.
[0193] Example 2 - Initial development of experimental parameters for optimal transfection Experiments have been conducted to study the physical and biological parameters that affect electroporation of Jurkat immortalized T-cell lines using the device of the present invention. Using industry standard flow cytometry methods, both cell viability (measured by 7AAD dye exclusion) and transfection efficiency (measured by GFP expression) of genetically engineered Jurkat cells were evaluated using the device of the present invention, both of which are common measures of electroporation success in the field of gene delivery.
[0194] Unless otherwise specified, experimental results shown below were obtained using 5 µg of plasmid (e.g., GFP-expressing plasmid) at 1 × 10 in 100 µL of buffer. 6 The transfection was generated by electroporating a population of Jurkat cells at a concentration of 100 μg / ml. Electroporation experiments were performed at 100 Hz with a square waveform and a pulse duration of 9.5 ms. After 24 hours of incubation, cells were stained with 7-AAD stain and analyzed by flow cytometry to measure viable cells and live GFP expressing cells. Three experiments were performed with error bars representing standard error of the mean (SEM). Table 1 below provides a summary of the parameters used for transfection using the device of the present invention. [Table 1]
[0195] Example 3 - Transfection data using the device of the present invention The device of the present invention exhibits peak transfection performance when the flow rate is maximized through the electroporation channel (FIGS. 3A and 3B). A pipette with controlled dispensing speed was utilized to achieve the desired flow rate to increase both viability and efficiency, corresponding to a residence time of the cell sample in the electric field of approximately 6.5 ms. A peak cell viability of 54% was achieved with a transfection efficiency of 65%, demonstrating a significant advance in the transfection of human immune cells with the device of the present invention.
[0196] 4A-4D illustrate a simulation of flow rates along an exemplary active zone of a device (i.e., from the first electrode lumen, through the electroporation zone, and into the second electrode lumen). In this embodiment, the medium contains flowing biological cells. From the simulated fluid flows at 10 mL / min and 100 mL / min, the average linear velocity of the sample through the electroporation zone is determined. The lower flow rate of 10 mL / min results in an average linear velocity of 324 mm / s. The higher flow rate of 100 mL / min results in an average linear velocity of 2,990 mm / s. The two linear velocities result in estimated residence times (τ) of 12.35 ms and 1.34 ms, respectively. res ), which can be correlated with the current flow rates of 16 mL per minute. These devices provided flow rates of 16 mL per minute. Notably, commercial systems require exposures of about 30 ms or longer under similar electric field exposure to produce comparable transfection efficiencies. This demonstrates that the combination of high flow rates and electric fields results in improved delivery of genetic material to living cells using the devices of the present invention.
[0197] The transfection efficiency using the device of the present invention is affected by the electric field strength. Figures 5A and 5B show the cell viability and transfection efficiency resulting from various electric field strengths, respectively. A transfection efficiency of 86% and a viability of 77% were achieved.
[0198] The device of the present invention showed an increase of about 20% in both cell viability and transfection efficiency by cooling the samples on ice to minimize any potential detrimental thermal effects that may affect cell viability due to increased temperature during electroporation (FIGS. 6A and 6B). Numerical modeling in COMSOL Multiphysics coupling electric field, fluid flow, and thermal effects was also developed to better understand the effect of sample temperature in the device of the present invention, using an applied voltage of 225V or 275V in this model. The results shown in FIG. 7A-7D show a substantially uniform electric field in the electroporation zone. FIG. 8A-8D show the temperature distribution in the device over time.
[0199] Electroporation using the device of the present invention showed no significant change in performance when electroporation was performed over a range of pulse durations at matching frequencies (FIGS. 9A and 9B). By varying the number of pulses from 1 to 5 within a 9.5 ms duration, no significant change in either viability or efficiency was observed, demonstrating waveform flexibility for electroporation using the device of the present invention. In this experiment, a peak cell viability of 83% was achieved with a transfection efficiency of 88%.
[0200] Electroporation using the device of the present invention showed no significant change in performance when electroporation was performed over a range of volumes and cell densities (Figures 10A and 10B). By varying cell numbers over a range of volumes from 25 to 100 μL, no significant change in either viability or efficiency was observed, demonstrating the flexibility of the physical response for electroporation using the device of the present invention. In this experiment, a peak cell viability of 83% was achieved with a transfection efficiency of 86%.
[0201] Electroporation using the device of the present invention showed no significant change in performance when electroporation was performed over a range of cross-sectional dimensions of the electroporation zone (FIGS. 11A and 11B). By varying the cross-sectional dimension of the electroporation zone from 500 to 900 μm, similar viability was observed, and there was no significant change in efficiency when the flow rate was modified to match the total residence time in the electroporation zone, demonstrating the flexibility of cross-sectional dimensions for electroporation using the device of the present invention. In this experiment, a peak cell viability of 51% was achieved, with a transfection efficiency of 67%.
[0202] The viability and efficiency depended on the voltage pulse waveform shape, as shown in Figures 12A and 12B. By varying the shape of the waveform, the time and intensity of the current to which each Jurkat cell was exposed was adjusted, thereby altering the viability or efficiency. In this experiment, high cell viability was observed in combination with high transfection efficiency (greater than 50%) using square, sine, and ramp waveform shapes. Exemplary waveforms useful for the device of the present invention are shown in Figures 12C-L.
[0203] Figures 13A and 13B show the viability and efficiency of the device of the present invention utilizing flow rates of 10-25 mL per minute with electric fields of 400-700 V / cm under cooling conditions. All of the optimizations performed allow for higher efficiency of nucleic acid delivery compared to the state-of-the-art commercial NEON transfection system in multiple independent experiments (Figures 13A and 13B).
[0204] Example 4 - Application of the device of the present invention to genetic engineering Therapeutic applications of primary human T cells have shown significant advances in the field of immuno-oncology by targeting a patient's immune system to be effective in fighting cancer. Several techniques, including chimeric antigen receptors and engineered T cell receptors, have shown clinical success in recent years. However, applications of genetically modifying a patient's immune system remain somewhat limited to the treatment of hematological cancers, as the tumor microenvironment of solid tumors inhibits T cell function at the tumor site. To overcome some of the biological challenges of tumor microenvironment suppression, it is hoped to further modify T cells to be more effective by knocking out genes that express regulatory ligands on the T cell surface. Identification of these genes is often achieved through CRISPR screening, where Cas9 and guide RNA libraries are delivered into T cells to knock out a wide range of endogenous genes to achieve enhanced function against specific tumors. However, delivery of these libraries remains a hurdle for the identification of genes in "hard-to-transfect" cell types such as primary T cells and natural killer cells. Typically, in these cases, CRISPR libraries are delivered as lentiviral particles that infect cells and transduce Cas9 / guide RNA sequences into the cell genome, then knock out the gene of interest in a sequence-specific manner. These libraries are very laborious to produce, requiring cloning of viral expression plasmids and purification of viral particles for delivery. Additionally, this methodology leaves behind the undesirable "baggage" of gene-integrated Cas9 / guide RNA sequences at random genomic insertion sites that may interrupt other functional genes. The use of non-viral delivery for Cas9 ribonucleoprotein complexes is an attractive way to overcome these hurdles, allowing researchers to screen large numbers of knockouts in the absence of viral integration using transient delivery of Cas9 protein complexed with guide RNA molecules.
[0205] Figure 13C is a flow chart of a method for delivering Cas9 ribonucleoprotein complexes to cells using the device of the present invention. Delivery of Cas9 ribonucleoprotein complexes to cells with electroporation allows high-throughput analysis of targeted CRISPR knockouts in a highly efficient manner, transforming the discovery process of novel gene targets for therapeutic applications. Studies utilize subsets of 200-1,000 or more genes, e.g., 25,000, from a commercially available cell surface receptor library to identify genes that inhibit tumor microenvironment suppression of T cell survival and persistence.
[0206] Example 5 - Electroporation of human cells Figures 14A and 14B show viability and efficiency data for electroporation of primary human T cells using two different molecular weights of fluorescent dextran molecules at a field strength of 700 V / cm. In this experiment, a peak cell viability of 30% was achieved with a transfection efficiency of 67%, demonstrating a significant advance in the transfection of primary human immune cells using the device of the present invention.
[0207] In a related experiment, electroporation using the device of the present invention shows significantly increased performance compared to NEON® in the THP-1 monocytic cell line (ATCC No. TIB-202) using the published NEON® Transfection System monocyte electroporation protocol (FIGS. 15A and 15B). In this experiment, a 56.4% increase in cell viability was observed using the device of the present invention compared to 23.4% with the NEON® Transfection System, while transfection efficiency remained at 6%.
[0208] Electroporation using the device of the present invention showed improved performance compared to the NEON® Transfection System in primary human monocytes using the published NEON® Transfection System monocyte electroporation protocol (FIGS. 16A and 16B). In this experiment, a 22.3% increase in cell viability was observed using the device of the present invention compared to 16.6% observed with the NEON® Transfection System, and a 21.6% increase in transfection efficiency was observed using the device of the present invention compared to 4.7% observed with the NEON® Transfection System.
[0209] Electroporation using the device of the present invention showed improved performance in independent experiments and for successful delivery of 40 kDa dextran molecules into natural killer cell lines of NK-92 (ATCC) (FIGS. 17A and 17B) and NK-92MI (ATCC) (FIGS. 18A and 18B) lineages compared to the NEON® transfection system. These results confirm the ability of the device of the present invention to deliver molecules outside the nucleic acid space with comparable cell viability and improved transfection efficiency relative to non-scalable commercial platforms.
[0210] SIRPα mRNA delivery into primary monocytes In another study, transient expression of SIRPα in primary human monocytes was achieved using the device of the present invention (Figures 19A-F). This delivery of non-GFP mRNA in primary human monocytes further showcases the ability of this transfection platform device to function in this historically "hard to transfect" immune cell population. As a control for this overexpression demonstration, primary T cells were used that were primarily SIRPα negative (only 3.4% of live T cells were positive for the surface marker, Figure 19B). After transfection, 86.9% of live T cells were positive for the SIRPα surface marker (Figure 19B). In primary monocytes with a high baseline (86.5% positive for the surface marker (Figure 19A)), mean fluorescence intensity (MFI) was quantified to determine whether receptor expression density increased after transfection. A 1.8-fold increase in SIRPα expression over control cell baseline was observed 24 hours after delivery of the mRNA (Figure 19F).
[0211] CXCR4-targeted Cas9-RNP delivery into primary macrophages eGFP-labeled Cas9-RNP has also been successfully delivered to monocyte-derived human macrophages using the device of the present invention. Delivery of eGFP-labeled Cas9-RNP to the nucleus was confirmed by microscopy and flow cytometry. eGFP expression was observed in up to 21.4% of differentiated macrophages 24 hours after transfection, and decreased to 5.1% within 5 days. No gene editing was observed at 24 hours, but by 48 hours, a KO efficiency of 13.9% was observed. The knockout efficiency, as determined by flow cytometry, then increased to 16.5% by day 5.
[0212] Manipulation of naive T cells by delivery of mRNA Isolated naive T cells (CD45RA + / CD45RO -)were electroporated with mRNA encoding GFP using the device of the present invention. After 24 hours, the cells were analyzed for viability and efficiency indicators. Naive cell counts and viability of electroporated cells were comparable to untreated cells, and a delivery efficiency of approximately 40% was observed (Figures 20A-D). Additionally, cells were stained for naive T cell markers CD45RA and CD45RO. This staining demonstrated that there was no change in the phenotype of the electroporated cells, and that the cells retained their "naive" CD45RA + / CD45RO - We demonstrated that the CD3 / CD28 activation agent sustained the condition (Figures 21A and 21B). Finally, naive T cells were expanded with CD3 / CD28 activation reagents. In this experiment, the growth rate of electroporated cells was comparable to that of untreated cells up to 6 days after activation (Figure 22).
[0213] Example 6 - Device for energizing multiple devices of the present invention 23A-23F show an exemplary embodiment of the electroporation device of the present invention integrated with an external device, which may be further integrated with a liquid handling system for energizing the device of the present invention to complete the electroporation process on an automated liquid handling platform. An external device called an electronic discharge machine (EDM) is used to energize the device of the present invention during the electroporation process. In the device shown in FIG. 23B, FIG. 23C, and FIG. 23E, 23.1 is a parallel beam integrated with the support rail. These beams are interchangeable, allowing for a change in electrical contact style / mechanism. Additionally, the beams allow for the final positioning of the electrical contacts. 23.2 is a mechanically retractable electrical contact. The electrodes use a spring-like mechanism to allow different regions of the device to slide through the EDM while maintaining contact with the body of the electroporation device. This element can be switched for other electrical contacts that are more flexible, such as leaf springs like the one shown in FIG. 23E, or wire brush type electrodes. 23.3 is the reservoir of the electroporation device of the present invention. 23.4 is a swinging support rail that allows additional deflection of the electrodes if necessary. This rail feature uses a spring-like mechanism to rotate and allow more deflection of the electrical contacts while the electroporation device is being placed in place by an operator or an automated system, such as a robotic arm. 23.5 is a sliding rail that allows translation of a sample holding plate, such as the sample plate shown in 23.6. 23.7 is an alignment system that provides correct electroporation device positioning on the sample plate. The alignment system is used as a visual indicator when there is no automated alignment feature, such as the absence of robotic control as applied in EDM. With the application of some form of translation device, the system has the ability to complete one or more samples in any array format. 23.8 is the electroporation zone of the device of the invention, which is fluidly connected to both the entry zone 23.9 and the recovery zone 23.10. 23.11 is a support rail that supports the mechanically retractable electrical contacts (23.2).The support rail 23.11 may be electrically conductive so that all the mechanically retractable electrical contacts (23.2) can be energized for simultaneous electroporation experiments. Alternatively, the support rail 23.11 may be a non-conductive material that insulates the mechanically retractable electrical contacts (23.2) so that individual electroporation experiments can be performed.
[0214] When configured as an automated system, a sample of the specimen of interest is aspirated by the device of the invention at another location on the liquid handling platform. The sample is then transported to an EDM whose electrode contacts are suspended above the surface of the sample plate. The device of the invention is then lowered into the device to establish contact with the electrode contacts of the EDM. The mechanism depicted in Figures 23A-C uses a pogo pin connection to close the circuit, while the embodiment of Figures 23D-F uses a flexible spring, e.g., a leaf spring, to close the circuit. Alternative methods of connecting the circuit include the use of a conductive fluid or electrolyte, a conductive diaphragm that is inflated to contact, or other conductive flexible material with a spring constant sufficient to deflect during the insertion process. This allows the EDM to be adapted for use with a variety of different sized devices of the invention. The system can be used to electroporate one or more samples, either independently or simultaneously, depending on the experimental objectives. This technology can be scaled up to improve in any respect. For example, an EDM can be used with multiple electroporation devices of the present invention, or alternatively, with a single device of the present invention in single sample experiments or multi-sample experiments by adding two linear mechanisms.
[0215] Figures 24A and 24B provide an exemplary embodiment of a housing configured to energize the conductive device of the present invention in a temperature-controlled manner. In the device of Figure 24A, 24.1 is a hollow electrode configured to be connected to a liquid handling manifold. The electrode may further incorporate an interaction collar to reduce stress on the electrode material induced by friction generated by the connection to the liquid handling manifold. 24.2 is a connecting channel fluidly connected to the hollow electrode and configured to amplify the electric field generated upon energization of the electrode. The connecting channel further acts like a barrier to confine the fluid flow to enhance and control the electric pulse the sample receives. 24.3 is a conductive base electrode that connects to the connecting channel 24.2. 24.4 is a support base configured to hold the hollow electrode 24.1, the connecting channel 24.2, and the conductive base electrode 24.3. 24.5 is a conductive base that supports the hollow electrode 24.1, the connecting channel 24.2, the conductive base electrode 24.3, and the support base 24.4, and electrically connects to the conductive base electrode 24.3 to complete the electroporation circuit. The conductive base 24.5 includes fluid connections 24.6 for flowing heating or cooling fluids through the conductive base 24.5 to regulate the temperature of the electroporation process. In FIG. 24B, 24.7 is an outer frame that supports the other components.
[0216] In the device of Figures 24A and 24B, as fluid flows from the hollow electrode 24.1, the conductivity of the sample fluid forms a closed circuit through interaction with the surface of the base electrode 24.3. The base electrode 24.3 can be of any shape that allows for systematic and controllable electric field exposure to the cells that induced electroporation. The position of the hollow electrode 24.1 can be manipulated in Z coordinate from the support base 24.4 to limit cell exposure to the electric field. In this configuration, the base electrode 24.3 is elevated from the bottom of the support base 24.4 to a position that rests beyond the specified volume collection limit. The electroporated cells will experience a finite electric field throughout the entire sample (other than to close the electroporation circuit). This design reduces shear effects on the sample cells and increases the uniformity of flow in the area where electroporation occurs. In addition, to create a stable electric field or to further manipulate the electric field, a connecting channel 24.2 is added to the end of the hollow electrode 24.1, allowing the operator to amplify and control the electric pulse, and therefore the electric field, experienced by the specimen. In addition, the electrode configuration of the present system uses a non-parallel electrode configuration where the cannula is circular and parallel to the axis of the flowing specimen, but the surface of the base electrode 24.3 is at some angle greater than 0 degrees to the axis of the cannula. A variation of this design is the use of a floating electrode that levitates above the well plate. As the sample flows across the surface of the base electrode 24.3 and is electroporated, the sample falls into the well. In this configuration, the electrodes are not physically attached to the well plate.
[0217] Example 7 - Fluidic chip-based electroporation device 25A-B show an exemplary embodiment of a fluidic chip-based electroporation device configured to accept industry standard 1-5,000 μL conventional pipette tips to introduce sample into the device. In the device of FIG. 25A, 25.1 and 25.2 are electrodes fluidically and electrically connected with the electroporation zone. 25.3 is a pipette tip insertion area fluidically connected to the electroporation zone, and 25.4 is a collection reservoir. Electrodes 25.1 and 25.2 of the fluidic chip-based electroporation device are energized by an external power source. In the exploded view of FIG. 25B, 25.5 is a pipette tip, 25.6 is the fluidic chip-based electroporation device of FIG. 25A, and 25.7 shows a collection plate for holding seeds after electroporation.
[0218] The pipette tip 25.5 levitates above the surface of the fluidic chip-based electroporation device 25.6. The fluidic chip-based electroporation device includes two components: an electroporation plate that contains encapsulated arranged electrodes, and a cover plate with embedded microfluidic channels that allow the user to modulate the pulses of the electric field delivered to the cells. The electroporation plate allows for the flow of multiple samples through the electroporator simultaneously or individually, as desired. After electroporation of the specimens is performed within the electroporation plate, the samples flow towards the bottom of the collection plate 25.7. The system uses industry standard liquid handling components, such as 1-5,000 μL pipette tips, facilitating integration into industry standard liquid handling manifolds.
[0219] Example 8 - Scalable continuous flow electroporation device Figures 26A-B show an exemplary embodiment of a continuous flow electroporation device designed for use in large volume cell manufacturing. In the embodiment shown in Figure 26A, 26.1 and 26.2 are inlets and outlets, respectively, for circulating fluids, such as buffer solutions. 26.3 is an outer housing that holds the electroporation device. 26.4 is the electroporation zone, fluidly connected to fluid inlet 26.5 and fluid outlet 26.9. After inlet 26.5 and before outlet 26.9 are cylindrical electrodes 26.7 and 26.8 with holes 26.6 on their surfaces. 26.10 is a reservoir for holding fluids, such as growth medium.
[0220] In this embodiment, the cylindrical electrodes 26.7 and 26.8 are made of a conductive porous material that allows fluid to move through the pores 26.6 of the conductive porous material into the cavity of the device. The pores 26.6 of the cylindrical electrodes 26.7, 26.8 allow a buffer solution to stabilize the chemical reaction on the surface of the cylindrical electrodes 26.7, 26.8 and minimize the pH transitions observed due to the application of an electric potential during the electroporation process. The buffer introduced by the porous cylindrical electrodes 26.7, 26.8 allows for changes in fluid flow to create a "lubrication" or sheath flow on the inner surface of the cylindrical electrodes 26.7, 26.8 or to induce other hydrodynamic elements into the electroporation process (such as rotation of the suspension with cells) as the cells are electroporated. The reduction in pH transitions reduces the negative effects of high fluctuations in the pH of the suspension specimen used during electroporation. Cylindrical electrodes 26.7 and 26.8 fulfill external circuit requirements and allow the system to be energized using an external power source. In an alternative embodiment, the outlet 26.2 of the electroporation device can be used to remove a high conductivity buffer, such as growth medium or PBS, and the inlet 26.1 can be used to introduce a low conductivity buffer to minimize heating of the liquid sample as it flows through the electroporation zone 26.4. This buffer exchange will result in higher cell viability and higher transfection efficiency, which will ultimately generate a higher number of successfully engineered cells. The low conductivity buffer can then be extracted in the outlet after the electroporation zone and replenished with growth medium when it comes into contact with the inlet after the electroporation zone.
[0221] Example 9 - Modeling the electric field in a novel spiral electrode Flowfect devices have been designed and computationally modeled with specific electrode configurations that help improve the transformation / transfection efficiency of flow cells. FIG. 27A shows the helical nature of the electrode configuration that is responsible for rotating the electric field as the cell flows through the electroporation region. Without being bound by theory, this configuration requires a lower electric field to achieve the same effect by allowing a larger portion of the cell surface to be electroporated. FIG. 27B-F show the cross-sectional area of the electroporation region as viewed from different axes. The energized and grounded electrodes are perpendicular to the flow direction, rather than parallel, as in FIG. 1A-C. This design allows for lower sample volumes and reduced applied voltages, which are desirable in applications such as electroporation of primary human cells (e.g., immune or stem cells) where cell numbers are limited. In another embodiment, the helical electrodes are not in fluid contact with the electroporation zone, and the use of radio frequency pulses can induce an electric field inside the electroporation zone (e.g., through an intermediate medium) to deliver compositions into the cells.
[0222] Example 10 - Two-part device of the present invention for creating scalability Figures 28A-C show an embodiment of the device of the invention configured to be manufactured with two separate components that fit together to form a complete device that can be used with commercially available liquid handling systems. In this configuration, insert molded electrodes, shown as small dots near the junction of the two components in Figures 28A-B, are then welded together by established industrial processes (e.g., spin welding, sonic waves, e.g., ultrasonic, heat welding, e.g., hot plate, or laser). In this design, the fluid flow of the sample, e.g., cell-DNA sample, through the device is separated from the electric field exposure required for electroporation.
[0223] 29A and 29B show the device depicted in FIGS. 28A-28C with identical internal dimensions, e.g., 4 mm distance between insert electrodes above and below the 700 μm diameter electroporation zone. The difference between this embodiment of the device of the invention and the embodiment shown in FIGS. 28A-28C is that in this concept, fluid flow control is coupled with electric field exposure. Specifically, the cannula (shown on the top of the device in FIGS. 29A-29B) is the interface between the liquid handling system and the electroporation device of the invention. When the electroporation device of the invention is coupled to the cannula, the embedded electrodes (shown in red on the device in FIGS. 29A and 29B) are electrically connected to a power source for voltage pulse delivery. In the embodiment shown in FIGS. 29A-29B, a single cannula is shown, but the system of the invention can be scaled up to include a system including multiple electroporation devices of the invention, e.g., 96 or 384 electroporation devices of the invention configured to electroporate cells suspended in a fluid in parallel.
[0224] Example 11 - Housing and interface examples Figures 30A and 30B provide an exemplary embodiment of a device of the present invention showing an outer housing containing a user interface (Figure 30A) and a plurality of devices of the present invention fluidly connected to a liquid dispensing manifold and a sample plate (Figure 30B).
[0225] FIG. 30A is an embodiment of a continuous flow transfection / transformation system. The 3D model shows a standalone electroporation system that includes a touch screen user interface (30.1) or another alternative user interface(s) that allows the user to select parameters such as flow rate, waveform, applied potential, electroporation volume, time delay, cooling characteristics, heating characteristics, electroporation status, progress, and other parameters used to optimize the electroporation protocol. The interface also includes pre-formulated parameter selections that allow the user to operate the system at standard conditions as previously verified by the user or recommended by the manufacturer. The interface can be connected to programming that allows automated execution of the system and / or to execute algorithms that optimize electroporation of a given sample of a known cell type. The device also includes a cartridge (30.2) that encapsulates one or more of the aforementioned inventions or another electroporation device used for continuous flow electroporation. The device also includes a cooling / heating area / enclosure (30.3) for cell / buffer storage during, before, and after electroporation of the specimen. The system is externally powered. The system also includes algorithms that have the ability to independently / autonomously adjust parameters if the user selects this functionality, allowing for continuous adjustment of parameters used in the electroporation process that may depend on cell type, conductivity, suspension volume, viscosity, electroporation cartridge age, suspension physical state, or electroporation device state.
[0226] Figure 30B shows an array of electroporation devices as previously described herein. 30.4 is a liquid handling manifold that transports the invention across a liquid handling platform and allows the device to aspirate fluids. 30.5 is the device shown in Figures 1A-1C. 30.6 is a well plate used to store samples before, during, and / or after specimen transfer.
[0227] Example 12 - Flow cytometry gating strategy to optimize electroporation parameters FIG. 31 provides an example comparing the two gating strategies. Historically, developers of electroporation technology have used a regular "lymphocyte" pre-gate that ignores cells that are not within the "lymphocyte" population, such as those with altered morphology or undergoing apoptosis. As shown in FIG. 31, this artificially increases the viability index by selecting a specific subpopulation of cells for analysis. The "whole cell" pre-gating is a more accurate depiction of the experimental outcome from electroporation. Thus, although the reported viability shown in the table below may appear lower than expected in the field, the data has been processed to focus on performance metrics that depict the impact of the electroporation device of the present invention on all input cells. In FIG. 31, FSC stands for forward scatter and SSC is side scatter, showing how cell morphology data is collected during flow cytometry analysis.
[0228] Using the gating strategy described herein, the performance data of Jurkat cells, activated primary human T cells, THP-1 monocytes, primary human monocytes, and differentiated primary human macrophages are shown in Table 2 below. In Table 2, the yield represents the ratio of the number of cells that are viable and express the payload of interest to the input number of cells that entered the process. For example, a yield of 0.5 times means that half of the input cells are viable and express the desired payload at the time of analysis. For reference, if the yield with viral delivery is approximately greater than 0.1 times at the time of harvest, the cell therapy product is administered to the patient. [Table 2]
[0229] Example 13 - Electroporation into Chinese Hamster Ovary (CHO-K1) and Human Embryonic Kidney (HEK-293T) Cells Electroporation of CHO-K1 (Chinese Hamster Ovary Cells) and HEK-293T (Human Embryonic Kidney Cells) cell lines has been performed. The device of the present invention can be used for electroporation of adherent cells that have been lifted and resuspended in electroporation buffer. CHO-K1 (Figures 32A and 32B) and HEK-293T (Figures 33A-33D) cells can be successfully transfected with GFP plasmid DNA using the device of the present invention. Peak transfection efficiency of HEK-293T cells was observed after 48 hours of culture after electroporation. Without being bound by theory, the reduced cell viability may be due to lifting adherent cells and suspending these cells for analysis by flow cytometer, whereas microscopy showed healthy GFP+ cells with normal morphology (Figures 34A, 34B, 35A, and 35B).
[0230] Example 14 - Transfection of primary T cells Studies have been conducted in primary T cells. Fluorescent reporters that have been utilized primarily to analyze electroporation efficiency include fluorescent small molecules (e.g., FITC-labeled dextran), genes expressed from plasmid DNA (e.g., GFP), and genes expressed from mRNA (e.g., GFP). Delivery and expression of these reporters are determined using flow cytometry, where live cells are pre-gated using a gating strategy as described herein to determine fluorescent detection on a single-cell basis. These assays demonstrate cell-to-cell detection of fluorescent reporters, and in some cases, direct nuclear delivery. Due to the gentle nature of the electroporation performed with the device of the present invention, higher cell numbers are achieved after transfection compared to commercial systems, such as the Lonza NUCLEOFECTOR 4D™ system or the NEON® transfection system (Thermo Fisher, Carlsbad, CA).
[0231] Demonstration of expanded T cells The device of the present invention was used to deliver fluorescently labeled (FITC) dextran molecules (40 kDa) to primary human T cells. 6 Electroporation was performed using a commercial benchtop electroporation device (e.g., Thermo Fisher NEON® Transfection System) for four metrics: total cell count (post-EP), cell viability, transfection efficiency, and total number of live transfected cells. The results are shown in Figures 36A-D. In addition to the data shown in Figures 36A-D using fluorescently labeled molecules, delivery of plasmid DNA encoding GFP (3.5 kB) into primary human T cells (10 6 The number of GFP-expressing T cells (at cell density of cells / experimental conditions) was tested using the device of the present invention. These experiments again demonstrated superiority over the NEON® transfection system, shown as the total number of GFP-expressing T cells after 24 hours of incubation depicted in FIG. 37. Importantly, expression of GFP from a DNA plasmid also demonstrated the efficient delivery of genetic information (i.e., nucleic acid) into the nucleus, where the DNA is transcribed into RNA prior to translation into the final GFP protein.
[0232] b. mRNA delivery by platform comparison Delivery of mRNA to cells was also demonstrated using the device of the present invention. These experiments were performed with commercially provided mRNA at two operating cell densities. Experiments were then completed with two commercially available systems (Lonza NUCLEOFECTOR 4D™ and Thermo Fisher NEON® transfection system) and the device of the present invention for comparison, shown in Figures 38A-38D. The device of the present invention outperformed the commercial system in terms of viability, efficiency, and yield. In addition, the performance of the device of the present invention was not dependent on cell concentration, unlike the commercial system, as shown by the experimental results shown in Figures 38A-38D.
[0233] Example 15 - Delivery of non-transient payloads Each of the payloads described in Examples 13 and 14 is transient upon delivery. To demonstrate delivery of stable genomic modifications (i.e., CRISPR gene knockout) of the reagent, experiments were performed using Cas9 ribonucleoprotein complexes (RNPs) for CRISPR knockout in primary cells. As shown in Figures 39A-39D, knockout of endogenous genes in primary T cells, as confirmed through single cell-based surface receptor staining, was successful using the device of the present invention and confirmed using flow cytometry. The device of the present invention can also be used for simultaneous CRISPR integration of exogenous genes to demonstrate stable genomic integration through electroporation of Cas9 RNPs.
[0234] Example 16 - Monocyte (THP-1) and Natural Killer (NK-92MI) Cell Line Transfection Figures 40A and 40B show bar graphs comparing the delivery of GFP plasmid and FITC-labeled dextran to THP-1 and NK-92MI cells, respectively, using the device of the present invention and the commercial NEON® transfection system. As seen in Figures 40A and 40B, electroporation using the device of the present invention consistently outperforms NEON® in producing viable transfected cells of any type with any payload. As an additional comparative example, Figures 41A and 41B show increased cell viability and transfection efficiency in samples containing THP-1 monocytes, where GFP mRNA was delivered using the device of the present invention compared to the NEON® transfection system.
[0235] THP-1, an immortalized monocyte cell line, was further used for comparative studies with both monocytes and macrophages. Activation of THP-1 cells with LPS (lipopolysaccharide) endotoxin induces macrophage-like THP1-Mac immortalized cells. As shown in Figures 42A-C and 43A-B, both THP-1 (Figures 42A-C) and THP1-Mac (Figures 43A-B) cells were successfully transfected with GFP mRNA using the device of the present invention.
[0236] Example 17 - Primary monocyte and differentiated macrophage transfection Primary human monocyte cells, a cell type that is notoriously difficult to transfect through conventional means, were successfully transfected using the device of the present invention. As shown in Figures 44A-44D, primary human monocytes isolated from peripheral blood were successfully transfected with FITC-labeled dextran molecules and GFP mRNA using the device of the present invention.
[0237] Figures 45A and 45B show the expression of specific markers in primary peripheral blood monocytes transfected with GFP mRNA using the device of the present invention. As shown in Figures 45A and 45B, CD86+ monocytes (gated on live GFP+ cells) maintained their ability to be activated (represented here as CD80 expression) after LPS stimulation for up to 96 hours, indicating that electroporation does not adversely affect the expression of the activation marker CD80 (Figure 45A) or the lineage marker CD86 (Figure 45B).
[0238] Furthermore, primary monocytes electroporated using the device of the present invention retained the ability to differentiate into macrophages, as shown in Figures 46A-C, indicating that the cells retain their function after electroporation. As shown in Figures 47A-D, differentiated human macrophages were successfully transfected with FITC-labeled dextran molecules (Figures 47A-B) and GFP mRNA (Figures 47C-D) using the device of the present invention. Macrophages electroporated using the device of the present invention polarized to M1 or M2 phenotypes (as shown in Figures 48A-B), suggesting that cell health and function are maintained after electroporation using the device of the present invention. Electroporated macrophages polarized to M1 (Figure 48A) or M2 (Figure 48B) phenotypes and retained GFP mRNA expression for up to 72 hours after electroporation using the device of the present invention.
[0239] The device of the present invention outperforms commercial transfection systems for electroporation of primary monocytes. As shown in Figures 49A-C, delivery of FITC-labeled dextran into primary monocytes using the device of the present invention exceeds the performance of the NEON transfection system for primary human cells, significantly increasing the total number of successfully transfected output viable cells.
[0240] Example 18 - Continuous flow device of the present invention: Cell production in large volumes and high cell numbers The device of the present invention can be used for electroporation of large volumes and high cell number suspensions in a truly continuous flow mode. Existing technologies such as the Lonza 4D-NUCLEOFECTOR™ LV unit and the Maxcyte Scalable Transfection System (STX, VLX, or GT) rely on fluid flow to load the sample into the NUCLEOCUVETTE™ cartridge or processing assembly, respectively. However, during electric pulse delivery, the cell and payload suspensions are stationary. Commercially available electroporation systems process static or stationary cell suspensions, which is an important difference with the device of the present invention. The device of the present invention allows for a continuous flow of cell and payload suspensions during exposure to an electric field. Specifically, rapidly flowing cells are exposed to an electric field sufficient to disrupt the cell membrane and internalize the genetic payload of interest, but are instantly dispensed into their growth medium for cell harvesting. Additionally, any heat generated during the electroporation process is dissipated due to convective heat transfer facilitated by the sample flowing directly into the harvesting medium. This study significantly further elaborates on the data generated at both the cell type and electroporation scale.
[0241] a. Initial demonstration in Jurkat cells A range of cell densities and electroporation volumes were used to demonstrate the scalability of the continuous flow platform relative to a single device platform using the device of the present invention. These experiments demonstrate that the scalable platform of the present invention operates over a wide range of Jurkat cell densities, as shown in Figures 50A-50D.
[0242] b. Comparative study of the present invention's platforms Follow-up experiments were performed to compare the electroporation performance of the device of the present invention with the continuous-flow electroporation platform of the present invention using the same delivery conditions for both Jurkat cells and primary T cells. These comparative experiments processed 5 million cells through the continuous-flow platform and showed comparable results to the single channel device of the present invention for Jurkat cells and primary T cells, as shown in Figures 51A and 51B.
[0243] Increasing the scale of cT cell electroporation To test whether electroporation is cell density dependent, the electroporation experiments described in Figures 51A and 51B were extended to cell suspensions containing up to 100 million primary T cells. In the first experiment, increasing numbers of T cells were processed at the same cell density, and the scale was increased from 5 million (as shown in Figure 51B) to 100 million (as shown in Figures 52A-D) without loss of yield. The desired cell density was then assessed, and T cells were cultured at up to 100 x 10 6 We demonstrated that T cells can be processed through our scalable platform at 100 million cells / mL. Importantly, processing of 100 million T cells was successful with a 5-fold lower amount of mRNA compared to T cells processed at the lowest cell density, demonstrating potential cost-of-goods savings for payloads delivered at high cell densities. Total processing time for 100 million T cells in this experiment ranged from 2.4 to 24 seconds.
[0244] Comparative study with d.Lonza Large Volume (LV) system We performed a comparison between the scalable platform of the present invention and the Lonza 4D LV system using primary T cells with both FITC-dextran and EGFP mRNA payloads. The experiment was performed with 50 million T cells. At 24 hours, cell staining revealed that the morphology and phenotype of Lonza-treated cells was significantly different from untreated cells (shown in the flow cytometry plot in Figure 54). Additionally, there was a significant dead cell population observed in Lonza LV-treated cells. These outcomes did not occur in T cells electroporated with the continuous flow platform of the present invention, indicating that the continuous flow platform of the present invention maintained T cell morphology throughout the electroporation process. As shown in Figure 55, the total cell yield using the continuous flow platform of the present invention is higher than the Lonza 4D LV system, regardless of the payload delivered, e.g., FITC-labeled dextran or GFP mRNA.
[0245] The continuous flow platform of the present invention has demonstrated successful electroporation of payloads into suspensions with very high densities, e.g., 1 billion cells. As shown in Figures 56A and 56B, 1 billion THP-1 cells (100 x 10 6 A total of 1000 x 100 cells / mL of cultured cells were successfully transfected with 40 kDa FITC-labeled dextran molecules using the continuous flow platform of the present invention. Figure 57 shows the measured yield up to 72 hours post-electroporation, expressed as raw FITC cell counts, for the experiment shown in Figures 56A and 56B. At this time point, the number of FITC-positive cells was approximately 500 million, resulting from an input cell count of 1 billion, demonstrating the ability of the continuous flow platform of the present invention to deliver one in two input cells as a modified cell product at 72 hours.
[0246] Example 19 - Pulse waveforms, DC voltages, high voltage-low voltage combinations, and combinations thereof The device of the present invention was tested with both pulsed and direct current (DC) power sources, as shown in Figures 58A-58D. At the higher voltages tested, both power sources showed similar delivery efficiency of FITC-dextran in Jurkat cells. Additionally, initial electroporation combining high and low voltages was tested for the same system. As shown in Figures 59A-59D, we analyzed the use of modified waveforms for enhanced electroporation using the device of the present invention combining high and low voltages, initially with FITC-dextran, for optimization of primary human T cell delivery. The experiment in Figures 59A-59D was repeated for delivery of a commercially available mRNA payload encoding eGFP fluorescent reporter protein, as shown in Figures 60A-60D.
[0247] Example 20 - Dynabead electroporation To demonstrate the compatibility of the device of the present invention with a particular T cell expansion protocol, CD3 / CD28 Dynabead-expanded T cells were electroporated using the device of the present invention. Electroporation of Dynabead-expanded samples was performed on a suspension of 1 million primary human T cells either immediately after bead addition (5 min prior to electroporation) or after overnight (OVN) treatment, and both time periods demonstrated comparable efficiency results from the presence of magnetic beads to the absence of beads (Figure 61).
[0248] Example 21 - Outer structure for energizing a device of the present invention The present inventi...
Claims
1. 1. A method for introducing a composition into a plurality of cells suspended in a flowing liquid, comprising: (a) providing a device, said device comprising: (i) a first hollow cylindrical electrode including a first lumen having a first outlet, a first inlet, and a diameter; (ii) a second hollow cylindrical electrode including a second lumen having a second outlet, a second inlet, and a diameter; (iii) a cylindrical electroporation zone disposed between the first outlet and the second outlet, the electroporation zone comprising a minimum cross-sectional dimension greater than 500 μm, the electroporation zone having a substantially uniform cross-sectional area; providing, wherein the first outlet, the electroporation zone, and the second inlet are in fluid communication, a cross-sectional dimension of the electroporation zone is sized such that there are no constrictions that would contact a cell and deform a cell membrane, and the first hollow cylindrical electrode and / or the second hollow cylindrical electrode comprise gold, platinum, or conductive carbon; (b) generating an electric field in the electroporation zone by applying a potential difference between the first hollow cylindrical electrode and the second hollow cylindrical electrode; (c) passing the plurality of cells and the composition through the first hollow cylindrical electrode, the electroporation zone, and the second hollow cylindrical electrode to increase the permeability of the plurality of cells and introduce the composition into the plurality of cells.
2. 2. The method of claim 1, wherein the plurality of cells is in a separate liquid other than the composition prior to step (b) and / or step (b) comprises applying positive fluid pressure.
3. 3. The method of claim 1 or 2, wherein none of the diameter of the first lumen, the diameter of the second lumen, or the smallest cross-sectional dimension of the electroporation zone temporarily compresses a cross-sectional dimension of any of the plurality of cells suspended in the liquid.
4. 4. The method of any one of claims 1 to 3, wherein a flow rate of the plurality of cells in liquid and / or suspension delivered from a fluid delivery source from the first lumen to the electroporation zone is between 0.001 mL / min and 1,000 mL / min, the fluid delivery source is configured to deliver the plurality of cells in liquid and / or suspension through the first lumen to the second outlet, and / or the residence time of the plurality of cells suspended in liquid in the electroporation zone is between 0.5 ms and 50 ms.
5. The method according to any one of claims 1 to 4, wherein the electric field is generated by a voltage pulse.
6. 6. The method of claim 5, wherein the voltage pulse energizes the first hollow cylindrical electrode with a specific applied voltage while the second hollow cylindrical electrode is energized with a specific applied voltage, thus applying a potential difference between the first hollow cylindrical electrode and the second hollow cylindrical electrode.
7. 7. The method of claim 5 or 6, wherein i) the voltage pulses each have an amplitude of -3 kV to 3 kV; and / or ii) the voltage pulses have a duration of 0.01 ms to 1,000 ms; and / or iii) the voltage pulses are applied to the first and second hollow cylindrical electrodes at a frequency of 1 Hz to 50,000 Hz; and / or iv) the voltage pulses comprise a waveform selected from the group consisting of DC, square, pulse, bipolar, sinusoidal, ramp, asymmetric bipolar, any, and any superposition or combination thereof; and / or v) the electric field generated from the voltage pulses has a magnitude of 1 V / cm to 50,000 V / cm; and / or vi) the duty cycle of the voltage pulses is 0.001% to 100%.
8. 8. The method of claim 1, wherein the liquid has a conductivity of 0.001 mS / cm to 500 mS / cm, and / or the temperature of the plurality of cells suspended in the liquid is between 0° C. and 50° C., and / or the concentration of the composition in the liquid is between 0.0001 μg / mL to 1000 μg / mL.
9. 9. The method of any one of claims 1 to 8, wherein the composition comprises at least one compound selected from the group consisting of a therapeutic agent, a vitamin, a nanoparticle, a charged molecule, an uncharged molecule, DNA, RNA, a CRISPR-Cas complex, a protein, an enzyme, a peptide, a virus, a polymer, a ribonucleoprotein, a polysaccharide, an engineered nuclease, a transcription activator-like effector nuclease (TALEN), a zinc finger nuclease (ZFN), a homing nuclease, a meganuclease (MN), a megaTAL, and a transposon.
10. 10. The method of any one of claims 1 to 9, wherein the plurality of cells suspended in the liquid is selected from the group consisting of eukaryotic cells, prokaryotic cells, plant cells, mammalian cells, animal cells, red blood cells, human cells, primary cells, cell lines, cells in suspension, adherent cells, stem cells, blood cells, Chinese hamster ovary cells, immune cells, human embryonic kidney cells, unstimulated cells, stimulated cells, activated cells, induced pluripotent stem cells, primary human induced pluripotent stem cells, embryonic stem cells, mesenchymal stem cells, hematopoietic stem cells, and synthetic cells.
11. 11. The method of claim 10, wherein the immune cells comprise peripheral blood mononuclear cells, adaptive immune cells, innate immune cells, antigen presenting cells, monocytes, T cells, B cells, dendritic cells, macrophages, neutrophils, natural killer cells, Jurkat cells, primary human T cells, THP-1 cells, primary human macrophages, primary human monocytes, primary human natural killer cells, unstimulated cells, activated cells, or stimulated cells.
12. The method of any one of claims 1 to 11, further comprising storing the plurality of cells suspended in the liquid in a collection buffer after perforation.
13. 13. The method according to any one of claims 1 to 12, wherein the cross-section of the electroporation zone is a shape selected from the group consisting of a circle, a disk, an ellipse, a regular polygon, an irregular polygon, a curved shape, a star, a parallelogram, a trapezoid, and an irregular shape, in particular the electroporation zone has a substantially circular cross-section.
14. The electroporation zone has a minimum cross-sectional dimension of between 0.5 mm and 5 mm and / or a minimum cross-sectional dimension of about 7850 μm 2 ~Approx. 2000mm 2 and / or the electroporation zone has a length between 0.1 mm and 50 mm, and / or the lumen of either the first hollow cylindrical electrode and / or the second hollow cylindrical electrode has a minimum cross-sectional dimension between 0.01 mm and 500 mm.
15. 15. The method of any one of claims 1 to 14, wherein the ratio of the diameter of the lumen of either the first hollow cylindrical electrode or the second hollow cylindrical electrode to the smallest cross-sectional dimension of the electroporation zone is between 1:10 and 10:1, and / or the ratio of the smallest cross-sectional dimension of the electroporation zone to the length of the electroporation zone is between 1:100 and 100:1, and / or the ratio of the cross-sectional area of the lumen of either the first hollow cylindrical electrode and / or the second hollow cylindrical electrode to the cross-sectional area of the electroporation zone is between 1:10 and 10:1.
Citation Information
Patent Citations
Methods and devices related to a regulated flow electroporation chamber
US20050282200A1
Hydrodynamically controlled electric fields for high throughput transformation & high throughput parallel transformation platform
WO2017210334A1
